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ABSTRACT 
The work described in this thesis was undertaken to investigate physicochemical, 
biochemical and physiological factors contributing towards the rarity of kidney stone disease 
in the South African black population. Healthy, age-matched male subjects from the black 
and white population groups were recruited for this purpose. In several of the studies, 
subjects followed a standardized diet and were required to provide 24 hour urine collections. 
These were analyzed for sodium, potassium, calcium, oxalate, uric acid, citrate, chloride, 
magnesium, phosphate, sulphate and creatinine using standard laboratory techniques. Urine 
composition values were used as input data for the calculation of relative supersaturation 
(RS) values for calcium oxalate (CaOx), calcium phosphate (CaP, or brushite) and uric acid 
(UA) using the computer programme EQUIL and for the calculation of the Tiselius Risk 
Index (TRI). CaOx crystallization experiments were performed. These included CaOx 
metastable limit (MSL) and BONN Risk Index (BRI) determinations, particle formation 
kinetics, 14C-oxalate crystal deposition kinetics and CaOx crystal aggregation and nucleation 
inhibition. Crystallization experiments were also supplemented with scanning electron 
microscopy (SEM) and zeta potential measurements. Urine compositions, crystallization data 
and physicochemical risk indices were analyzed statisitically using ANOV A. 
Several different investigations were undertaken. These included crystallization 
experiments involving urinary macromolecules from both race groups, crystal matrix extract 
isolation (with osteopontin as its major component) from both race groups and its testing for 
inhibitory capacity in ultrafiltered urine from both race groups. Similar crystallization 
experiments were conducted with commercially available osteopontin. In addition, a 
comprehensive trial was conducted in which the ingestion of three sodium salts (sodium 
chloride, sodium bicarbonate and sodium citrate) was investigated for their effects on urinary 
risk factors of CaOx stone formation and for their effects on bone turnover markers in urine 
and in serum. 
For the biochemical isolation of crystal matrix extract, COD-CME was precipitated in 
urine from both black and white subjects. The proteins included in COD-CME were detected 
using sodium dodecyl sulfate polyacryalamide gel electrophoresis (SDS-PAGE). Western 
Blotting was used for semi-quantitative analysis of OPN. 
v 
For the trial involving different sodium salts, four experimental protocols were investigated. 
The four protocols included low NaCl (3 g/day), high NaCl (12 g/day), sodium bicarbonate (6 
g/day) and sodium citrate in the form of Citro-Soda (16 g/day). A Latin Square Design was 
followed for the random assignment of participants to sequences of protocols. 
The studies on macromolecules showed that those in the urine of black subjects were 
more potent inhibitors of CaOx crystal deposition and aggregation than those in the urine of 
white subjects. Isolation and characterization of the crystal matrix extract in COD crystals 
confirmed that osteopontin is the main intracrystalline protein in the extract. The 
crystallization experiments performed on the crystal matrix extract isolated from the urine of 
both race groups demonstrated that the extract isolated from the urine of black subjects was a 
superior inhibitor of CaOx deposition, growth and aggregation. Crystallization studies 
performed on commercially available osteopontin in urine from black and white subjects 
showed that this protein is a more effective inhibitor of CaOx crystal deposition, growth and 
nucleation in the urine from the former group compared to that from the latter. 
The studies on supplemental sodium salts demonstrated that the two race groups 
respond differently to lithogenic and anti-lithogenic dietary challenges. High NaCl protocol 
resulted in a favourable and counter-intuitive significant decrease in free unbound calcium in 
samples from black subjects whereas no such change was observed in white subjects. 
Supplemental sodium bicarbonate and sodium citrate induced favourable decreases in urinary 
total calcium, urinary ionized calcium, BRI, RS of CaOx, RS of uric acid and RS of brushite, 
and a favourable increase in urinary citrate and pH in both groups. Interestingly and more 
importantly, these factors were more prominent in samples from black subjects than those 
from white subjects. 
Bone turnover measurements showed that urinary deoxypyridinoline (DPD) levels 
were lower while serum osteocalcin (OC) levels were higher in blacks than in whites at 
baseline, but these differences were not statistically significant. Smaller increases in urinary 
DPD levels after high aCl and sodium bicarbonate and corresponding bigger increases in 
serum osteocalcin (OC) levels after these protocols (and sodium citrate) in black subjects 
than in white subjects indicate less bone resorption and higher bone formation, respectively, 
in the former group. 
Vl 
The results presented in this thesis have provided convincing evidence that in the context of 
CaOx kidney stone formation, several physicochemical, biochemical and physiological 
factors are different in black and white South African subjects and that these factors are more 
effective in the former group with respect to providing protective mechanisms against CaOx 
kidney stone formation. 
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Urolithiasis (kidney stone disease) occurs throughout the world afflicting about 8 - 20 % of 
the population in western societies (Robertson and Hughes 1994: Balla et al. 1998: Pak 1998: 
Kamoun et al. 1999: Bennani et al. 2000: Ramello et al. 2000; Bill and Meyers 2001; 
Decoster et al. 2002: Morton et al. 2002: Bulo et al. 2004: Parmar 2004: Trinchieri 2006). 
The most common component of these stones is calcium oxalate (CaOx). Of great interest is 
that the incidence of urolithiasis in the South African black population is extremely rare while 
in the white population it is similar to that which occurs in other western societies (Muskat 
1951: Modlin 1967: Whalley et al. 1998). This provides basic scientists with a unique 
opportunity to study the two population groups with a view to identifying and characterizing 
the multiple factors which cause the one group to be stone-free and the other group to be 
stone-prone. Numerous physicochemical, biochemical and renal handling mechanisms are 
likely to be involved in explaining this phenomenon. The present thesis describes 
investigations into some of these processes. 
1.1 KIDNEY STONES AND THEIR CHEMICAL COMPOSITION 
Urolithiasis is one of mankind's oldest diseases and continues to pose a universal health 
problem (Robertson and Peacock 1982: Ryall 1993: Tiselius 2000. 2003: Khan and Kok 
2004). Kidney stones are hard, solid pellets that form in the urinary tract and are the cause of 
one of the most painful ailments. In addition to pain, kidney stones can also lead to renal 
failure (Koga et al. 1991: Ramello et al. 2000: Bihl and Meyers 2001: Pietrow et al. 2006: 
Trinchieri 2006). In many cases they are very small and can pass through the urinary tract 
without any problems and discomfort (Robertson and Peacock 1972: Hallson and Rose 1976: 
Finlayson et al. 1990: Khan and Kok 2004). However, if a stone (even a small one) becomes 
lodged and blocks the flow of urine, excruciating pain may result. Occasionally salts form in 
urine from various ions such as calcium and oxalate that nucleate to form calcium oxalate 
(CaOx) crystals which build up on the inner surfaces of the kidney (Robertson et al. 1978: 
Coe and Parks 1988: Kumar et al. 2003). These salts can become concentrated under certain 
circumstances e.g. if the volume of urine is significantly reduced; or if extremely high 
amounts of crystal-forming ions are present. When concentration levels exceed 
Chapter 1 
supersaturation levels, alts can precipitate and form crystals which could later grow and 
aggregate to form a stone. 
Generally there are four types of stones, namely calcium, uric acid, struvite and 
cystine stones (Finlayson 1977: Finlayson 1978: Khan and Hackett 1987: Coe and Parks 
1988). Calcium stones are the most common of all kidney stones, and occur in the form of 
calcium oxalate (CaOx) or calcium phosphate (CaP) (Khan et al. 1979: Nancollas 1983: 
Tiselius et al. 1995: Aggarwal et al. 2000: Kok 2002: Coe et al. 2005). About 70 % of 
calcium-containing stones are caused by hypercalciuria (abnormally high calcium in the 
urine). 
CaOxstones 
CaOx stones are either composed of pure calcium oxalate or a mixture of calcium oxalate and 
calcium phosphate (Gibson 1974: Iida et al. 2003: Worcester et al. 2006). Approximately 85 
% of calcium stones are composed of pure CaOx. Because of this predominance, CaOx 
stones comprise the basis for the origin of this thesis. CaOx is an insoluble complex that 
forms when calcium is chemically bound to oxalate. Pure CaOx containing stones exist either 
in monohydrate (COM) or dihydrate (COD) crystal form or in rare cases trihydrate (COT) 
(Herring 1962: Streit et al. 1998: Grases et al. 1998: Bithelis et al. 2004: El-Shall et al. 2004 ). 
COM is the most common form of CaOx crystals in renal stones. This type of stone is due to 
hypercalciuria and/or hyperoxaluria (excess oxalate in urine), and in most cases are idiopathic 
(indicating the absence of any clinical cause of the disease) (Marangella et al. 2000: Coe et al. 
2005). The pathogenesis of idiopathic CaOx stone formation is multifactorial. Most of these 
factors are epidemiological, physicochemical and dietary and each of them will be discussed 
in detail in the following pages. 
CaPstones 
About 10% of calcium stones are composed ofCaP (Mandel and Mandel 1989). This type of 
stone is relatively uncommon and occurs in patients with metabolic or hormonal disorders 
such as hyperparathyroidism (excessive parathyroid hormone levels) (Buck 1990: Hess and 
Jaeger 1993) and renal tubular acidosis (inherited condition in which the kidneys are unable 
to excrete acid) (Carlisle et al. 1991 ). High urinary pH and low urinary citrate are the driving 
forces for the formation of these stones (Pak et al. 1978). CaP stones exist in two forms: 
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hydroxyapatite (Calcium hydroxyl phosphate; Ca5(P04)3(0H)) and brushite (calcium 
hydrogen phosphate CaHP04.2H20). Hydroxyapatite is the most thermodynamically stable 
CaP crystal phase and is the major component in mixed CaOx/CaP stones (Tiselius and 
Larsson 1992: Baumann et al. 2001 ). Brushite has a very high recurrence rate in patients with 
this stone type compared to hydroxyapatite (Tiselius 2000). Brushite stones are very 
physically resistant structures which are difficult to break with shock waves. However both 
CaP stone forms are soluble in acidic media (Klee et al. 1991: Evan et al. 2005) . 
Uric Acid stones 
About 5 to 10 % of stones are made up of uric acid, which is a breakdown product of purine 
(Ramello et al. 2000: Coe et al. 2005). Uric acid is produced in the liver and enters the 
bloodstream, where most of it passes into the kidneys and is eliminated in urine. This type of 
stone is mainly due to hyperuricosuria which is caused by high levels of uric acid and low 
urinary pH levels (Pak et al. 2002: Sakhaee et al. 2002: Abate et al. 2004: Zarse et al. 2004 ). 
Struvite stones 
Struvite stones (magnesium ammonium phosphate) are almost always caused by urinary tract 
infections due to bacteria (e.g. Proteus, Pseudomonas etc.) that secrete certain enzymes. 
These enzymes degrade urea to ammonia and carbonate. This in turn, raises urine 
concentrations of ammonia and causes the urine to be more alkaline. This alkalinity 
subsequently promotes the formation of struvite stones (Ramello et al. 2000) . 
Cystine stones 
Cystine stones develop from genetic defects that cause abnormal transport of amino acids in 
the kidney and gastrointestinal system leading to a build-up of cystine (cystinuria) which is 
one of these amino acids. The tendency to form these stones is inherited and they are marked 
by rapid growth and recurrence, which, if not treated promptly, can eventually lead to kidney 
failure (Font-Llitj6s et al. 2005 ). About 2 % of this type of stone is found in adults and up to 
8% in children and is reported to occur in between 0.07 and 0.40 % of the population (Font-
Llitj6s et al. 2005) . Cystine is highly soluble at pH > 7.2 and this is even more pronounced in 
the presence of urinary macromolecules (Nakagawa et al. 2000) and with increasing ionic 
strength (Pak and Fuller 1983). Cystine is an oxidized dimeric form of cysteine (an alpha 
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amino acid containing sulphur that is found in most proteins especially in keratin) molecules 
joined together by a weak disulfide bond (Aslaksena et a!. 2006). Cystine has a chemical 
formula ofC6H12N20 4S2 and that of cysteine is C3H7N02S (Aslaksena eta!. 2006). 
1.2 EPIDEMIOLOGICAL RISK FACTORS OF STONE FORMATION 
The incidence of kidney stones varies throughout the world and may be correlated to age, 
gender, race, geography, climate and diet (Scott 1985: Beukes et al. 1987: Sakhaee et al. 
1987: Rodgers and Spector1981: Ramella et al. 2000). 
1.2.1 Age and Gender 
Kidney stones affect about 15 % of men and 5 % of women by the time they are 30 to 50 
years old (Blacklock 1982: Hesse et al. 1986: Iguchi et al. 1999). Twice as many males are 
afflicted by this disease than females (Blacklock 1982: Hesse et a!. 1986: Hess and Kok 
1996: Iguchi et a!. 1999: Heller et a!. 2002). The higher incidence in men compared to 
women may be due to the fact that men generally excrete more calcium, oxalate and uric acid 
than women (Robertso'1 et a!. 1980: Blacklock 1982). Generally, the incidence of kidney 
stones in children is very low and this can be accounted for by their relatively low excretion 
of calcium and high excretion of polyanion inhibitors (Robertson et a!. 1980: Robertson and 
Peacock 1983 ). These inhibitors consist of glycosaminoglycans (GAGS) and non-
polymerised proteins which have the ability to retard aggregation and growth of CaOx 
crystals (Robertson and Peacock 1983 ). 
1.2.2 Race 
The incidence of kidney stones has been reported to be higher in whites than blacks, 
irrespective of the geographical and environmental area (Robertson and Peacock 1981: 
Whalley eta!. 1998: Ramella eta!. 2000). These reports have been supported by a very recent 
study conducted by Maloney et al. (2005) in which 1,141 stone patients from the same 
geographic region (North Carolina, USA) participated. Out of these patients, only 9 % were 
non-white. This study reported a higher prevalence of hypercalciuria in whites compared to 
the non-white group (67 % vs. 25 % respectively). A low incidence of kidney stones is also 
reported in other race groups such as Eskimos, Black Americans and Aborigines 
(Widdowson and McCance 1970: Bateson 1997). In USA and Brazil, the ratio of white to 
black stone-formers is reported to be four-to-one (Ramella eta!. 2000). 
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In South Africa, kidney stone formation in the black population is extremely rare, while in 
the white group it occurs with a frequency rate of about 10- 15 % (Modlin 1967; Beukes et 
al. 1987; Meyers et al. 1994; Whalley et al. 1998; Pinnock et al. 2004 ). This intriguing 
phenomenon provides the overall motivation for the present PhD project. The multiple 
aspects associated with this unique situation will be discussed later in this chapter. 
1.2.3 Geography 
In the USA, the highest occurrence of kidney stones occurs in the south while the lowest 
occurs in the west (Boyce and Strawcutter 1956; Prince and Scardino 1960). It is suggested 
that the higher incidence may be due to a higher rate of hypertension in the south and certain 
dietary habits, particularly lower intake of magnesium and low use of calcium supplements 
(Boyce and Strawcutter 1956). In the South Eastern Stone Belt (South Eastern United States), 
the incidence of stone disease has been reported to be higher than elsewhere in the USA 
(Boyce and Strawcutter 1956; Prince and Scardino 1960; Blacklock 1982). This high 
incidence could be due to high atmospheric temperatures which lead to dehydration through 
sweating. This trend is also reported in Australia (Blacklock 1982), Europe (Blacklock 1982: 
Schwille and Hermann 1987: Decoster eta!. 2002), Asia (Balla et al. 1 998) and Saudi Arabia 
(Robertson 1999) and is even more pronounced during the hot summer time than in winter 
(Pak 1991: Balla et al. 1998; Kamoun et a!. 1999; Bennani et a!. 2000; Decoster et a!. 2002). 
In some regions of Africa e.g. Nigeria (Esho 1978: Olapade-Olaopa et a!. 2004), Southern 
Sudan (Kambal et al. 1981 ), Tanzania (Mkony et a!. 1991) and South Africa (with racial 
differences (Modlin 1967; Whalley eta!. 1998; Pinnock et al. 2004)) the occurrence of stones 
is extremely rare. However, there are other African countries such as Cameroon (Angwafo et 
al. 2000), Algeria (Han·ache et a!. 1997) and Egypt (Loutfi et al. 1 978) in which endemic 
bladder stones occur in the black population. In Northern Sudan (Ibrahim 1978: Kambal et al. 
1981) and Kenya (Clennon et al. 2004; King et al. 2004) a prevalence ofCaOx upper urinary 
tract is reported. 
1.2.4 Climate 
People who are exposed to hot sunny climates (e.g. people in the geographic areas discussed 
above and those who live in desserts) are generally susceptible to CaOx urolithiasis 
(Robertson et al. 1974: Hallson and Rose 1976: Blacklock 1982). Hot sunny climates 
adversely influence some of the main urinary risk factors (Robertson and Peacock 1983) such 
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as low urinary volume and pH which result from excessive loss of liquid through sweating 
(Sch~ille and Herman 1 1987). Another risk factors which is adversely affected in hot 
climates is urinary calcium excretion. An increase in urinary calcium can occur as a result of 
prolonged exposure to ultra-violet radiation (vitamin D) which subsequently leads to 
increased intestinal calcium absorption (Robertson et al. 1980: Broadus et al. 1984 ). 
1.2.5 Diet 
Diet is a highly important epidemiological factor which can significantly influence urine 
composition. The multiple aspects of diet in the pathogenesis of urolithiasis are fully 
discussed in Section 1.6. 
1.2.6 Geneticfactors 
CaOx stone disease has been reported to be a polygenic disorder (Goodman et al. 1995). This 
is supported by studies by Curhan et al. ( 1997) and Mente et al. (2006) which reported an 
increased risk of stone formation in first-degree relatives of kidney stone formers. Studies in 
South Africa have also revealed that cystine stones (inherited stones) and struvite stones are 
very rare in the black population compared to their white counterparts (Abdel Goad and 
Bereckzy 2003: Pitmock et al. 2004). 
1.3 MECHANISM OF STONE FORMATION 
There are several maj or fundamental physicochemical mechanisms involved in stone 
formation. These include supersaturation, nucleation, crystal growth and aggregation (Hess 
and Kok 1996: Khan and Kok 2004 ). 
1.3.1 Supersaturation 
Supersaturation is the first and the most essential step in crystallization which eventually 
leads to stone formation. It is the thermodynamic driving force that occurs when there is a 
phase change from liquid to solid and it is a representation of excess free energy between the 
two phases (Finlayson 1978: Hess and Kok 1996: Kmanagh 2006 (a)). This driving force or 
free energy (~G) is given by the equation: 
~G=RTln(A/Aeq) 
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where R is the gas constant, T is the temperature, A is the activity of the unionized salt in the 
supersaturated solution and Aeq is the activity of the solution at equilibrium (Finlayson 1978; 
Hess and Kok 1996; Kavanagh 2006 (a), (b)) . The supersaturation ratio, (A I Aeq), is referred 
to as the relative supersaturation (RS). When RS < 1, the solution is said to be undersaturated 
and any stone forming salts that are present can freely dissolve. When RS = 1, the solution is 
saturated. In such a case, salts which are already present will not dissolve while new salts will 
not form. At RS > 1, the solution is supersaturated. In this situation, existing crystals may 
grow (Finlayson 1978; Hess and Kok 1996, Coe et al. 2005). Researchers have reported that 
urine from stone formers tends to be more supersaturated than those of non-stone formers 
(Robertson et al. 1968; Marangella et al. 1985: Coe and Favus 1986: Kok and Papapoulos 
1993). Contrary to this, other researchers (Robertson et al. 1968: Ryall 1993; Hess and Kok 
1996: Kavanagh 2006 (a)) have reported that some people who have never formed a stone 
nonetheless pass highly supersaturated urine. Supersaturation, therefore is insufficient to 
explain the occurrence and formation of stones (Robertson et al. 1968: Kok and Papapoulos 
1993: Ryall 1993). 
1.3.2 Crystal Nucleation 
Nucleation is the initial kinetic step that allows phase transformation from liquid into a solid 
phase in a supersaturated solution (Finlayson 1978: Brown and Purich 1992: Kok and Khan 
1994). The initial step in this process is the coalescence of stone forming salts in solution into 
loose clusters that may increase in size due to the addition of new clusters (Boskey 1981: Kok 
and Khan 1994 ). Gradually, these clusters become crystal embryos with all the already 
developing nuclei (Kok and Khan 1994). 
Aqueous solutions of CaOx can remain crystal-free even when RS values lie between 
80 and 100. Such solutions are referred to as being in the zone of metastability (Hess and Kok 
1996). When the solution surpasses the upper limit of metastability, the solution rapidly 
becomes unstable, and new crystals are spontaneously formed. This process of spontaneous 
formation of new crystals is called homogeneous nucleation (Hess and Kok 1996). The 
supersaturation that is required for homogeneous nucleation is much higher than the 
equilibrium saturation but can be reduced by foreign particles which act as nucleation 
catalysts. Heterogenous nucleation occurs in the presence of foreign impurities and is thought 
to be the most common and frequent process in stone formation as most stones consist of 
mixtures of more than one type of crystals and a mixture of proteins (Hess and Kok 1996). 
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Many urinary macromolecules act as heterogeneous nucleators of stone formation, in whose 
presence crystal precipitation takes place at lower RS values (Hess and Kok 1996). 
1.3.3 Crystal Growth 
The incorporation of crystal components into an already formed CaOx crystal nucleus is 
termed crystal growth (Hess and Kok 1996). This occurs once a crystal nucleus has achieved 
its critical size and RS always remains above 1 (Kavanagh 2006 (a)) . In order for crystal 
growth to occur, the newly formed crystal in the urine has to migrate through the solution and 
attach to the surface of the existing crystals. This process is called adsorption (Brown and 
Purich 1992; Hess and Kok 1996). 
Precipitation of CaOx crystals might not pose a problem as long as the formed crystals can 
pass freely through the urinary tract. The normal transit through the kidney is not long 
enough for crystals to grow to size range in which can be trapped in the renal tubules. 
However, once these crystals are retained and become too big to pass freely through the renal 
tubules they disturb the urinary flow. Crystal growth is therefore considered important in 
stone formation because, unless the crystals grow to a very sufficient size, they will not form 
a stone (Finlayson et aL 1984; Kok and Khan 1994 ). The rate at which crystal growth takes 
place is also dependent on supersaturation (Kavanagh 2006 (a). (b)) . 
1.3.4 Crystal Aggregation 
Crystal aggregation is the process by which several particles in solution stick together to form 
larger particles (Hess and Kok 1996). Aggregation of larger particles is energetically 
favoured and can therefore occur in all states of saturation (Kok and Khan 1994; Hess and 
Kok 1996). It is achieved through several basic forces, which have opposing effects 
(Finlayson 1978; Robertson et al. 198 L Hess 1991; Kok and Khan 1994). The attractive van 
der Waals force favours particle aggregation and increases strongly when interparticle 
distances are very small. Zeta potential is the repulsive electrostatic force that favours 
disaggregation of crystalline particles. Curreri et al. ( 1979) reported that in water, COM 
crystals have a zeta potential of + 20 m V; whereas in urine zeta potential becomes negative 
due to the adsorption of negatively charged urinary molecules such as citrate and 
macromolecules (Finla) son et al. 1984). These negative charges set up repulsive forces 
which retard aggregation. 
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Several researchers believe that crystal aggregation is the most important factor for kidney 
stone formation (Meyer et a!. 1971; Blomen 1982; Finlayson and Reid 1978; Iv, ata et a!. 
1985). This is due to the fact that CaOx crystal growth alone may be too slow to produce 
clinically significant particles within the time that urine passes through the renal tubules, 
whereas aggregation occurs within seconds. In addition to this, microscopic and 
ultrastructural analyses of kidney stones have revealed that stones are highly aggregated 
structures (Meyer et al 1971; hvata et a!. 1985 ). Interestingly, urine from stone-formers 
contains more aggregated crystals whereas that from healthy subjects has less aggregated 
particles (Kok and Khan 1994). 
1.4 INlllBITORS OF CALCIUM OXALATE CRYSTALLIZATION 
The process of stone formation discussed in the previous pages is counteracted by inhibitors 
of CaOx crystallization 1 Hess and Kok 1996 ). 
Inhibitors of calcium oxalate crystallization are classified into two categories: macro-
molecules and rnicromolecules. Macromolecules such as glycosyaminoglycans (GAGS) and 
proteins such as nephrocalcin (NC), Tarnm-Horsfall protein (THP), albumin, urinary 
prothrombin fragment- ! (UPTFl ), bikunin, crystal matrix extract protein (CME) and 
osteopontin (also called uropontin; OPN) are discussed below. Micromolecules (citrate, 
magnesium and pyrophosphate) will be discussed under urinary risk factors (Section 1.5). 
1.4.1 Glycosyaminoglycans (GAGS) 
GAGs are long unbranched polysaccharides consisting of a repeating disaccharide unit. The 
disaccharide unit consists of an N-acetyl-hexosarnine (amino sugar) and a hexose or 
hexuronic acid, either or both of which may be sulfated. Both constituents are linked together 
by a glycoside bond. The combination of the sulfate group and the carboxylate groups of the 
uronic acid residues gives them a very high density of negative charge (Nishio et a!. 1985; 
Roberts and Resnick 19X6). 
The well-known urinary GAGS are heparan sulphate (HS), chondroitin sulfate (CS), 
dermatan sulphate (DS), keratan sulphate (KS), and non-sulphated hyaluronic acid (HA). 
Some of these are found in urinary crystals and stones but it is not clear whether this selective 
inclusion is due to differences in excretion rate or calcium affinity for calcium salt crystals 
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(Khan and Kok 2004 ). GAGS generally inhibit CaOx crystal growth, aggregation and 
nucleation (Koide et al. 1981; Sallis et al. 1981; Ryall and Marshall 1984: Breslau et al. 
1994 ). HS has been reported to have the highest inhibitory potential followed by CS and HA 
(Sidhu et al. 1986: Khan et al. 1988; Kok et al. 1988: Ryall et al. 2001; Lieske et al. 1995; 
Verkoelen et al. 1996: Khan et al. 2000). 
There are contradicting reports on the excretion levels of GAGS by stone-formers and 
healthy individuals. Some studies report a decreased excretion by stone formers (Conte et al. 
1989: Michellacci et al 1989: Shum and Gobel 1993: Akcay et al. 1999) whereas others 
show an equal excretion by both stone formers and non-stone formers (Samuell 1981; 
Fellstrom et al. 1986; Akinci et al. 1991; Trinchieri et al. 1992: Harangi et al. 1996). 
However, Erturk et al. (2002) found that GAGS from stone formers had an increased 
nucleation promoting activity. 
1.4.2 Urinary proteins 
Crystal Matrix Protein Extract (CME) 
The discovery of an organic component of kidney stones called the crystal matrix dates back 
to 1684 when Von Hyde discovered that stones have an organic framework composed mainly 
of selectively incorporated proteins generally characterized by high glutamic and aspartic 
acid content and y-carboxyglutamic acid (Butt 1956: Binette et al. 1996). In general, urinary 
stones contain about 2-5 %organic matrix (Boyce and Garvey 1956: Stacholy and Goldberg 
1985) and reports by Boyce (1968) have demonstrated that 67 % of this matrix is protein. 
In 1987, Khan and Hackett (1993) had demonstrated that the organic matrix becomes 
closely incorporated in the crystals during the early stages of crystal formation. Prior to this 
report, Morse and Resnick ( 1988, 1989) had identified proteins incorporated in CaOx crystals 
induced in human urine and they found that this process is a selective phenomenon. 
The theory of urinary protein inclusion and adsorption into CaOx crystals was also 
tested by Khan and co-workers using transmission electron microscopy (Khan et al. 1988). 
Their results showed that proteins have a strong affinity for CaOx crystals. They also 
discovered that adsorption of anionic proteins was sensitive to calcium ion concentration 
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whereas cationic protein adsorption depended upon the oxalate ion concentration (Khan et al. 
1988). 
The effect of CME on CaOx crystallization has been tested in undiluted urine (Koide 
et al. 1981; Doyle et al. 1995: Sorensen et al. 1995). From these studies it was reported that 
CME inhibits CaOx crystal growth and aggregation. 
Researchers have investigated and identified several proteins associated with CME. 
These include THP (Doyle et al. 1991 ); albumin (Ryall et al. 1991: Cerini et al. 1999), 
nephrocalcin (Hess et al 1989; Worcester 1996), UPTF1 (Ryall et al. 1997), inter-a-inhibitor 
(Atmani et al. 1996: Dean et al. 2000) and OPN (Worcester 1996: Asplin et al. 1998: Ryall et 
al. 2005). Studies involving these individual proteins (rather than the composite mixture 
described in the previous paragraphs) are discussed below. 
Tamm-Horsfall Protein (THP) 
Tarnm-Horsfall Protein (THP) is the most abundant protein in normal human urine with a 
molecular weight of approximately 80 kDa. Its concentration in human urine varies between 
20 to 100 mg/day (Khan and Kok 2004). THP exists in a monomeric state but tends to self-
aggregate to a polymeric form in the presence of increased concentrations of free calcium, 
magnesium, sodium and at low pH. Inhibition or promotion of CaOx crystallization is 
influenced by its state of aggregation. The aggregated form of THP is a poor inhibitor in this 
regard compared to the non-aggregated entity (Hess et al. 1989). 
Aggregation studies by Hess et al. ( 1989) have demonstrated that THP is a potent 
inhibitor of crystal aggregation by 50 % at urinary concentrations of 1 X 1 o-8 mol/L and this 
increases up 90 % at concentrations of 5 X 1 o-8 mol/L. THP isolated from urine from normal 
subjects has been shown not to be significantly different in terms of concentration from the 
one isolated from stone formers but structurally the latter contains less carbohydrates (sialic 
acid) (Hess et al. 1995 (a)). The less sialic acid content in THP from stone formers makes it a 
poor inhibitor ofCaOx crystallization (Hess et al. 1995 (a)) . 
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Albumin 
Albumin is the second most abundant protein in urine (Boyce and Garvey 1956; Fraij 1989). 
It has been detected in the crystal matrix (Atmani et a!. 1998, 2002) derived from whole 
human urine and also from urinary stones (Boyce 1968: Fraij 1989). The daily excretion of 
albumin by healthy humans ranges from 1.6 - 34.2 mg/day. In solution albumin is known to 
exist either in monomeric or polymeric forms and in metastable CaOx solutions both forms 
promote nucleation of CaOx crystals (Cerini et a!. 1999). On the other hand, it has been 
shown that albumin binds to CaOx as well as to uric acid crystals and inhibits CaOx crystal 
aggregation and growth (Worcester 1994; Dussol et a!. 1995: Hess et a!. 1995 (a); Grover et 
a!. 1998). According to a study by Cerini et al. ( 1999), nucleation by albumin leads 
exclusively to COD crystal formation which is less adherent to renal epithelial cells and this 
might be a protective feature by albumin against COM crystal formation. 
Urinary Prothrombin Fragment-] (UPTFJ) 
A study conducted by Doyle et al. ( 1991) showed that UPTF1 is the principal protein of the 
organic matrix of CaOx crystals induced in human urine. It was originally called crystal 
matrix protein (CMP) because it was the first protein to be identified in the organic crystal 
matrix. Studies conducted later with CMP showed that its N-terrninus was identical to that of 
UPTF1, leading to the conclusion that it was the urinary form of prothrombin F1 (Stapleton et 
a!. 1993). UPTF1 has a molecular weight of 31 k:Da and when subjected to a series of 
cleavages it releases fragments which include fragment 1 (F1) and fragment 2 (F2) or a 
combination of both F1 + F2. The daily urinary excretion of UPTF1 is 13.4 nmol/L (Bezeau 
et al. 1984). In pregnant women it increases to 47.2 nmol/day. UPTF1 is located in the 
ascending limb of the loop of Henle in the human kidney and is present in greater quantities 
in stone formers compared to healthy controls (Stapleton et al. 2000). It also occurs in CaOx 
stones (Hoyer 1994; Stapleton eta!. 2000). 
The inhibitory capability of UPTF1 rests in the presence of 10 y-carboxyglutamate 
(Gla) residues which contribute to the inhibition of CaOx crystal growth and aggregation by 
virtue of their calcium-binding affinity (Grover and Ryall 2002: Webber et a!. 2002). The 
protein contains about 154 amino acids and 23 % are glutamic and aspartic acids and 10 of 
the carbonic acids are y-carboxylated (Grover and Ryall 2002) which also play a role in its 
calcium affunity. 
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Bikunin 
Bikunin, also known as Inter-a-Trypsin Inhibitor (ITI) is a member of the I a I family which 
is a group of plasma protease inhibitors (Hochstrasser et al. 1976; Enghild et al. 1989; Salier 
et al. 1996) composed of a combination of heavy chains with molecular weights of 60 kDa 
(H1), 70 kDa (H2) and 90 kDa (H3) which are covalently linked to a light chain with a 
molecular weight of 35 - 45 kDa. Numerous investigators have reported different 
concentrations of bikunin in normal human urine: 0.225 - 0.650 J..Lg/ml (Dean et a!. 2000), 
5.01 ± 0.91 J..Lg/ml (Medetognon-Benissan eta!. 1999), 10.13 ± 1.13 J..Lg/ml and 6.72 ± 0.93 
J..Lg/ml in healthy men and women respectively (Nishio et al. 2001 ), 4.82 ± 2.46 mg/day and 
3.86 ± 1.35 mg/day in healthy men and women respectively (Usui et al. 1984) and 17.5 
mg/day (Kobayashi et a•. 1998). It is even more increased in the urine of patients with renal 
disease (Suzuki et al. 1999; Khan and Kok 2004). Contrary to this, (Medetognon-Benissan et 
al. 1999) have reported that the concentrations are higher in healthy controls (5 mg/L) than in 
stone formers (2.54 mg/L). Of interest is the study by Atmani et al. (1994) who demonstrated 
that bikunin isolated from kidney stone patients contains less sialic acid than that purified 
from the urine of healthy subjects and that it inhibits crystallization to a lesser extent. These 
results were subsequently supported by a study conducted by Medetognon-Benissan ( 1999). 
Many investigators have shown that ITI is an inhibitor of CaOx crystallization 
(Atmani et al. 1993 (a), (b), 1994; Kobayashi et al. 1998; Atmani and Khan 1999; 
Medetognon-Benissan 1999; Dean et al. 2000). Bikunin has also been shown to inhibit CaOx 
crystal adhesion to renal epithelial cells at minimum concentrations of 1 0 ng/ml and 
completely blocked it at 200 ng/ml (Ebusino et a!. 1999). 
Nephrocalcin (NC) 
Nephrocalcin is a glycoprotein with a molecular weight of 14 kDa (Coe et al. 1994). 
However, it has a tendency to polymerize into dimers, trimers and tetramers with varying 
molecular weights of 23-30, 45-48, 60-68 kDa respectively (Nakagawa et al. 1983, 1985. 
1987). Several studies have shown that NC inhibits growth, aggregation and nucleation of 
CaOx crystals at urinary concentrations of 10-6 to 10-8 mol/L (Nakagawa et aL 1983, 1985: 
Asplin et al. 1991; Coe et al. 1991; Tiselius et a!. 1995: Worcester 1996). This inhibition 
may be attributed to electrostatic repulsive forces created when NC binds to CaOx crystals 
and the presence of glutamic and aspartic acid which have a high affunity for calcium 
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(Nakagawa et al. 1983 ). NC also inhibits binding of COM crystals to epithelial cells (Lieske 
and Toback 1993). Nakagawa et al. (1983, 1985) reported that NC isolated from the urine of 
stone formers did not contain the Gla residues and thus showed less inhibitory activity 
towards COM crystal formation. 
Osteopontin (OPN) 
Osteopontin (OPN), also known as uropontin (when isolated from urine), is a multifunctional 
noncollagenous phosphoprotein that was originally isolated from mineralized bone matrix. It 
has a molecular weight which varies from 44 to 75 kDa (Malyankar eta!. 1997). This huge 
variation in molecular weight is assumed to be due to differences in glycosylation and 
phosphorylation (Denha ·dt and Guo 1993 ). It is synthesized within the kidney and is detected 
in the thick and thin ascending limb of the loop of Henle and distal convoluted tubules 
(Kleinman et al. 2004). OPN exists as a monomer but may also form aggregates which 
appear at very high molecular weights of 120 - 150 kDa (Johnson-Tardieu et al. 2000, 
Webber et a!. 2003). It undergoes considerable post-translational modification and is easily 
phosphorylated and glycosylated (Denhardt and Guo 1993: Mazzali et al. 2002). 
OPN contains about 50 % of glutamic and aspartic acid residues which easily bind to 
calcium (Franzen and Heinegard 1985: Chen et a!. 1992: Denhardt and Guo 1993: Hunter et 
a!. 1996) and as such, may have an inhibitory role in CaOx crystallization as proposed by 
Kohri et al. ( 1990). On the other hand, some researchers have proposed that OPN promotes 
stone formation, by supporting attachment of CaOx crystals to tubular cell membranes (Kohri 
et al. 1993: Yam ate et a!. 1998) via its arginine-glycine-aspartic acid sequence (Kohri et a!. 
1990). This sequence is referred to as RGD, where each symbol specifically represents the 
respective amino acids. Contrary to this, some researchers have reported that OPN blocks 
COM crystal adhesion to renal tubular cells (Lieske et al. 1999: Kumar et a!. 2003). The 
differences in the potency of OPN from stone formers and healthy controls in CaOx 
crystallization is still unclear (Kleinman eta!. 2004 ). 
The mean OPN excretion for normal humans varies between 2.4 and 3.7 mg/day 
(Chalko et a!. 1992) but it has also been reported as being as low as 1.9 Jlg/ml (Min et a!. 
1998). Studies by Nishio et al. (200 1) reveal that stone formers excrete less OPN than stone 
free people, presumably due to the incorporation of OPN in the growing stone crystals. In 
their respective studies, Worcester et al. (1995) and Asplin et al. (1998) have demonstrated 
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that OPN is a potent inhibitor of CaOx crystal nucleation, growth and aggregation. On the 
other hand Wesson and co-workers have reported that OPN promotes crystallization of COD 
in preference to COM (Wesson et al. 1998), but they make the point that crystals of the 
former type have a lower affinity for renal epithelium cells than COM crystals, thereby 
leading to the prevention or minimization of kidney stone formation. 
In a very recent study investigating the selective inclusion of proteins in CaOx 
crystals, OPN was found to be the main intracrystalline protein in COD crystals (Ryall et al. 
2005). This contradicts the report by Hoyer (1994) that OPN was found in COM stones 
(with very low concentrations in COD stones). 
General Comment 
As mentioned earlier, kidney stones are extremely rare in the South African black population. 
The Kidney Stone Research Laboratory at the University of Cape Town (of which the author 
of this thesis is a member) has investigated several urinary proteins in this context. These 
include UPTFl (Durrbaum eta!. 2001: Webber et al. 2002), Tamm-Horsfall Protein (Craig et 
a!. 1999. 2000. 2001 ), albumin (Rodgers et al. 2006) and bikunin (Mabizela 2006). Details of 
these investigations are provided in section 1.8 of this thesis. In the present PhD project, an 
investigation into the relative effects of crystal matrix extract and osteopontin was undertaken 
as one of several objectives to gain insights into the mechanisms by which the South African 
black population attains protection against kidney stone formation. The objectives themselves 
are described in Section 1.9. 
1.5 URINARY RISK FACTORS 
Urinary risk factors (also known as biochemical risk factors) are regarded as being the main 
determinants of CaOx crystallization (Robertson et al. 1978: Finlayson et al. 1984: Hess et al. 
1996). They are measured in 24 hour urine samples and are calcium, citrate, magnesium, 
oxalate, uric acid, phosphate, pH and volume. Each of these is discussed below. 
1.5.1 Urinary calcium 
An abnormally high urinary calcium excretion (hypercalciuria) is one of the most important 
factors that contribute to a high supersaturation of both CaOx and CaP. Most researchers 
have reported a normal upper limit of 7.5 mmol per 24 hours for calcium for men and 6.25 
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mmol per 24 hours for women or 0.10 mmollkg body weight (for both men and women) 
(Breslau 1994: Jaeger 1998). Once the 24 hour calcium excretion reaches 10 mmol, there is 
an increase in the risk of stone formation (Robertson eta!. 1978). 
Pak ( 1981) and Buck ( 1990) reported three different types of hypercalciuria in stone 
formers namely absorptive (idiopathic), renal and resorptive. Idiopathic hypercalciuria is the 
most common form and is caused by an overproduction of 1 ,25-dihydroxy-vitamin D3 
[1 ,25(0H)2D3] which controls the transportation of calcium ions through the intestinal cell. 
Patients with idiopathic hypercalciuria absorb more calcium from food than healthy 
individuals and this leads to high serum levels of calcium which in turn leads to high urinary 
calcium (Buck 1990: Bres1au 1994: Jaeger 1998: Parmar 2004: Coe et a!. 2005). Renal 
hypercalciuria occurs as a consequence of impaired renal tubular absorption of calcium 
(Parmar 2004: Coe et a!. 2005). This occurs in about 2 % of patients with recurrent stone 
formation. In resorptive hypercalciuria, increased bone resorption occurs as a result of 
primary hyperparathyroidism (excessive secretion of parathyroid hormone, PTH) (Pak et al. 
1974: Stewart et a!. 1982: Mollerup et al. 2002). The major action of PTH is to mobilize 
calcium from bone, conserve calcium in the kidney and indirectly increase gastrointestinal 
calcium absorption. Increased PTH levels induce hypercalciuria. This is observed in about 5 
%of patients with recurrent stone formation (Mollerup eta!. 2002: Parmar 2004). 
Dietary calcium is not the only determinant of urinary calcium excretion. Numerous 
studies have reported that a high sodium intake is associated with increased urinary calcium 
excretion (Shortt and Flynn 1990: Massey and Whiting, 1996). This is due to an intimate 
association between renal tubular mechanisms involved in the reabsorption of calcium and 
sodium ions (Walser 1961: King et al. 1964: Kleeman eta!. 1964: Modlin M 1966: Massry et 
al. 1968: Willis et al. 1969, Matkovic et al. 1995). 
1.5.2 Urinary citrate 
The association of citrate with calcium stone disease had been reported since 1934 when it 
was discovered that citrate and calcium form a soluble complex of calcium citrate. By 
complexing with calcium, citrate lowers the calcium activity which in turn lowers the ion-
activity of both CaOx and CaP. Numerous studies have reported urinary citrate to be an 
inhibitor of CaOx and CaP crystal nucleation, growth and aggregation (Meyer and Smith 
1975: Sur and Pandey 1981: Hallson eta!. 1983: Kok et al. 1986: Nicar et al. 1987: Pak 1987: 
Chapter 1 17 
Tiselius et a!. 1990: Bek-Jensen and Tiselius 1991: Schwille et a!. 1999). Citrate is also 
known to bind to the CaOx crystal surface, and it is this property that probably explains its 
influence on both crystal growth and aggregation (Ryall 1997). This gives citrate the potential 
not to be just a calcium reducing agent, but also a crystal chelator. 
The 24 hour urinary excretion of citrate is between 0.6 and 3.5 mmol (Pak 1994: 
Hesse et a!. 1997: Tiselius 1997). Hypocitraturia (low urinary citrate excretion) has been 
reported to occur in calcium stone formers (Pak et a!. 1978: Nicar eta!. 1987). Administration 
of alkaline citrate is therefore recommended for stone formers as it increases urinary citrate 
thereby reducing the risk of forming stones. This aspect is discussed in detail in Section 1.6.6. 
1.5.3 Urinary magnesium 
The role of magnesium in CaOx urolithiasis was first suggested in 1932 when it was shown 
that renal calcification occurred in rats that were fed a magnesium deficient diet (Cramer 
1932). This finding was confirmed by Rushton and Spector ( 1982). In this study, rats were 
fed magnesium deficient food and intratubular calcium oxalate monohydrate deposits were 
observed within 24 hours after the administration. The control rats (on regular diet) did not 
display any renal tubular deposition (Rushton and Spector 1982). Urinary magnesium has 
been shown to decrease the incidence and recurrence of CaOx stone formation (Trinchieri et 
al. 1992). This is mainly due to its ability to form soluble complexes with oxalate thereby 
reducing the free oxalate in urine that could form an insoluble CaOx complex with calcium. It 
is this capacity of magnesium to chelate oxalate that makes it an inhibitor of CaOx 
crystallization. Urinary magnesium is also reported to shift the relationship between 
supersaturation and inhibitory activity towards a situation less favourable for crystal 
nucleation (Li et al. 1985), aggregation (Domerus et a!. 1978: Li et a!. 1985) and growth 
(R) all et al. 1981 ). 
There have been contradicting reports on unnary magnesium concentration differences 
between stone formers and healthy individuals. Several studies have reported that no major 
differences exist between the groups (Robertson et al. 1968: Welshman et a!. 1975: 
Robertson eta!. 1978) while others have revealed lower levels in stone formers than controls 
(Trinchieri eta!. 199L 1992). 
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1.5.4 Urinary oxalate 
Oxalate complexes with calcium in urine to form an insoluble salt of CaOx which is the most 
common stone-forming compound. Excessive oxalate in the urine (hyperoxaluria) is 
responsible for about 30 %of calcium stones (Bihl and Meyers 2001: Mente et al. 2006). The 
upper limit of 24 hour urinary oxalate excretion ranges from 0.4 to 0.5 mmol. Several studies 
have reported that patients with CaOx stones have a higher urinary oxalate excretion than 
normal subjects (Robertson et al. 1978: Schwille et al. 1989: Wilson et a!. 1989). However, 
other studies have not detected any differences (Osther eta!. 1993: Tiselius 1996: Holmes et 
a!. 1998). 
Hyperoxaluria may be due to various factors which include deficiencies in vitamin B6 
(Street1and and Donckerwolcke 1989: Curhan et a!. 1999) and Oxalobacter formigenes 
(Allison et al. 1986: Sidhu et a!. 1999) as well as short bowel syndrome (Khursheed 2002: 
Kato et al. 2003: Parnsh 2005). Severe vitamin B6 deficiencies (usually due to genetic 
disorders) can result in overproduction of oxalate (Street1and and Donckerwolcke 1989: 
Parrish 2005). Administration of Vitamin B6 reduces the production of oxalate from 
glycolate by enhancing the activity of alanine-glyoxylate transaminase, AGT (Danpure and 
Jennings 1986: Edwards and Rose J 991: Tommasso et a!. 2002). Alanine-glyoxylate 
transaminase inhibits this oxidation process and its activity depends on vitamin B6 (Danpure 
and Jennings 1986: Nishijima et al. 2003: Danpure 2003. 2005). When AGT is deficient, 
glycolate is oxidized to oxalate thus increasing the urinary oxalate and risk of CaOx 
crystallization (Danpure et al. 2003. 2005). Oxalobacter formigenes is an oxalate degrading 
bacterium and low levels in the intestine increase the risk for oxalate absorption and stone 
formation (Allison et a!. 1986: Sidhu et al. 1999). Short bowel syndrome is marked by 
malabsorption which is the inability of the intestines to absorb fat and nutrients properly 
(Earnest et al. 1974). In cases of malabsorption, calcium may bind to unabsorbed fat instead 
of oxalates. This results in excess oxalate being absorbed by the intestines and eliminated 
through the kidneys (Dobbins and Binder 1976). 
Urinary oxalate is the most powerful determinant of the ion activity product of CaOx. Very 
small increments of oxalate lead to pronounced changes in supersaturation and crystallization 
(Finla; son 1978: Robe1ison et al. 1981: Tiselius 2000). It is therefore advisable for kidney 
stone-formers to reduce their oxalate intake. 
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1.5.5 Urinary uric acid 
Hyperuricosuria plays a major role in uric acid stone formation and may be related to three 
factors such as low urinary volume, urinary pH less than 5.5 and over-production of uric acid 
(Coe 1983). Uric acid is the end product of purine (animal protein) metabolism which can be 
derived from dietary sources such as meat and fish or endogenous production during cell 
turnover. Therefore dietary intake of foods rich in purine should be avoided to prevent 
recurrence of uric acid stones (Coe 1978). Hyperuricosuria may be of pathological 
importance in calcium containing oxalate stones, because uric acid crystals tend to act as a 
crystal nucleus, around which calcium oxalate crystals precipitate and grow. Indeed, it occurs 
in 20 % of calcium oxalate stone formers resulting in uricosuric calcium oxalate syndrome 
(Coe and Kava1ach 1974: Coe 1978, 1983). 
Allopurinol therapy has been reported to be very effective in reducing uric acid and 
CaOx stone formation since it blocks the uric acid production and purine absorption (Pak et 
al. 1978: Ettinger 1991 ). 
1.5.6 Urinary phosphate 
Urinary phosphate is directly dependent on the type of diet ingested and is subject to huge 
variations. It is of great importance in establishing the degree of CaP crystallization (Kok et 
al. 1988). A normal urinary excretion of phosphate is 35 mmol/day (Hesse et a!. 1997). With 
elevated urinary phosphate concentrations, there is an increased risk of CaP crystallization 
especially if hypercalciuria is present. However, it is of great importance in inhibition of 
CaOx crystallization ( Schwille 1989: Baumann et al. 2001) for it binds to calcium resulting in 
reduced complexation of calcium and oxalate. 
1.5. 7 Urinary pyrophosphate 
Urinary pyrophosphate has been reported to inhibit CaOx crystal nucleation and aggregation 
(Robertson et al. 1973: Meyer and Smith 1975: Ryall 1997). This inhibitory effect is 
attributed to its potential to irreversibly bind to CaOx crystal surfaces (Ryall 1997). The 
other main inhibitory feature of urinary pyrophosphate is its capacity to retard and prevent the 
growth of COM while promoting that of COD crystals (Wikstrom et al. 1983). As stated 
earlier, this is of great pathological importance since COD crystals are less adherent to renal 
Chapter 1 20 
epithelial cells than COM crystals. Pyrophosphate excretion has been reported to be 
significantly reduced in stone formers compared to healthy controls (Fleish and Bisaz 1962: 
Wikstrom et a!. 1983 ). 
1.5.8 Urinary pH 
Urinary pH is one of the most important determinant factors of the ion-activity product of 
CaP (Tiselius 2003). It also has an effect on CaOx crystallization. Two individual studies by 
Kohri et al. ( 1993) and Pak: ( 1994) have reported that a high urinary pH reduces the risk of 
CaOx crystallization. An explanation to this is that at a higher pH, more phosphate and citrate 
ions are dissociated which in turn increases the complexation of calcium and citrate ions 
thereby reducing the urinary saturation of CaOx (Pak 1994: Hesse eta!. 1997). However, the 
risk of CaP crystallization is concomitantly increased, especially if hypercalciuria is present 
(Tiselius and Larsson 1992). This was also demonstrated in a study by H0jgaard et al. ( 1999) 
in which CaP crystals were precipitated at a pH of 6.45 and no CaOx crystals were formed. 
A separate study by Hess (Hess 2006) demonstrated that low urinary pH values may 
be associated with abundant uric acid crystallization and that subsequent stone formation 
involving this substance can occur. As reported by Hess, the majority of pure uric acid stone 
formers exhibit a low urinary pH as the main cause of stone formation. Prior to this report, 
two separate studies by Pak: et al. (2002) and Tiselius (2003) involving uric acid stone 
patients and healthy controls demonstrated that the former had significantly lower values of 
urinary pH. It is therefore advisable to maintain the urinary pH between 6 and 7 because this 
range exhibits high inhibition of CaOx crystallization and uric acid stone formation. 
A recent study by Rodgers et al. (2005) has shown that the formation of a calcium-
citrate-phosphate is favoured as the pH increases. This reduces the amount of free unbound 
calcium which would otherwise be available to combine with oxalate. The study therefore 
supports the finding that an increase in pH reduces the urinary saturation of CaOx (Pak 1994: 
Hesse et al. 1997). 
1.5.9 Urinary volume 
Urinary volume is yet another extremely important determinant of stone formation. A high 
volume of urine helps to reduce the relative supersaturation of the crystal components. In 
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addition to this, high urinary volume indicates high urine flow rate which in turn tends to 
wash out any crystals that have formed, thereby reducing the risk of crystal-cell adhesion 
(Borghi et al. 1996). High fluid intake (usually water) is therefore routinely recommended for 
kidney stone patients (S rauss et al. 1982; Pak et al. 1980; Curhan et al. 1998). Some studies 
encourage urinary outputs in excess of three liters per day (Sakhaee et al. 1987; Menon and 
Resnick 1999). 
The significance of increasing unnary volume on kidney stone reduction was 
demonstrated in a randomized clinical trial conducted by Borghi et al. (2002). In this study, 
stone recurrence occurred in only 12 % of the 99 patients who maintained a urinary volume 
of about 2.6 L/day over five years. However, stones recurred in 27 % of the 100 patients in 
the control group, whose urinary volume was about 1.2 Llday. 
Apart from water, other fluids can be safely consumed and are associated with a 
positive effect. A study conducted by Curhan et al. ( 1998) demonstrated that caffeinated and 
decaffeinated coffee, tea and wine were significantly associated with a lower risk of kidney 
stone formation whereas grapefruit was associated with a higher risk. This study was 
supported by other researchers who showed an inverse association of coffee and tea with the 
risk of stone formation (Shuster et al. 1985; Krieg 2005 ). 
1.6 DIET AND SUPPLEMENTS 
Diet can significantly affect urinary composition. As such, certain foods and supplements 
may be lithogenic whereas others may be protective. Some of the most important of these in 
both categories are dietary calcium, salt and phytate and supplemental citrate and 
bicarbonate. These will be discussed in detail in the following paragraphs. 
1.6.1 Dietary Calcium 
Dietary intake and urinary calcium excretion are the most important determinants of calcium 
retention in the body (Nordin and Marshall 1998). Low calcium intake and high losses of 
calcium in urine could reduce calcium distribution into bone (Matkovic et al. 1995). In the 
past there used to be contradicting reports on the effect of dietary calcium on CaOx 
urolithiasis. Some researchers believed that high dietary intake of calcium increases the risk 
of forming kidney stones (Robertson et al. 1981; Breslau 1994 ). Robertson (1999) also 
Chapter 1 22 
reported that one of the most common and effective recommendations given to calcium stone 
formers is to reduce the intake of calcium. 
Contrary to these reports, several studies showed that a reduction in calcium intake 
not only increases the risk of calcium stone formation, but also causes a negative calcium 
balance and further loss of bone tissue (Coe et al. 1992: Curhan et al. 1993: Curhan 1999: 
Lemann 2002). In their two separate studies, Curhan and his team (Curhan et al. 1993. 1997) 
revealed a 34 % lower incidence of kidney stone formation in subjects with a high intake of 
calcium compared to others with a low intake. These studies are in agreement with a recent 
study by Heller et al. (2003) which reported that a high calcium diet conferred an alkali load 
that led to an increase in urinary pH and citrate. Besides having a beneficial effect on CaOx 
saturation, it also significantly decreased the urinary saturation of CaP in this study. Curhan 
et al. (2004) also discovered that in previously non-stone forming younger women, higher 
intake of dietary calcium was inversely related to the risk of stone formation. 
Low dietary calcium has long been recognized as an enhancer of oxalate absorption in 
the gut and subsequent excretion in the urine (Epstein 1968: Marshall et al. 1972). Recent 
studies have confirmed this (Menon and Resnick 1999: Lemmm 2002). Therefore, a decrease 
in calcium intake without a concomitant decrease in oxalate intake leads to increased urinary 
oxalate which subsequently leads to a high risk of stone formation (Hughes and Norman 
1992: Liebman and Chai 1997). In addition, dietary restriction of calcium in stone formers 
increases their risk of bone loss whereas adequate calcium intake is required for the constant 
process of bone resorption and formation (Shortt and Flynn 1990: Nordin et al. 1991 ). 
In the light of these reports, it is therefore recommended that calcium stone patients 
consume dietary calcium within the Recommended Daily Allowance of 1,000 to 1,200 
milligrams daily with a well-maintained dietary intake of sodium and animal protein. 
1.6.2 Dietary Protein 
An increase in protein consumption has been reported to cause an increase in urinary calcium 
excretion (Robertson e al. 1980: Kerstetter et al. 2003 ). Robertson ( 1999) demonstrated a 
significant increase of 23 % in urinary calcium after an increase in animal protein intake to 34 
g/day. This study also reported an increase in urinary oxalate. This finding was also 
supported by a recent study by Massey (2005 ). It was reported that a 10 gram increase in 
Chapter 1 
dietary protein increases urinary calcium by 16 milligrams, and doubling dietary protein leads 
to a 50 % increase in urinary calcium excretion (Massey 2005). This direct relationship 
between dietary protein and urinary calcium excretion is attributable to the proposition that 
dietary protein increases the endogenous acid production which subsequently leads to 
metabolic acidosis (Brok.is et al. 1982; Bailey JL 1998: Boirie et al. 2000). Metabolic acidosis 
results in bone calcium resorption and increased calcium excretion (Brokis et al. 1982). This 
suggests that high protein intake not only has a negative effect on CaOx urolithiasis, but also 
osteoporosis as well. 
As mentioned earlier, a high purine-rich animal protein intake results in high uric 
acid, high pH and low citrate excretion which in turn leads to a high risk of uric acid and 
CaOx stone formation (Coe 1978: Trinchieri et al. 1991: Curhan et al. 1993: Nguyen et al. 
2001 ). A recent study by Lemann (2002) reported that vegetarians form stones at one-third 
the rate of those eating animal protein. This is attributable to high urinary uric acid excretion 
following animal protein intake (Breslau et al. 1994 ). Conversely, vegetarian diets result in 
reductions in urinary uric acid ( Breslau et al. 1994 ). A study conducted on 18 hypercalciuric 
stone formers found that a 15-day protein restriction had positive effects on urinary stone 
formation risk factors (Gimmini et al. 1999: Krieg 2005). In this study, significant decreases 
in urinary calcium, uric acid, phosphate, and oxalate and a beneficial increase in urinary 
citrate were observed. 
1.6.3 Dietary phytate 
Several studies have reported that phytate is one of the most powerful inhibitors of CaP and 
CaOx crystallization (Graf and Eaton 1990) and thus prevents urolithiasis (Grases and March 
1989: Grases et al. 1994 (a) and (b), 1998,2000 (a) and (b)) . Normal human urine has been 
reported to contain approximately 2.5 mg/L of phytate, but it is significantly lower in the 
urine of stone formers (1.5 mg/L) (March et al. 1998: Grases et al. 1999). There is an 
important positive correlation between dietary intake and urinary excretion of phytate (Taylor 
and Curhan 2004 ). 
A clinical study conducted by Conte et al. (1989) on CaOx stone formers showed that 
even low consumption doses of phytate significantly reduced the risk of developing stones. 
The potency of phytate in reducing risk of stone formation rests in its calcium binding 
affinity (March et al. 1998: Grases et al. 2000 (a)). It has been shown that even at low doses 
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ofphytate, 1- 5% ofthe extra ingested phytate is excreted in urine (Grases et al. :woo (b)). 
The relationship between CaOx urolithiasis and phytate ingestion was supported by a 
comparative study by Grases et al. ( 1999) between healthy subjects and stone formers, who 
showed that the consumption of fibre which is rich in phytate is lower in stone formers. 
Modlin ( 1980) also reported that the dietary intake of phytate in the white South African 
population is lower than in their black counterparts. 
1.6.4 Dietary carbohydrates 
Several studies have reported that high carbohydrate intake results in increased urinary 
calcium excretion (Raskin et al. 1978: Wood and Allen 1983: Iguchi et al. 1993: Coe and 
Parks 1994: Taylor and Curhan 2004 ). Carbohydrates also stimulate endogenous synthesis of 
oxalate which is eventually excreted in urine ( Lekcharoensuk et al. 200 I ). With high urinary 
concentrations of calcium and oxalate, the risk of forming stone is more pronounced as these 
are the main urinary CaOx risk factors. A diet low in carbohydrates is therefore 
recommended for stone-forming individuals. 
1.6.5 Dietary Sodium Chloride 
The effect of dietary sodium in CaOx stone formation has been extensively studied by many 
researchers since the 1930s (Aub et al. 1937: Kleeman et al. 1964: McCarron et al. 1981: 
Breslau et al. 1982: Silver et al. 1983: Burtis et al. 1994 ). Dietary sodium is a well-known 
determinant of urinary calcium excretion (Burtis et a!. 1994) and reducing dietary salt 
(sodium) helps to reduce the amount of calcium in the urine, which in turn reduces the 
tendency for calcium stone formation (King et al. 1964: Muldov.ney et al. 1982: Shortt and 
Flynn 1990: Shortt et a!. 1998). It has been reported that each 100 mmol increase in daily 
sodium intake is associated with an approximate increase of 1 mmol in urinary calcium 
excretion (Nordin et al. 1993: Lemann et a!. 1999). As mentioned earlier, this positive 
correlation between sodium intake and urinary calcium excretion is due to an intimate 
association between renal tubular mechanisms involved in the reabsorption of these two ions 
(Matkovic et al. 1995 ). 
This fmding has been supported by a recent study which investigated the effect of 
dietary salt intake on bone turnover markers and CaOx kidney stone risk (Massey 2005). This 
study showed that a sodium chloride intake of 200 mmol led to an unfavourable increase in 
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urinary calcium and urinary oxalate. However, no changes in urinary magnesium and citrate 
were observed. 
According to a hypothesis developed by numerous researchers, the salt induced 
increase in urinary calcium causes a huge drop in plasma ionized calcium, which in turn 
stimulates parathyroid hormone (PTH) release (Goulding 1980: Goulding et al. 1986: Shortt 
and Flynn 1990: Evans et al. 1997). Increased PTH stimulates bone resorption which in turn 
releases calcium into the plasma and returns serum calcium to its physiologic level. 
An increase in dietary salt intake not only has an unfavourable effect on the risk of 
kidney stone formation but also influences bone loss which eventually leads to osteoporosis 
(Goulding and McParland 1990: Shortt and Fl) nn 1990: Massey and Whiting 1996: Ginty et 
al. 1998: Lin et al. 2003 Massey 2005). Several studies had been undertaken to determine the 
effect of sodium chloride ingestion on bone formation and resorption turnover markers 
mainly in pre- and post-menopausal women (Goulding 1981: Goulding and Lim 1983: Shortt 
and Flynn 1990: Matkovic et al. 1995: Evans et al. 1997: Lietz et al. 1997: Ginty et al. 1998: 
Sellmeyer et al. 2002: Lin et al. 2003: Masse) 2005: Wigertz et al. 2005). These studies 
report contradicting results as some of them have found no change ( Gint) et al. 1998: Evans 
et al. 1997: Lietz et al. 1997: Lin et al. 2003) while others have reported an increase in bone 
turnover markers (Evans et al. 1997: Wigertz et al. 2005). Not surprisingly, decreases have 
also been reported (Evans et al. 1997: Sellmeyer et al. 2002: Massey 2005 ). 
Of great interest is a study comparing in calcium retention in response to dietary salt 
in adolescent girls of different races (Wigertz et a!. 2005 ). In this study black adolescent girls 
showed a higher retention of calcium than their white counterparts who had the same calcium 
intake. Prior to this report, studies on black and white adolescent girls had also demonstrated 
a higher calcium balance of 12% in the bone mass of black relative to white women (Bryant 
et al. 2003) which was consistent with a 10 - 13 % higher adult bone density reported in the 
former group (Kleerekoper et al. 1994: Hui et al. 2003: Palacios et al. 2004). From these 
studies it was concluded that notwithstanding the importance of sodium as a determinant of 
urinary calcium retention, race could be a major determinant as well. 
These studies are extremely interesting in the context of the South African 
phenomenon in which kidney stone formation is almost non-existent in the black population. 
Indeed, the relative renal handling of sodium chloride in South Africa' s two population 
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groups poses an intriguing question. As such, this aspect was adopted as another objective for 
the present PhD thesis. 
1.6.6 Supplemental Citrate 
The significance of alkaline citrate therapy in preventing calcium stone recurrence has been 
reported in many clinical studies (Lemann et al. 1989: Pak 1987. 1991. 1994: Schwille 1985. 
1987. 1997: Rumenapf and Schwille 1987: Whalley et al. 1998). 
Alkali therapy has been recognized as a powerful agent for treating nephrolithiasis 
since Sir Astley Cooper in 1826 prescribed liquor potasse, potassium carbonate and sodium 
carbonate for uric acid stones (Atsmon et al. 1963 ). Since then, stone patients have been 
treated with alkali agents either in the form of bicarbonate or citrate salts (Ho\\.ard 1954: 
Gregory et al.. 1981: Sakhaee et al. 1991; Pak 199 L 1994 ). Supplemental citrate is the most 
common therapeutic agent that is used to prevent CaOx and uric acid stones. The powerful 
inhibitory potency of citrate rests in its ability to alkalinize urine, and to form soluble 
complexes with calcium. Such complexation reduces urinary supersaturation for CaOx and 
CaP and retards the nucleation, aggregation and growth as well as agglomeration of 
preformed CaOx crystals (Pak and Fuller 1983: Kok et al. 1986: Fan et al. 1995: Parks et al. 
1996: Laube et al. 2002 (a): Ettinger et al. 1997: B;er and Khan 2005). 
The therapeutic effect of various different citrate salts as alkali therapy on CaOx 
crystallization inhibition has been tested extensively. These salts include potassium citrate 
(Sakhaee et al. 1983: Pak et al. 1985: Hofbauer et al. 1994: Whalley et al. 1998: Sellmeyer et 
al. 2002), sodium citrate (Sakhaee et al. 1983: Allie-Hamdula; and Rodgers 2005), 
magnesium citrate (Schwille et al. 1999), potassium-magnesium citrate (Ettinger et al. 1997), 
calcium citrate (Sakhaee et al. 2005), calcium-sodium citrate (Schwille et al. 1997) and 
sodium-potassium citrate (Pak and Adams 1987: Achilles et al. 1990: Hofbauer et al. 1994 ). 
Numerous investigators have reported reductions in the rate of recurrent stone formation by 
60% to 96% following administration of alkali citrate therapy (Pak et al. 1985: Preminger et 
al. 1985 (a) and (b): Pa · and Fuller 1983: Pak and Peterson 1986: Ettinger et al. 1997). 56% 
of stone forming patients who experienced severe pain, reported spontaneous elimination to 
be painless and stone formation was decreased by 31 % following citrate therapy (Hofbauer 
et al. 1994: Pak and Peterson 1986). These data demonstrate that alkali citrate therapy for 
CaOx stone formers might be justified on the basis of virtually no incidence of side effects 
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and physiological processes remain unaffected (Hofbauer et al. 1994: Pak and Peterson 
1986). 
A comparative study (on CaOx stone formers) on the effect of potassium citrate and 
sodium citrate showed that both salts produced a significant increase in urinary citrate 
excretion and in pH (Sdkhaee et al. 1983). However, while potassium citrate significantly 
reduced urinary calcium excretion, the same effect was not achieved by sodium citrate. 
Despite this, the therapeutic potency of sodium citrate in the management of CaOx 
urolithiasis risk factors in male and female controls and stone formers was recently 
demonstrated in the Kidney Stone Research Laboratory at the University of Cape Town 
(Allie-Hamdulay and Rodgers 2005). This study reported an increase in citrate excretion and 
urinary pH and a concomitant decrease in calcium excretion in all groups following 
administration of sodium citrate. Crystallization experiments conducted in this study support 
the view that sodium citrate could be a potential prophylaxis in the management of CaOx 
urolithiasis (Allie-Hamdulay and Rodgers 2005). 
The present PhD project proposes to extend the aforementioned study by Allie-
Hamdulay and Rodgers to involve an in-depth investigation into the renal handling of sodium 
citrate by the black and white population groups, with a view to exploring whether 
differences exist in the renal handling thereof by the respective race groups, and if so, 
whether these differences might contribute towards understanding why stone rarity occurs in 
the former group. 
1.6. 7 Supplemental Bicarbonate 
As mentioned earlier, alkali therapy has long been recognized as a powerful agent for treating 
nephrolithiasis (Atsmon et al. 1963). However, the therapeutic potential of alkali therapy 
depends on attaining a metabolically optimal range of plasma bicarbonate that is higher than 
that comprising its normal range. To accomplish this, one needs to understand the effect of 
alterations in acid-base balance on urinary calcium excretion and calcium balance. 
Metabolic acidosis and increased acid production are accompanied by increased urinary 
calcium excretion which arises as a consequence of inhibition of net renal tubular calcium 
reabsorption (Lemann et al. 1965, 1966, 1967, 1986: Morris and Sebastian. 2002). This 
acidosis also has a negative impact on osteoporosis as it decreases intestinal calcium 
reabsorption and stimulates bone resorption, thereby affecting calcium balance (Lemann et al. 
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1966, 1979). Metabolic acidosis can be reversed by alkali therapy which leads to metabolic 
alkalosis (McSherry and Morris 1978; Osther et al. 1993: Morris and Sebastian 2002). 
Metabolic alkalosis is achieved by administration of bicarbonate which is 
accompanied by reduction in urinary calcium excretion (Lemann et al. 1979). Bicarbonate 
has been investigated in the form of potassium (Sakhaee et al. 1983; Lemann et al. 1989; 
Sebastian et al. 1994, 2005; Frassetto et al. 2005) and sodium bicarbonate (Sakhaee et al. 
1983; Lutz 1984; Lemann et al. 1989). Both supplemental forms have been reported to reduce 
urinary calcium excretion and increase positive calcium balance, plasma bicarbonate and a 
reverse induction in net renal acid excretion (Morris and Sebastian 2002). Bicarbonate not 
only reduces the risk of stone formation, but also osteoporosis. Several researchers have 
reported an improved external balance of calcium as demonstrated by reductions in the 
urinary excretion rate, followed by an increase in serum concentrations of bone formation 
markers of osteocalcin and a decrease in urinary concentrations of bone resorption markers 
(Lutz 1984; Lemann et al. 1989: Sebastian et al. 1994. 2005: Frassetto et al. 2005; Sakhaee et 
al. 2005). 
As was the case with sodium chloride and sodium citrate (sections 1.6.5 and 1.6.6), an 
investigation into the relative renal handling of sodium bicarbonate in South Africa' s two 
population groups is warranted. Hence, such a study is yet another objective of the present 
PhD project. 
1. 7 KIDNEY STONES AND OSTEOPOROSIS 
Osteoporosis is a chronic, slowly developing disease that is characterized by a reduction of 
bone mass and impairment of the structural integrity of the bone, making patients more 
susceptible to bone fractures (Clowes and Eastell 2000). It generally occurs with increasing 
age and in post-menopausal women. The pathogenesis of osteoporosis, fragility fractures and 
metabolic disease is associated with many factors such as genetic, environmental, 
biomechanical, chronic disease and the effects of endogenous hormones. Throughout life, 
bone is in a dynamic state of continuous resorption and formation and this process is called 
bone remodelling. In childhood and early adulthood, formation exceeds resorption so that 
bone density increases and plateaus in the age range of 30 to 40 years. After 40 years of age, 
resorption exceeds formation, and bone density decreases throughout the rest of life. Bone 
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remodeling, or turnover, consists of two opposing activities: the breakdown (resorption) of 
old bone by osteoclasts, and the formation of new bone by osteoblasts (Delmas 1990. 1993). 
Osteoporosis is characterized by an increase in bone resorption and a decrease in bone 
formation (Price et al. 1983: Delmas 1993. 2000). 
Bone turnover can be assessed by measuring levels of various biochemical markers 
which are released into the blood or urine (Delmas 1992. 2000). Markers exist for both bone 
formation and bone resorption. Bone formation markers are released during osteoblast 
synthesis of new bone protein matrix and can be only measured in blood. Bone resorption 
markers are released into the circulatory system as by-products of osteoclast action on bone. 
Resorption markers can be measured in both blood and urine. Some of resorption markers 
result from the breakdown of type I collagen, which is a major component of bone matrix, 
comprising about 90 %of the bone's organic content. Examples of both categories of bone 
markers are given in Table 1.1 and some are discussed below. 
Table 1.1: Biochemical markers of bone turnover 
Bone formation markers Bone resorption markers 
Total alkaline phosphatase (TALP) Calcium 
Bone alkaline phosphatase (BALP) Hydroxyproline 
Procollagen-I extension peptide Pyridinolines (PYD) 
Osteocalcin ( OC) Deoxypyiridinolines (DPD) 
COOH-terminal telopeptides (CTX) 
NH2-terminal telopeptides (NTX) 
Alkaline phosphatase (ALP) and osteocalcin are the most widely used bone formation 
markers. 
ALP is a ubiquitous enzyme that plays an important role in osteoid formation and 
mineralization. Serum ALP activity is the most commonly used marker of bone formation, 
but it lacks sensitivity and specificity (Seibel 2005). Nevertheless, studies by Delmas ( 1992. 
1993) and Osther et al. ( 1993) have shown that its activity increases with aging in adults, 
especially in women after menopause. In patients with vertebral osteoporosis, values are 
either normal or slightly elevated and poorly correlated with bone formation (Delmas 1993 ). 
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Osteocalcin is predominantly synthesized by the osteoblasts and incorporated into the 
extracellular matrix of bone, but a fraction of newly synthesized osteocalcin is released into 
the circulatory system (Price et al. 1983 ). Circulating osteocalcin has a short elimination half-
life and is rapidly cleared by the kidney (Delmas et al. 1983). Serum osteocalcin is a sensitive 
and specific marker for osteoblastic activity that accurately reflects both gradual age-related 
and accelerated postmenopausal increases in bone turnover (Johansen et al. 1988). It contains 
three y-carboxyglutamic acid (Gla) residues, which are responsible for the calcium binding 
properties of this protein (Johansen et al. 1988: Delmas 1993). It is also considered as a 
specific marker of osteoblast function as its levels correlate with bone formation rates. 
Pyridinolines (PYD) and deoxypyridinolines (DPD) are the hydroxypyridium 
crosslinks of collagen and are formed during the extracellular maturation of fibrillar collagens 
and are released upon the degradation of mature collagens (Robins 1999: von der Mark 
1999). Their measurement is not influenced by the degradation of newly synthesized 
collagens and independent of dietary sources. They are excreted in urine in free form 
(approximately 40 %) and in peptide-bound form (60 %). Urinary PYD and DPD are 
increased by 50 - 100 % at the time of menopause and return to premenopausal levels with 
estrogen therapy (Johansen et al. 1988). In patients with vertebral osteoporosis, the urinary 
DPD levels are correlated with bone turnover. Both PYD and DPD appear to be more 
sensitive than hydroxyproline as markers of bone resorption, and are also significantly 
increased in patients with primary hyperparathyroidism, malignant hypercalcemia and 
hyperthyroidism (Delmas et al. 2000: Seibel 2005). These two bone resorption markers are 
relatively specific for bone turnover and they do not appear to be metabolized in vivo prior to 
their urinary excretion. PYD and DPD are at their highest peak during the night and were 
lowest during the afternoon and this probably reflects a nocturnal increase of bone turnover 
and resorption (Eastell et al. 1992: Kraenzlin and Seibel 1999: Seibel2005). 
As stated previously, osteoporosis, just like kidney stones is a multi-factorial disease. 
It is correlated with age, gender and ethnicity (Delmas et al. 2000). Khosla et al. (1997) and 
Fatayerji and Eastell ( 1999) reported that children have significantly higher biochemical 
markers than adults, particularly at puberty when they have 2-1 0 times the levels found in 
adults. In women there is a huge increase in bone turnover markers at menopause, while for 
men there is no change with age (Khosla et al. 1997: Fatave1ji and Eastell 1999). 
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Higher levels of bone markers have been reported in young men in their third and fourth 
decade than young women, but in older men the levels are lower in men than in 
postmenoupausal women (Delmas et a!. 2000). A comparative study of black and white 
populations in France has reported that in children and young adults, bone resorption markers 
are 20% lower in black subjects than in white subjects (Delmas et al. 2000). 
Interestingly, it has been reported that serum osteocalcin and urinary hydroxyproline 
are significantly decreased and increased, respectively, in kidney some formers with renal 
tubular acidosis ( Osther et al. 1993 ). It has also been reported that some patients with renal 
tubular acidosis had either kidney stones or nephrocalcinosis (Weger et a!. 1999). Citrate 
treatment has been reported to inhibit osteoclastic resorption and to stimulate osteoblastic 
formation (Sebastian eta!. 1994: Bushinsky. 1996 ). 
As mentioned in the previous pages, the effect of sodium chloride (Muldowney eta!. 
1982: Shortt eta!. 1998: Shortt and Flynn 1990: Ginty et al. 1998: Sellmeyer et al. 2002: Lin 
et al. 2003: Massey 2005: Wigertz et al. 2005), bicarbonate (Lematm et al. 1965. 1966. 1967. 
1986: Morris and Sebastian et a!. 2002: Frassetto et al. 2005: Sakhaee et a!. 2005) and 
citrate (Sebastian et al. 1994: Bushinsky 1996: Ettinger et a!. 1997: Laube et al. 2002 (a): 
Sellmeyer et al. 2002) on kidney stone formation as well as bone turnover markers of 
osteoporosis has been extensively studied, albeit that the latter investigations have been 
mainly in pre- and post-menopausal women. Thus, a further objective of the present PhD 
project is to investigate the effect of these salts on bone turnover markers in the South 
African racial context. 
1.8 UROLITIDASIS IN SOUTH AFRICA 
As stated previously, the incidence of kidney stones in the black South African population is 
extremely rare (< 1 %) compared to 12 - 15 % reported in the white population (Modlin. 
1967: Meyers et a!. 199-l. Whalley et a!. 1998: Pinnock et al. 2004 ). This prevalence rate in 
the white population is similar to that in Westernized countries (Modlin 1967: Whalley et al. 
1998). The rarity of stones in the black South African population group is most likely due to a 
multitude of factors which may or may not include differences between their urine chemistry, 
urinary proteins and dietary habits (Modlin 1967. 1980: Beukes et a!. 1987: Pinnock et a!. 
2004). 
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1.8.1 Urine Chemistry 
In an attempt to understand and explain the low stone incidence in the black South African 
population, the Kidney Stone Research Laboratory (KSRL) at the University of Cape Town 
has extensively investigated the aforementioned factors. Studies by this group and others 
have revealed that black subjects have lower urinary calcium (Modlin 1967: Whalley et al. 
1998: Rodgers and Le\\andowski 2002), lower urinary citrate, lower urinary phosphate and 
lower urinary pH (Modlin 1967: Lewandowski et al. 2001) and higher urinary oxalate 
(Rodgers and Lewandowski 2002). Several of these results are surprising as they are counter-
intuitive. For example, the lower urinary citrate and pH and the higher urinary oxalate would 
be expected to increase the risk of CaOx stone formation. On the other hand, while the lower 
urinary calcium and phosphate might culminate in a lower stone incidence rate in black 
subjects, they cannot account for the virtual absence of stones in this group as their levels lie 
within the normal range. 
1.8.2 Biochemical Factors: Urinary Proteins 
Since routine urine composition cannot explain the difference in kidney stone occurrence in 
South Africa' s two population groups, the Kidney Stone Research Laboratory at the 
University of Cape Town has extensively investigated the role of several urinary proteins in 
this regard. Studies on the so-called crystal matrix extract (CME) derived from precipitated 
calcium oxalate monohydrate (COM) crystals showed that the extract was an inhibitor of 
CaOx crystal nucleation and aggregation, and that the extract from black subjects was 
superior in this regard to that from whites (Durrbaum et al. 2001 ). 
Studies on UPTFl (isolated from COM-CME) showed that it is a potential inhibitor 
of CaOx crystal growth and aggregation and that the protein isolated from the urine of black 
subjects was superior to that from white subjects (Durrbaum et al. 2001: Webber et al. 2002). 
Similarly for THP, the form isolated from the urine of black subjects was found to be a 
stronger inhibitor of CaOx crystal aggregation than that from white subjects (Craig et al. 
1999, 2000, 2001). Albumin isolated from black subjects has also been shown to be a 
superior inhibitor of CaOx crystal growth and aggregation than that from white subjects 
(Rodgers et al. 2006). Finally, bikunin isolated from the two race groups demonstrated strong 
inhibition of CaOx crystal growth and aggregation and a weak inhibition of CaOx crystal 
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nucleation; however aggregation inhibition by bikunin from black subjects was superior 
(Mabizela PhD Thesis, 2006) . 
An interesting result which emerged from all of these studies was the observation that 
a synergistic relationship exists between the inhibitory performance of the protein and the 
chemical composition of the urine milieu in which it was tested. Thus, UPTFl isolated from 
black subjects was found to be a more efficient inhibitor of CaOx crystal growth and 
aggregation than that isolated from white subjects in their endogenous urines (Durrbaum et 
al. 2001: Webber et al. 2002 ). THP from black subjects inhibited CaOx crystal growth in 
urines from both black and white subjects, whereas THP from the white group promoted 
CaOx crystal growth in its own urine but inhibited this mechanism in urine from black 
subjects (Craig et al. 1999, 2000, 2001 ). On the other hand, while albumin from both groups 
inhibited CaOx crystal growth and aggregation in their endogenous urines, that isolated from 
black subjects was more efficacious (Rodgers et al. 2006). Bikunin inhibited CaOx crystal 
growth and aggregation in both urines and that isolated from black subjects was superior in 
this regard (Mabizela PhD thesis, 2006). 
1.8.3 Diet and Supplements 
As in urine composition studies, few adult population studies have been undertaken to 
identify dietary similarities and differences in South Africa's black and white population 
groups (Segal 2002: Steyn 2003 ). 
Oxalate 
The South African black population has been reported to have a high dietary intake of oxalate 
(because of the regular intake of spinach) (Viljoen and Gericke 2001 ), a low intake of 
calcium (because of lactose intolerance) (Viljoen and Gericke 2001) and a low magnesium 
intake (correlated with their low ingestion of vegetables) (Whalle) et al. 1998: Charlton et al. 
2005). These dietary habits are widely regarded as hyperoxalurogenic i.e. favouring the 
excretion of relatively high urinary oxalate. However, despite these eating habits, urinary 
oxalate in this race group lies within the normal range (Whalle)' et al. 1998: Rodgers and 
Lewandowski 2002: Le\\andowski et al. 2005). 
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To test the effect of dietary challenges and the ability to handle oxalate in the two South 
African population groups, three studies were conducted with these two groups 
(Lewandowski et a!. 200L 2005; Rodgers and Lewandowski 2002). A high oxalate-low 
calcium diet given to both groups significantly changed the urinary oxalate only in whites but 
not in blacks (Lewandowski et a!. 200 l ). Two other independent diets, one low in calcium 
and the other high in oxalate were administered. The low calcium diet resulted in an increase 
in oxaluria in blacks whereas the urine biochemistry was not changed in whites (Rodgers and 
Lewandowski 2002). Despite the induced oxaluria in blacks, the relative supersaturation of 
CaOx decreased significantly (Rodgers and Lewandowski 2002). The high oxalate diet 
induced a significant increase in urinary pH in whites and an increase in urinary citrate in 
blacks (Rodgers and Lewandowski 2002). 
These results demonstrated that the South African black population handles dietary 
hyperoxalurogenic challenges in a different way to that of their white compatriots. 
Salt 
Interestingly, the black South African population has been reported to have a diet that is high 
in salt relative to the white group (Modlin 1967: Whalley eta!. 1998). However, despite this, 
their urinary calcium is lower (Rodgers and Lewandowski 2002). This suggests once again 
that the South African black population group has a different handling mechanism of 
lithogenic agents than their white compatriots. 
Even though high sodium intakes may be a risk factor for osteoporosis and CaOx 
urolithiasis, some sodium salts such as sodium citrate and sodium bicarbonate have been 
shown to have no significant effect on urinary calcium in whites (Allie-Hamdulay and 
Rodgers 2005). An obvious question which arises is whether such salts have any influence 
on urinary calcium in South African blacks. Indeed, this forms the basis of yet another 
objective in the present PhD project. 
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1.9 OBJECTIVES OF TIDS THESIS 
As stated in the opening paragraph of this thesis, the presence of stone-prone and stone-free 
population groups in South Africa provides basic scientists with a unique opportunity to 
study kidney stone pathogenesis with a view to gaining insights into the key factors for stone 
formation on the one hand, and stone prevention on the other. Other sections in Chapter 1 
have drawn attention to various intriguing phenomena in this context. These provide the basis 
for the following objectives which were undertaken for the present thesis: 
• To investigate the relative inhibitory capacities towards CaOx crystallization, of urine 
from healthy black and white male subjects, with reference to urinary macromolecules 
of size> 10 kD. 
• To investigate the relative inhibitory capacities towards CaOx crystallization of 
crystal matrix extract (CME) derived from calcium oxalate dihydrate crystals 
precipitated from the urine of healthy black and white male subjects. 
• To repeat the CME studies in ultrafiltered urine from both race groups using a cross-
over design, with a view to exploring the influence of the respective urine milieus on 
the inhibitory performance of CME. 
• To investigate the inhibitory capacity of commercial osteopontin in ultrafiltered urine 
from both race groups, with a view to exploring the influence of the respective urine 
milieus on the performance of the protein. 
• To investigate the effects of the oral administration of three different sodium salts 
(sodium chloride, sodium citrate and sodium bicarbonate) on urinary calcium and 
other biochemical and physicochemical risk factors for CaOx stone formation in black 
and white healthy male subjects, with a view to exploring whether the renal handling 
of these salts is different in the two population groups. 
• To investigate the effects of the aforementioned sodium salts on markers of bone 
turnover, with a view to further exploring whether the renal handling thereof is 
different in the two population groups. 
• To investigate whether urinary alterations following oral administration of the 
aforementioned sodium salts change the crystallization properties of urine in the two 
population groups. 




This chapter mainly focuses on the general methods that were used for the various studies 
described in this thesis. These experiments commenced with the collection and treatment of 
24 hour urine samples followed by their physicochemical analyses and the determination of 
CaOx metastable limits (MSLs), CaOx crystallization kinetics involving particle number, 
volume and volume-size distributions, 14C-oxalate deposition kinetics and sedimentation 
experiments to assess CaOx crystal nucleation and aggregation inhibition. The studies on 
aggregation were supplemented with zeta potential measurements. Finally, scanning electron 
microscopy was used to visualize deposited crystals in an attempt to confirm mechanisms 
arising from interpretation of the data obtained in the aforementioned experiments. 
2.2 METHODS 
2.2.1 Urine collection, treatment and physicochemical properties 
Age matched black and white healthy males with no history of kidney stone formation 
participated in the various studies described in this thesis. 24 hour urine samples were 
collected from each. Each sample was tested for haematuria and nitrite using urinalysis test 
strips (Medi Test Combi 5N, Macherey-Nagel; Diiren), and those that tested positive for 
either were discarded. All urine samples were analysed for sodium, potassium, calcium, 
oxalate, uric acid, citrate, chloride, magnesium, phosphate, sulphate and creatinine. Sodium, 
potassium, magnesium and calcium were measured using atomic absorption spectroscopy 
(Varian 1275 Model; Australia) (Willis 1969; Trudeau and Freier 1967; Fernandez and Kahn 
1971) while commercially available assay kits from Sigma Aldrich and Boehriner Mannheim 
were used for oxalate ( Chiriboga 1963) and citrate, respectively (Gruber and Mollering 
1966). Chloride was determined using a chloride sensitive electrode. Creatinine (Rock et al. 
1986), phosphate (Drye and Routh 1963), and urate (Fossati et a!. 1980) were measured 
using Synchron LX assay kits (Beckman Coulter Inc.). 
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The urinary relative superaturations of CaOx, brushite and uric acid were calculated using the 
computer programme EQUIL2 (Werness et al. 1985). The Tiselius Risk Index (TRI) was 
calculated for each sample using urine composition data (Tiselius 1982). The Tiselius Risk 
Index formula of 1982 was used to be consistent with other urinary studies at the University 
of Cape Town involving South African black and white subjects. Urine composition data 
were analysed statistically using analysis of variance (ANOVA) and if p :::; 0.05 the results 
were considered statistically significant. Variances were pooled on the assumption that 
groups had equal variances. 
Albumin in the urine in any more than the most trifle quantity is considered a clear 
indicator of kidney disease with altered (diseased) renal metabolism affecting renal handling 
of other urine constituents as well. In the present study, the samples were tested for protein 
and blotted for albumin (chapter 4) and virtually none was detected. 
2.2.2 Crystallization Experiments 
Crystallization experiments except for crystal aggregation were conducted in duplicates for 
each sample and the mean of the two values was reported. The two measurements for each 
sample were more than 85 % reproducible. 
CaOx Metastable Limit (MSL) 
Urine samples were prepared for the determination of the CaOx metastable limits by filtering 
successively through a 0.75 J.tm pre-filter (Macherey-Nagel; GmBH and Co. , Germany) and 
0.45 J.tm nitrocellulose filter (Sartorius AG, Germany). The MSL of each sample was 
determined following the method described by Ryall and co-workers (Ryall et al. 1985). 
Aliquots ( 1 0 mL) of each sample were added into Coulter cups and incubated at 3 7 °C in a 
shaking water bath at 100 rpm (Labcon Marketing Services, Johannesburg). The aliquots 
were dosed with 100 J.!l of progressively increasing concentrations of sodium oxalate (Na20x; 
0.015 mol/L to 0.195 mol/L) at 2 minute intervals and incubated for a total of 30 minutes 
each. The particle number and volume were measured using a Coulter Multisizer I (Coulter 
Electronics Ltd., England) fitted with a 140 J.!m orifice (2.8 - 90.0 J.!m particle size range). 
The concentration of Na20x corresponding to the dose which caused a sudden increase in 
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particle number was taken as measure of the metastable limit of the particular sample under 
investigation. A representative curve which shows the determination of the metastable limit is 
shown in Figure 2.1. The concentration which corresponds to the metastable limit is shown 
by a red dot. 
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Figure 2.1: A typical graph for the determination of the 
CaOx MSL. 
CaOx Crystallization Kinetics 
Once the MSL of each sample had been determined, 100 mL aliquots were incubated for 10 
minutes at 1 00 rpm and at 3 7 °C in a shaking water bath (Labcon Marketing Services, 
Johannesburg). An aliquot of 10 % (v/v) Na20x equivalent to 30 mmol/L above the 
previously described MSL was then added to the sample to induce crystallization. Thereafter, 
the sample was incubated and a zero time measurement of particle number, volume and size 
was recorded using the Coulter Counter. Incubation continued for 2 hours during which time 
Coulter measurements were made at 30 minute intervals. 
Scanning Electron Microscopy (SEM) 
All urine samples were dosed with aqueous Na20x in the kinetics experiment as described in 
the previous paragraph prior to examination by scanning electron microscopy. This procedure 
was adopted because natural undosed samples in all experiments did not reveal crystals large 
enough to be visualized by SEM. Despite this exogenous method for producing crystalluria, 
comparison of different samples in this way is regarded as being valid and appropriate, as all 
urines were treated in the same way. 
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After the 2-hour incubation period, the samples were filtered through 0.22 11m filters and 
dried at room temperature for 1 hour. Once the filter papers were dry, the crystals were 
mounted on aluminium stubs and were splutter-coated for 10 minutes with 3 - 5 nm of Au/Pd 
(Bio-Rad, SEM Coating System). The deposited crystals were then viewed using a Leica 
S440 scanning electron microscope (Leica Cambridge Ltd, Cambridge, England) operating at 
a working distance of 10-15 mm, an accelerating voltage of 10 kV and a probe current of20-
30 pA. Micrographs for a particular series of experiments were always recorded at the same 
magnification so that valid comparisons could be made. Obviously, the actual magnification 
varied from one series to another. 
14 C-Oxalate Deposition 
Inhibition of CaOx deposition in each sample was tested using radio labelled oxalate (Do} le 
et al. 1995). Each urine sample (30 mL) was added to a designated soda-lime glass flask (to 
prevent crystals from adhering to the walls of the flask) and incubated in a shaking water bath 
at 37 °C and 150 rpm for 10 minutes. This was followed by addition of3.125 11Ci 14C-oxalic 
acid per 100 mL of urine (NEN, Boston, USA). 30 mmol/L ofNa20x (10% v/v) above the 
previously determined MSL was added to each urine sample, each of which was then 
incubated for 120 minutes. To stop any further crystal deposit or growth, samples were 
filtered into concentrated hydrochloric acid (10 % v/v) at 30-minute intervals. Duplicate 
aliquots (1 mL each) of the acidified urine were added to a 1 Oml scintillation fluid (Zinsser 
Analytic, Great Britain) and 14C-oxalate was counted using a scintillation counter (Beckman 
LS 5000TD Scintillation Counter). The percentage of precipitated 14C-oxalate was 
determined from the equation (Doyle eta!. 1995): 
100 - 1 OOx (counts per minute at x min I counts per minute at 0 minute). 
CaOx Crystal Aggregation 
Inhibition of CaOx crystal aggregation was determined according to the method described by 
Hess et al. ( 1989). This method requires the preparation of calcium oxalate monohydrate 
(COM) and/or calcium oxalate dihydrate (COD) crystals. 
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(a) Preparation of calcium oxalate monohydrate (COM) crystals 
Before the aggregation experiment was conducted, COM crystals were prepared following 
the method of Pak et al. (1975). Equal volumes of 100 mmol/L CaCh and 100 mmol/L 
Na20x solutions were mixed at a constant rate of 1 mL/min using a peristaltic pump (Gilson, 
France). The mixture was then stirred at 6 °C for one week. Thereafter, the crystals were 
filtered through 0.22 Jlm filters and dried at 37 °C for one hour. 
(b) Preparation of calcium oxalate dihydrate (COD) crystals. 
COD crystals were prepared according to the method of Brown et al. ( 1989) with some 
modifications to the incubation temperature, pH and final volume. A solution containing 
1.398 g (38.5 mmol/L) of sodium citrate, 1.423 g (46.2 mmol/L) of magnesium sulphate and 
2.403 g (255 mmol/L) of potassium chloride in 250 mL dH20 was prepared and mixed with 
0.920 g (25 mmol/L) calcium chloride solution in 250 mL dH20. The resulting mixture was 
adjusted to pH 6.5 and left to equilibrate at 25 °C in a shaking water bath for 10 minutes. A 
Na20x solution, 0.216 g (6.40 mmol/L) of Na20x in 250 mL dH20 was added to the pH 
adjusted solution and equilibrated at 25 °C for a further 10 minutes. The crystals of the final 
mixture were collected by filtration through a 0.22 Jlm pore size, washed with methanol and 
dried at 37 °C for at least one hour. 
(c) Characterization of CaOx crystals. 
Crystals prepared in (a) and (b) were characterized using x-ray powder diffraction (XRD). 
Powdered crystals were packed into aluminium trays and x-ray diffraction patterns were 
recorded using a Philips PW 1050/80 vertical goniometer in the 12-40 ° 28 range with CuKa 
radiation wavelength of 1.5418 A produced at 40 kV and 25 rnA. The observed peaks were 
assigned by referring to the standard interplanar spacing and relative intensities for COM and 
COD shown in Table 2. 1. 
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Table 2.1: Interplanar spacings and relative intensities of powder patterns of the two 
hydrates of CaOx (Sutor and Scheidt 1968). 
Calcium oxalate monohydrate 
(COM) 


















Calcium oxalate dihydrate 
(COD) 


















Figures 2.2 and 2.3 show the x-ray diffraction patterns obtained for CaOx crystals prepared 
using the methods of Pak et al. ( 1975) and Brown et al. ( 1989), respectively. Comparison 
with the standard x-ray diffraction data given in Table 2.1 confirms that the crystals are 
calcium oxalate monohydrate and calcium oxalate dihydrate, respectively. 
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Figure 2.3 : XRD pattern of CaOx crystals prepared using the method of Brown et 
al. (1989). 
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(d) Determination of COM and COD crystal aggregation inhibition 
The COM and/or COD crystals (0.8 mg/mL) were added separately in a buffer containing 10 
mmol/L Tris-aminomethane (Tris).HCl and 90 mmol/L NaCl, pH 7.2 (Hess et al. 1989) 
resulting in a crystal slurry. The crystal slurry was equilibrated overnight at 37 °C with 
constant stirring at 1100 rpm. The equilibrated slurry was mixed with urine at a ratio of 4:1 
(1600 JJL: 4001JL) or it was mixed with the test protein at a final concentration of 0.5 mg/L 
and further equilibrated for 2 hours at 1100 rpm. This 4:1 ratio was chosen because the study 
by Hess et al. ( 1989) showed that the higher the urine concentration relative to the crystal 
slurry, the less the inhibition of aggregation. The absorbance of the equilibrated mixture was 
monitored at 620 nm and 37 °C for 9 minutes using a spectrophotometer (Spectronic Unicam, 
England). Crystal aggregation was induced by slow stirring at 1100 rpm until equilibrium had 
been reached which was demonstrated by a constant absorbance. Stirring was then stopped 
and a decrease in absorbance was monitored indicating the sedimentation rate of the 
COM/COD crystals. The slope of the linear decrease in absorbance of the slurry (labelled 
"absorbance slope" in Figure 2.4) indicated the degree of crystal aggregation of COM/COD 
crystals in the presence of urine. The percentage inhibition of aggregation by the urine 
sample was determined from the equation (Hess et al. 1989): 
1- [St (slope of the test sample)/Sc (slope of the COM/COD slurry without urine)] X 100 
A typical experimental curve is shown in Figure 2.4. 
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Figure 2.4: A typical CaOx crystal sedimentation plot of 
absorbance vs. time. 
CaOx Crystal Nucleation 
Inhibition of CaOx crystal nucleation was determined using the method ·developed by Hess et 
al. ( 1995). Stock solutions of 8.5 mmol/L of calcium chloride, CaCb and Na20x (1.0 
mmol/L) each containing 200 mmol/L sodium chloride and 1 0 mmol/L sodium acetate, were 
prepared and the pH was adjusted to pH 5.7. The stock solutions were filtered through a 0.22 
~m filter to remove any debris that might interfere with the spectrophotometric 
measurements. 
The experiment was performed at 37 °C using a circulating water bath. CaCb solution 
(1 mL) was transferred into a 10-mm cuvette placed in a spectrophotometer (Analytikjena, 
specord 40), regulated at 37 °C and constantly stirred at 500 rpm. 1 mL of the Na20x solution 
was added to the CaCh solution, resulting in fmal assay concentrations of 4.25 mmol/L 
calcium and 0.5 mmol/L oxalate, respectively. The automated time course measurement of 
OD62o was performed after the addition ofNa20x solution to the CaCh solution. These values 
were recorded every 0.5 seconds for 60 minutes. The maximum slope of increase of OD620 
with time representing crystal nucleation for the control was termed (SN). Once equilibrium 
had been reached, crystals neither nucleated nor grew but there was a progressive decrease of 
OD620· A typical crystal nucleation curve is shown in Figure 2.5. 
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Figure 2.5: A typical plot of absorbance vs. time for the determination 
of CaOx nucleation and aggregation assay. 
This experiment was performed in the presence of (i) urine, (ii) commercially available 
osteopontin or CME and (iii) urine + osteopontin. The fmal concentration of 0.5 mg/L of 
protein was used. This concentration corresponds to that which achieved maximum inhibition 
of crystal aggregation in the study reported by Doyle et al. (1995). The urine samples were 
tested at a ratio of 800 J.tL of CaCb: 400 J.tL of urine: 800 J.tL of Na20x. OD6zo was recorded 
every 0.5 seconds over 60 minutes. This urine concentration of 400 J.tL urine/ 2mL total 
solution corresponds to that which was used for the aggregation experiment described on the 
previous page and it achieved the highest inhibition of crystal aggregation as reported by 
Hess et al. (1989). The maximum slope increase (positive slope) of OD62o obtained with time 
was termed (SN) and used for the calculation of nucleation inhibition. The percentage 
inhibition of nucleation by the test sample was determined from the following equation: 
%NIN = 
Nucleation inhibition 
Slope in the presence of test sample 
Slope of nucleation of the control without test sample 
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CaOx crystal Zeta Potential 
(a) The concept of zeta potential 
As explained by several authors, aggregation of particles in solution is governed by an 
interplay of several basic forces which either have aggregating or disaggregating effects 
(Finla) son 1978: Robettson et al. 1981: Hess 1991 ). Two forces which favour aggregation 
are the attractive van der Waals forces and viscous binding. The main force which favours 
disaggregation is the zeta potential (Hess and Kok 1996). Zeta potential is the repulsive 
electrical potential that exists at the interface between a layer of chemically adsorbed ions on 
a crystal surface (solid phase) and its surrounding solution (continuous phase) (Scurr and 
Robertson 1986 ). In water COM crystals have a zeta potential of about + 20 m V (Curreri et al. 
1979). In urine, the zeta potential becomes more negative because of the adsorption of 
negatively charged urinary molecules such as citrate, pyrophosphate, and acidic 
macromolecules (Finlayson et al. 1984 ). It has been shown that highly anionic 
macromolecules such as GAGS, THP and nephrocalcin can induce zeta potentials between-
15 and -40 mV (Scun· and Robertson 1986: Hess et al. (1989). These authors regard zeta 
potential as an indicator of the potency of a compound to inhibit aggregation by virtue of its 
repulsive negative charge. The greater the magnitude of the negative charge, the greater is the 
inhibition. 
(b) Preparation of COM and COD crystal slurries for zeta potential measurements 
The slurries were prepared following the method of Hess et al. ( 1989). A 10 mmol/L sodium 
acetate buffer was prepared by mixing 10 mmol/L of sodium acetate with 270 mmol/L of 
sodium chloride. The pH was adjusted to 5.7 by addition of sodium hydroxide. Crystal 
slurries were then prepared by addition of 0.03 mg/mL of COM or COD crystals to the pH-
adjusted sodium acetate buffer. The slurries were equilibrated overnight with constant stirring 
at 1100 rpm and 25 °C. 
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(c) Measurement of zeta potential 
The equilibrated slurries were mixed with either CME (from black and white subjects) or 
commercially available osteopontin (at a final concentration of 0.5 mg/L) and further 
equilibrated for 2 hrs at 1100 rpm. The zeta potential of the slurries without the proteins was 
measured in triplicate using a Zetasizer Nanoseries (Malvern Instruments, England) and used 
as a control. Thereafter, the zeta potential of the crystals in the presence of CME or 
osteopontin (triplicate measurements) was also determined. 
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CHAPTER THREE 
INHffiiTORY ACTIVITY OF URINARY MACROMOLECULES (MW > 
10 kDa) FROM BLACK AND WHITE SUBJECTS 
3.1 INTRODUCTION 
Robertson and his co-workers reported that CaOx urolithiasias may be the net result of an 
imbalance between the two opposing influences of urinary supersaturation and urinary 
inhibitors (Robertson e al. 1976 ). Several studies (Robertson et al. 1968: Coe al. 1980: 
Drach et al. 1980) hav reported a deficiency in the inhibitory activity of urine from stone-
formers. 
Since urme physico-chemical and relative supersaturation analyses alone do not 
distinguish between healthy individuals and stone-formers (Tiselius et al. 1995), and indeed 
between South Africa's two population groups (Rodgers 2006), potential differences in the 
inhibitory properties of the urinary macromolecules in both race groups warrants 
investigation. Studies suggest that most of urine' s inhibitory activity with respect to CaOx 
resides in macromolecules which are active at submicromolecular concentrations (Nakagawa 
et al. 1983: Atmani et ilL 1996: R)all 1997). Many of these macromolecules have been 
found in the protein matrix that is a part of all calcium stones (Worcester 1996). Most 
previous workers have concluded that macromolecules greater than 10 kDa, considered 
altogether, exert an inhibitory effect on CaOx crystal growth and aggregation in whole human 
urine (Edyvane et al. 1987: Koide et al. 1990: Sorensen et al. 1995: Tiselius and Fomander 
1990: Bek-Jensen and 1 iselius 1991: Ryall et al. 1991: Ebisumo et al. 1999). Nevertheless, 
some macromolecules such as Tamm-Horsfall Protein (THP) have been reported to promote 
CaOx crystallization (Hallson and Rose 1977: Grover et al. 1990). 
Since urinary macromolecules greater than 10 kDa have not been previously studied 
in the context of the South African black and white paradox, the study described in this 
chapter was undertaken with this purpose in mind. 
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3.2 AIMS AND OBJECTIVES 
• To analyze 24 hour urine samples from black and white healthy males for routine 
physico-chemical properties. 
• To investigate the relative inhibitory roles ofurinary macromolecules in concert(> 10 
kDa) from black and white healthy males towards CaOx crystallization by 
determining CaOx metastable limits, 14C-oxalate deposition kinetics and CaOx crystal 
aggregation. 
3.3 MATERIALS AND METHODS 
3.3.1 Urine collection and treatment and physichochemical properties. 
24 hour urine samples were obtained from 10 black (B) and 10 white (W) healthy males. 
Each sample was tested, treated and analyzed as described in Chapter 2. After filtration (0.75 
J.lm pre-filter and 0.45 J.lm nitrocellulose filter), a portion of each prefiltered sample (P) was 
retained for further experiments and the rest was ultrafiltered using a 1 0 kDa membrane cut-
off (Millipore® TM, Minitan System, USA) to produce a concentrate (C) and an ultrafiltrate 
(UF). The crystallization properties of each of these three fractions were tested in various 
experiments, as follows. 
3.3.2 Crystallization Experiments 
CaOx Metastable Limit (MSL) 
The CaOx MSL of each urine fraction (n = 1 0) was determined following the method 
described by Ryall and co-workers (Ryall et al. 1985 ) as described in Chapter 2 . 
Scanning Electron Microscopy (SEM) 
Once the MSL of each urine fraction had been determined, crystallization was induced and 
the deposited crystals were viewed using SEM as described in Chapter 2. All the fractions in 
5 samples from each group were examined. 
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Inhibition of14C-Oxalate Deposition 
Inhibition of CaOx deposition in each urine fraction from all 10 subjects in each group was 
tested using radiolabelled oxalate as described in Chapter 2 (Do) le et al. 1995). 
Inhibition of CaOx Crystal Aggregation 
50 
The previously described COM crystal slurry was equilibrated overnight at 37 °C with 
constant stirring at 1100 rpm as previously described in Chapter 2. Portions of the 
equilibrated slurry were individually mixed with each urine fraction from all 10 subjects from 
each group at a ratio of 4:1 slurry to urine and further equilibrated for 2 hours at 1100 rpm. 
The absorbance of the equilibrated mixture was monitored at 620 nrn and 3 7 °C for 9 minutes 
using a spectrophotometer (Spectronic Unicam, England) and the percentage inhibition of 
aggregation by each urine fraction was calculated as previously described (Chapter 2, page 
43). 
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3.4 RESULTS 
3.4.1 Urine composition and physicochemical parameters of 24 hour samples 
The mean composition and physicochemical parameters of individual ultrafiltered 24 hour 
urine samples from black and white subjects are shown in Table 3.1. Individual parameters 
for each sample from both groups are shown in Appendix 1, Tables 1.1 and 1.2. Parameters 
that showed a significant difference (p :S 0.05) between the two groups are denoted with an 
asterisk. Urinary citrate, magnesium, uric acid and RS of CaOx and RS of uric acid were 
significantly lower in samples from black subjects than those from white subjects. 
Table 3.1: Mean composition and physicochemical parameters (± SE) of 24 hour urine 
samples from black and white subjects (n = 1 OB, n = 1 OW). 
Parameters B±SE W±SE p-value 
pH 6.37 ± 0.130 6.21 ± 0.130 0.371 
Volume (mL/24hr) 1526 ± 157 1272 ± 157 0.272 
Calcium (mmol/24hr) 3.31 ± 0.480 4.33 ± 0.480 0.181 
Citrate (mmol/24hr) 1.43 ± 0.180 2.26 ± 0.180 *0.003 
Chloride (mmol/24hr) 127 ± 12.2 126 ± 12.2 0.958 
Creatinine (mmol/24hr) 12.2 ± 1.46 16.5 ± 1.46 *0.052 
Magnesium (mmol/24hr) 2.26 ± 0.480 3.37 ± 0.480 *0.034 
Oxalate (mmol/24hr) 0.160 ± 0.0200 0.150 ± 0.0200 0.609 
Phosphate mmol/24hr) 16.3 ± 3.76 37.9 ± 3.76 *0.001 
Potassium (mmol/24hr) 145 ± 39.2 48.7± 39.2 0.101 
Sodium (mmol/24hr) 74.0 ± 17.9 95.7 ± 17.9 0.409 
Sulphate (mmol/24hr) 12.2 ± 1.63 19.0 ± 1.63 *0.011 
Uric acid (mmol/24hr) 2.65 ± 0.410 4.09 ± 0.410 *0.023 
RS Brushite 1.79 ± 0.640 2.00 ± 0.640 0.813 
RS CaOx 0.33 ± 0.350 2.47 ± 0.350 *0.001 
RS Uric acid 0.74 ± 0.310 1.69 ± 0.310 *0.040 
. . .. 
*Dtfference ts stattsttcally stgntftcant: p s 0. 05, B (Unne sample from black subjects); W (Unne sample 
from white subjects). RS: Relative Supersaturation. 
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3.4.2 Crystallization Experiments 
CaOx Metastable Limit 
Tables and plots for individual urines are given in Appendix 1, Tables 1.3 and 1.4 as well as 
Figures 1.1 and 1.2, respectively. In order to compare these, particle counts for the individual 
experiments were averaged, yielding the mean plots shown in Figures 3.1 (a) and (b) below. 
However, it is recognized that such an approach might not necessarily give absolute values 
for the MSL. Nevertheless, the approach allows a semi-quantitative comparison to be made 
between black and white subjects. 
The concentration that corresponds to the MSL of each fraction is denoted by a colour coded 
arrow. All the urine fractions from white subjects had the same MSL (0.015 mol/L). The 
MSL for the urine fractions from black subjects followed the trend C > UF > P, where C: 
concentrate, UF: ultrafiltrate and P: prefiltrate with the corresponding values of 0.060, 0.045, 
and 0.030 mol/L, respectively. These values show that urines from white subjects for all the 
three fractions have significantly lower MSL (0.015 mol/L; p < 0.05) than urine from black 
subjects (range: 0.030 - 0.060 mol/L; p < 0.05). 
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Figure 3.1: Mean metastable limit (MSL) plots for three urine fractions: ultrafiltrate 
(UF); prefiltrate (P); and concentrate (C) from (a) 10 black (B) and (b) 10 white (W) 
male subjects. 
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Comment 
The significantly higher MSL of all the fractions from black subjects is an indication of 
resistance to CaOx crystal formation in urine from this group. Moreover, the results clearly 
demonstrate that the arious fractions of the urine from black subjects have different 
inhibitory capacities themselves whereas those from white subjects are indistinguishable in 
this regard. Of even greater interest, is the observation that while removal of macromolecules 
> 10 kDa in whites had no effect on the MSL, concentrating the macromolecules in the urine 
from black subjects caused the MSL to increase. 
Scanning Electron Microscopy (SEM) 
Representative scanmng electron micrographs of crystals obtained after the induction of 
CaOx crystallization in urine fractions from black and white subjects are shown in Figures 
3.2 and 3.3, respectively. Crystals deposited in urine fractions from black subjects were 
mainly COM compared to COD from white subjects. Generally, the degree of aggregation 
was greater in all the fractions from white subjects compared to those from black subjects. In 
both groups, aggregation decreased in the sequence UF < P <C. It was observed that crystals 
in all the fractions from black subjects were smaller than those in white subjects. 
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Figure 3.2: Scanning electron micrographs of crystals induced from the three urine 
fractions from black subjects: ultrafiltrate (BUF); prefiltrate (BP); concentrate 
(BC) at 10 K magnification. 
Figure 3.3: Scanning electron micrographs of crystals induced from the three urine 
fractions from white subjects, ultrafiltrate (WUF); prefiltrate (WP); and 
concentrate at 1 0 K magnification. 
Comment 
54 
These results suggest that urinary macromolecules (MW > 10 kDa) in black subjects are more 
effective inhibitors of CaOx crystal growth and aggregation than those in the urine of their 
white compatriots. The fewer number of individual crystals demonstrated by the micrographs 
in the concentrate (C) and the prefiltrate (P) of samples from black subjects suggests more 
effective inhibition of crystal nucleation and aggregation in this group. 
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14C-Oxalate Deposition 
The mean percentage of 14C-oxalate deposited by each urine fraction from black and white 
subjects is shown in Figures 3.4 (a) and (b), respectively. Individual graphs for each urine 
fraction are shown in Appendix 1, Figures 1.3 and 1.4. 
Both figures demonstrate that the percentage deposition follows the trend concentrate < 
prefiltrate < ultrafiltrate (C < P < UF). Deposition induced by all urine fractions from white 
subjects (52 %, 40 % and 35 % for WC, WP and WUF, respectively) was slightly higher 
compared to those from black subjects (48 %, 32 % and 31 % for BC, BP and BUF, 
respectively) but these differences were not statistically significant. 
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Figure 3.4: Mean percentage [ 14C]-Oxalate deposited in three urine fractions: 
ultrafiltrate (UF); prefiltrate (P); and concentrate (C) from 10 black (a) and 10 white 
(b) male subjects. 
Comment 
The similar trend C < P < UF demonstrated by both groups indicates that unnary 
macromolecules in both race groups are inhibitors of CaOx crystal deposition. It is evident 
from these results that there is no distinction that can be made between the relative efficacies 
of the macromolecules from the two groups in this regard. Nonetheless, all the fractions from 
black subjects displayed a trend which suggested a slightly stronger inhibition of CaOx 
deposition than that from the white subjects. 
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CaOx crystal aggregation inhibition 
Figure 3.5 shows the mean plots of absorbance vs. time from which the sedimentation rates 
of a COM crystal slurry were determined before and after the addition of the urine fractions 
at a ratio of 4:1 of COM slurry to urine, from both black and white male subjects. Table 3.1 
shows the average slopes obtained and the corresponding calculated percentage inhibition 
demonstrated by each of the urine fractions. 
Figure 1.5 in Appendix 1 shows the individual COM plots from which the mean COM slurry 
slopes were calculated. Individual plots and percentage inhibition values are shown in 
Appendix 1, Figures 1.6 and 1.7 and Tables 1.5 and 1.7 for urine fractions from black and 
white subjects respectively. 
It was noted that the percentage inhibition by the concentrate and prefiltrate was the same 
within a particular race group (83 %for blacks and 76% for whites). It was also noted that 
the extent of inhibition was higher in the black group (range 76%- 83 %) than in the white 
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Mean slopes of absorbance vs. time graphs, R2 and percentage inhibition of 
aggregation (lA %) induced by each urine fraction from black subjects. 
Slope X -to·-' (OD/sec); (R2) 1_, o;., (p-values , wrt p-values 
COM) 
29; (0.955) 
5.0; (0.962) 83 (p < 0.05) 
5.0; (0.991) 83 (p < 0.05) 




7.0; (0.971) 76 (p < 0.05) 
7.0; (0.990) 76 (p < 0.05) 







* md1cates that the difference 1s stat1st1cal/y significant: p :::; 0. 05 
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Figure 3.5: Mean COM crystal sedimentation plot of absorbance vs. time 
before and after the addition of urine fractions from (a) black and (b) white 
subjects at a ratio of 4:1 slurry to urine. The arrows show the time at which 
stirring was stopped and the trendline indicates the absorbance slope used for the 
calculation of aggregation inhibition. 
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Comment 
These results demonstrate a higher aggregation inhibition by the urine concentrates and 
prefiltrates than the ultrafiltrates from both race groups. This indicates that the urinary 
macromolecules from both race groups are strong inhibitors of CaOx crystal aggregation. The 
same extent of aggregation inhibition by the concentrate and prefiltrate is surprising since it 
suggests that the efficacy of the macromolecules to achieve inhibition of aggregation is 
independent of concentration. Indeed, no significant difference was observed between 
samples from black and white subjects. However, a significantly higher aggregation 
inhibition was noted in the concentrates from black subjects compared to the prefiltrates from 
the same group. 
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3.5 DISCUSSION 
Urine composition data demonstrated that citrate, magnesium, phosphate and uric acid were 
significantly lower in urine samples from black subjects. Relative supersaturation of CaOx 
and uric acid (UA) were also significantly lower in this group. All of these physiochemical 
risk factors are in agreement with the empirically observed lower stone incidence in black 
subjects relative to their white compatriots. However, all of these values lie within the normal 
range. Therefore, they alone cannot explain the virtual absence of stones in this race group. 
Normal urine itself retards and inhibits crystallization (Pak et a!. 1976: Coe et al. 
1991) and thus it is possible that the black population's urine is superior to whites in this 
regard. Indeed, the present study demonstrated this. MSLs showed that urine samples from 
white subjects have a relatively lower MSL compared to urine from black subjects and that 
this was independent of the composition of the urine with respect to macromolecules. This is 
in line with the results reported by Ryall et al. ( 1986), who demonstrated that stone formers 
have lower MSLs than healthy controls. As indicated earlier, the presence of macromolecules 
> 10 kDa in the urine from black subjects induced an increase in the MSL, whereas it had no 
effect on the MSL of the urine from their white counterparts. This provides compelling 
evidence that the macromolecules in the urine of blacks are superior inhibitors of CaOx 
crystallization. 
In both race groups, 14C-oxalate deposition followed the same trend for all the three 
urine fractions, namely C < P < UF. These results indicate that concentrated urine (which 
contains the greatest proportion of macromolecules) is a potent inhibitor of CaOx deposition 
in both race groups. 
Spectrophotometric data demonstrated a higher inhibition of aggregation by the urine 
concentrates than the ultrafiltrates from both race groups. Of great interest is that the 
concentrate and the prefiltrate fractions from both race groups inhibited crystal aggregation to 
the same extent. As mentioned earlier, this suggests that inhibition by these macromolecules 
proceeds independently of concentration. However, it also indicates synergism between 
macromolecules of all sizes in preventing CaOx crystallization. Comparing the two race 
groups, the inhibition induced by urine samples from the black group was 8 % higher than 
that of the white group. Even though this difference is relatively small, this result is in 
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agreement with that demonstrated by Asplin ( 1999) and Tiselius et al. ( 1995) when 
comparing the CaOx aggregation inhibition by normal men and stone formers. It is also 
noteworthy that when macromolecules > 1 0 kDa were removed, inhibition of CaOx 
aggregation decreased, thereby clearly indicating that this crystallization mechanism is 
controlled by macromolecules whose size exceeds this lower limit. 
The aggregates of large COD crystals observed in urine fractions from white subjects 
relative to the free COM crystals deposited in fractions from black subjects are in line with 
the results reported by Robertson et al. ( 1 968) and Dent ( 1971 ) who observed the identical 
differences in crystal type in the urine of stone formers and that of healthy men. This 
evidence supports the notion that normal urine contains some inhibitors of CaOx crystal 
aggregation (Robet1son and Peacock 1972 ). Moreover, the precipitation of COD crystals 
compared to COM crystals is considered to be of great pathological importance since the 
former are less adherent to renal epithelial cells (Wesson et al. 1998: Cerini et al. 1999). 
The results reported in this chapter have shown that filtration removes urmary 
macromolecules which in turn increases CaOx crystallization in both race groups. However, 
smaller crystals and a lower degree of crystal aggregation together with greater inhibition of 
crystal deposition and CaOx aggregation in samples from black subjects compared to their 
white fellow citizens suggest more effective inhibition in the former group. This 
demonstrates the inhibitory role of macromolecules in the black population group. Therefore 
macromolecular inhibitors of CaOx deposition and aggregation may play a role in 
contributing towards stone rarity in black subjects. 
40 ~ • ~ • " , " ~' ' r ~ ~"'- • '> ' • • 1 
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CHAPTER FOUR 
INHffiiTORY EFFECT OF URINARY PROTEINS ASSOCIATED WITH 
CALCIUM OXALATE DffiYDRATE (COD) CRYSTALS IN THE 
URINE OF BLACK AND WIDTE SOUTH AFRICAN MALES 
4.1 INTRODUCTION 
Approximately 2-5 % of total dry weight of CaOx renal stones is composed of the organic 
matrix (Boyce and Ganey 1956; Boyce and King 1959; Boyce 1968; Warpehoski et al. 1981: 
Stalcholy and Goldberg 1985). As initially analyzed by King and Boyce ( 1959), about 64% 
of this organic matrix is protein. In their experimental model, Khan and Hackett (1987) 
demonstrated that the organic material becomes intimately associated with crystals during the 
early stages of their development. Following these findings, the association of urinary 
macromolecules with CaOx crystals has been extensively studied (Doyle et al. 1991 and 
1995; Sorensen et al. 1995; Atmani et al. 1996; Honda et al. 1997: Atmani and Khan 2002: 
Webber et al. 2003; R)all et al. 2005). The major fmding of these studies is that proteins are 
selectively incorporated into CaOx crystals. 
Numerous studies have been conducted to identify and characterize the proteins 
incorporated into the crystals matrix extract (Atmani et al. 1996; Honda et al. 1997; Ryall et 
al. 2000: Atmani and Khan 2002) and to test their inhibitory properties against CaOx 
urolithiasis (Shiraga et al. 1992; Sorensen et al. 1995; Doyle et al. 1996; Webber et al. 2002). 
These studies have focused on the inhibitory properties of the matrix extract protein 
incorporated in CaOx crystals without attention being directed on either COM or COD. 
As described in Chapter 1, the black South African population has a relatively lower 
urinary calcium concentration compared to their white counterparts (Modlin et al. 1967: 
Whalley eta!. 1998: Rodgers et a!. 2002). Lower urinary calcium concentrations favour the 
formation of COM crystals while higher concentrations favour COD crystal formation (Burns 
and Finlayson 1980). Webber et al. (2002) have shown that urinary crystals precipitated from 
black subjects are mainly composed of COM compared to COD precipitated from white 
subjects. Considering the relatively lower urinary calcium concentration of blacks, this is not 
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surprising. The two main proteins in the organic matrix of CaOx crystals have been reported 
to be osteopontin (OPN) (Atmani et a!. 1996: Webber et a!. 2003: R}all et al. 2005) and 
UPTFI (Doyle eta!. 1995: Ryall et al. 2000: Webber eta!. 2002 and 2003: Ryall et al. 2005). 
UPTFI is the principal intracrystalline protein in COM crystals (Doyle eta!. 1995: Webber et 
al. 2002 and 2003; Ryall et al. 2005) and OPN in COD crystals (Atmani et al. 1996; Webber 
et al. 2003; Ryall et al. 2005). COM and COD crystals can be selectively precipitated from 
urine by adjusting the calcium concentration (Burns and Finlayson 1980). 
The study described in this chapter addresses for the first time, the inhibitory 
properties of the matrix extract protein included in COD crystals from the urine of black and 
white South African subjects. COD instead of COM was selected for this study because the 
latter has already been investigated in this context (Durrbaum et al. 2001: Webber et al. 2002 
and 2003; Rodgers et al. 2006). Since there is a high abundance of osteopontin in COD 
crystals (Atmani et al. 1996; Webber et al. 2003: R::. all et al. 2005) compared to other 
proteins, it was anticipated that by focusing attention on the COD crystal matrix extract from 
the two race groups, insights into the possible inhibitory role of this urinary protein in the 
context of the South African black versus white stone paradox, might be obtained. 
4.2. AIMS AND OBJECTIVES 
• To precipitate COD crystals in urine samples from black and white healthy subjects. 
• To isolate and characterize the crystal matrix extract (CME). 
• To semi-quantitatively measure osteopontin (OPN) in CME using Western Blotting. 
• To conduct a series of crystallization experiments investigating the possible inhibitory 
role of COD-CME proteins in ultraflltered urine of black and white healthy male 
subjects. 
• To repeat the investigation in a cross-over design involving the addition of COD-
CME proteins from black subjects in urine samples from whites, and vice versa. 
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4.3. MATERIALS AND METHODS 
4.3.1 Urine collection and treatment 
Individual 24 hour urine samples from 35 different black (B) and 35 different white (W) 
healthy males were obtained without preservatives and were tested and filtered as previously 
described in Chapter 2. Seven pools comprising 1.5 L from each of 5 urine samples were then 
constructed. Urine compositional analyses were not performed. 
4.3.2 Preparation and Isolation of COD-CME 
The calcium concentration of each pooled urme sample was measured usmg atomic 
absorption spectroscopy (Fernandez and Khan 1971 ). The CME was prepared from each 
pooled urine sample following a protocol described by Doyle et al. ( 1991 ). In this method, 
the urines were incubated at 37 °C in a shaking water bath (Labcon Johannesburg) and 1 
mol!L CaCh was added to a fmal concentration of 12 mmol/L. The CaOx MSL of the 
calcium-adjusted urine was measured using the method of Ryall et al. ( 1985). 30 mmol/L 
Na20x was added in excess of the previously determined MSL at 0, 1, 2, 3 hours to induce 
COD crystallization. Crystals were collected by filtration through 0.22 !Jffi filters and washed 
with distilled water, dried and analyzed by x-ray powder diffraction (Sutor and Scheidt 
1968). The collected crystals were then demineralized in 0.25 mmol/L EDTA pH 8.0 (250 
mmol!L per gram of crystals) yielding the calcium oxalate dihydrate crystal matrix extract 
(COD-CME), henceforth referred to as CME. This was desalted by extensive dialysis against 
deionized water at 4 °C for 48 hours using a dialysis membrane cut-off of 10 kDa. The 
resulting CMEs from the seven pools were combined and stored at -20 °C for further use. 
4.3.3 Characterization of COD-CME 
SDS-PAGE 
1 mg of COD-CME from each group was dissolved in 10 !JL of water. 2 !JL of 5 X SDS 
reduction buffer was added to the samples and boiled at 1 00 °C for 5 minutes. Once the 
samples had cooled down, a low molecular marker standard (Bio-Rad) was added and they 
were subjected to 10 % sodium dodecyl sulfate polyacryalamide gel electrophoresis (SDS-
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PAGE) and 3 % stacking gel. The gels were electrophoresed using Bio-Rad Mini Protean II 
apparatus (Bio-Rad Laboratories, Hercules, California, USA) at 25 rnA per gel for 1 hour. 
The electrophoresed gels were stained with Coomassie blue (0.05 % Coomassie, 50 % 
methanol and 7 % acetic acid) for 1 hour, for detection of protein bands followed by 
destaining with 25% ethanol and 7% acetic for 30 minutes or blotted in a blotting buffer for 
immunodetection of osteopontin (OPN). 
Western Blotting for OPN 
The electrophoresed gel together with a nitrocellulose membrane was equilibrated in a 
blotting buffer for 15 minutes (Appendix 2.1 ). The proteins from the gel were transferred 
onto a nitrocellulose membrane by running it at 100 V or 300 rnA for 60 minutes. The 
membrane was then blocked for 1 hour in blocking buffer (Appendix 2.1) followed by 3 X 15 
minutes washes in blocking buffer. This was followed by incubation with the primary 
antibody for 90 minutes. The primary antibody used was a rabbit polyclonal osteopontin 
antibody (Abeam, Cambridge, England) at a dilution of 1:500. After 3 X 15 minutes washes 
in blocking buffer the blot was incubated with the secondary rabbit antibody (Amersham 
Biosciences, New Jersey, USA) at a dilution of 1:2000 for 60 minutes. A third 3 X 15 
minutes wash was carried out prior to detection of OPN with 4-chloro-1-naphthol (Sigma-
Aldrich) for 20 minutes. 
Bradford Assay 
The Bradford assay, (Bradford 1976) was performed using bovine serum albumin (BSA) 
standards (Bio-Rad) to determine the total protein concentration in crystal matrix extracts 
from black and white subjects, henceforth referred to as BCME and WCME respectively. 
Triplicate standard solutions of BSA (Bio-Rad) were prepared and measured at 595 nm 
against the standard blank using a UV -vis spectrophotometer (Spectrophotometer, Anthelie, 
France). A standard curve was plotted from which the protein concentrations were calculated. 
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4.3.4 Crystallization Experiments 
The effect of the CME from both race groups on particle formation kinetics, [14C]-oxalate 
deposition kinetics, aggregation and nucleation of CaOx crystals was determined at a final 
concentration of 0.5 mg/L in 7 different pools (independent to those described in 4.3.1) of 5 
freshly collected 24 hour urine samples (200 mL each sample) from black and white healthy 
males. This concentration corresponds to that which achieved maximum inhibition of crystal 
aggregation in the study reported by Doyle et al. ( 1995). The pooled samples were 
prefiltered through 0.75 Jlm filters (Macherey-Nagel; GmBH and Co., Germany), followed 
by further filtration through a 0.45 Jlm nitrocellulose filter (Sartorius AG, Germany) and then 
ultrafiltered through a 10 kDa cut-off membrane (Millipore Corporation, Bedford; USA). 
The ultrafiltrate was used for the crystallization experiments. 
CaOx Metastable Limit (MSL) 
The MSL of the pooled ultrafiltrate (UF) samples was determined as described in Chapter 2 
following the method of Ryall et al. (1985). The MSL was not determined in the presence of 
the protein because it has been reported that it does not have an effect on the metastable limit 
(Doyle eta!. 1995). In all experiments, the ultrafiltrate was used as the control. 
Cross-over design experiment 
For the kinetics and [14C]-oxalate deposition experiments, a cross-over approach was adopted 
(Craig et a!. 1999). This permitted the effect of each protein to be tested in its parent urine 
and in the urine from the other race group. Thus, WCME and BCME were each 
independently tested in BUF and WUF (Figure 4.1) 
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BUF WUF 
! 1 ! 1 
BUF BUF + BCME BUF + WCME WUF WUF + BCME WUF+ WCME 
Figure 4.1: Cross-over design crystallization experiment. 
Effect of CME on particle number, volume and size 
Three conical flasks, each containing 50 mL ofBUF or WUF, were set up as shown in Figure 
4.1. The first flask served as a control and the proteins were added to the other flasks. Once 
the MSL had been determined (in BUF and WUF), 10% (v/v) ofNa20x at a concentration of 
30 mmol/L above the MSL was added to each flask and incubated at 3 7 °C for 2 hours in a 
shaking water bath set at 100 rpm (Labcon, Johannesburg). A zero time analysis was 
performed before the addition of Na20x and the reaction was monitored as previously 
described in Chapter 2 using a Coulter Multisizer I (Coulter Electronics Ltd., England). 
Effect of CME on [14 C)-oxalate deposition 
This experiment was conducted as described in Chapter 2. Three sets of soda-glass flasks 
each containing 30 mL of BUF or WUF were set up as shown in Figure 4.1. The first flask 
served as the control and once the proteins had been added to the other flasks, the reaction 
was continued as previously described in Chapter 2. The percentage of precipitated 14C-
oxalate by each protein was determined. 
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Effect of CME on COM and COD crystal aggregation inhibition 
For the aggregation experiment, the COM and COD crystals were treated the same way (but 
separately) as in Chapter 2 (Hess et al. 1989). After an overnight equilibration of COM 
crystals in 10 mmol!L Tris-aminomethane (Tris).HCl and 90 mmol/L NaCl, pH 7.2 buffer at 
37 °C with constant stirring at 1100 rpm, the resulting slurry was then mixed with UF and 
CME at a slurry-to-urine ratio of 4:1 (1600 j.JL: 400 j.JL) and a total protein concentration of 
0.5 mg/L and equilibrated for 2 hours at 1100 rpm. The absorbance of the equilibrated 
mixture was monitored at 620 nm at 37 °C for 15 minutes and inhibition of COM crystal 
aggregation was determined as described in Chapter 2. The protocol was then repeated using 
COD crystals except that the inhibition was determined in the absence of UF. 
Effect of CME on crystal nucleation 
The effect of CME on crystal nucleation was determined using the method developed by 
Hess et al. (1995) as previously described in Chapter 2. This experiment was performed with 
the protein only at a final concentration of 0.5 mg/L using 1 mL CaCh and 1 mL Na20x 
solutions. OD62o was recorded every 0.5 seconds over 60 minutes. 
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4.4 RESULTS 
4.4.1 Characterization of CME 
XRD was used for the identification of the crystals precipitated from the urine of black and 
white subjects after adjustment of the calcium concentration to 12 mmol/L. The XRD pattern 
obtained for crystals from both black and white subjects is shown in Figure 4.2. Interplanar d-
spacings for the most prominent reflections are indicated. This pattern corresponds with the 
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Figure 4.2: XRD pattern of crystals precipitated from B and W urine 
samples after adjusting Ca concentration to 12 mmol/L. 
4.4.2 SDS-PAGE and Western Blotting for OPN 
Figure 4.3 shows a Coomassie stained gel of 1 mg of BCME and WCME. Both samples 
showed bands at 30, 66 and 97 kDa, which might be due to low amounts ofUPTFl (30 kDa), 
and osteopontin, (66 and 97 KDa). The OPN immunoblot blot is shown in Figure 4.4. OPN 
was detected as an intense continuous band from 50 to 100 kDa in both race groups. The 
intensity of this band indicates that OPN is the dominant protein in CME. There is also a 
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Figure 4.3: Coomassie stained 10% 
SDS-PAGE of CME from black and 
white subjects. B: Black CME, W: 








w B kDa 
Figure 4.4: Western blot of CME from 
blacks and whites immunoblotted for 
OPN under non-reducing conditions. B: 
Black CME, W: White CME, MM: low 
molecular weight marker. 
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4.4.3 Bradford Assay 
A Bradford assay was performed to determine the total protein concentration in BCME and 
WCME. Table 4.1 shows the concentrations of BSA used to plot a standard curve for the 
determination of the protein concentrations while the BSA standard curve is shown in Figure 
4.5. 
Table 4.1: Standard curve data for Bradford bovine serum albumin (BSA) protein assay. 
BSA (~g/ml) Mean Standard 
deviation 
1 0.081 0.024 
2 0.150 0.015 
3 0.198 0.006 
4 0.254 0.009 
5 0.316 0.020 
10 0.577 0.027 
Bradford BSA Assay 
- y = 0.0546x + 0.0352 E c: 0.8 
R2 = 0.9988 It) 
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Figure 4.5: Bradford bovine serum albumin 
(BSA) protein assay standard curve. 
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Table 4.2 shows the total urinary protein concentrations from both BCME and WCME. The 
protein concentration ranged from 17 to 65 mg/L in black subjects and from 20 to 45 mg/L in 
white subjects. There is a higher mean total protein content included in BCME compared to 
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4.4.4 Crystallization Experiments 
Determination of CaOx MSL 
The mean MSL of black and white pooled UF (n = 7) are given in Figure 4.6 (a) and (b) 
respectively. These show that pooled urines from black subjects have a significantly higher 
MSL (0.090 moVL) than pooled urine from white subjects (0.045 moVL), p ~ 0.05. Individual 













I BUF 10000 
8000 ~ 
/ ~ 6000 
! 4000 
1\retastabl~mt I 
2000 .. ~ ...... 
0 
-..-
0 0.05 0.1 0.15 0.2 
Na20x Concentration (moi/L) 
WUF 
25000 .,----------------__l.-----1 
0 0.05 0.1 0.15 0.2 
Na20 x Concentration (moi/L) 
Mean MSL plots ofUF from (a) black (BUF) and (b) white (WUF) 
Chapter 4 74 
Comment 
Previous work on CME protein has shown that it has no effect on the MSL (Doyle et a!. 
1995). This study therefore did not investigate the effect of this protein on the MSL but only 
compared the MSL of pooled ultrafiltered urine samples from black and white subjects. 
Pooled ultrafiltered samples from the former group were found to have a significantly higher 
MSL compared to those from the latter. This is in qualitative agreement with the results 
obtained for individual urines in Chapter 3. However, it is important to note that the MSLs of 
the ultrafiltered urines obtained for this chapter are significantly higher than those for the 
ultrafiltered samples in Chapter 3. The only explanation to this could be the fact that in 
Chapter 3 the MSL of individual samples was reported whereas in the current study it was a 
combined effect of 5 pooled samples. 
Effect of CME on particle number 
Table 4.3 shows the number of particles in BUF and WUF before and after the addition of 
BCME and WCME measured at 120 minutes after the addition ofNa20x 30 mmol/L above 
MSL. Figure 4.7 shows the rate of particle formation from 0 to 30 after the addition of 
Na20x. The raw data for each experiment is presented in Appendix 2, Table 2.3 and 2.4. 
In all seven BUF samples, addition of BCME or WCME induced an increase in particle 
number. On the other hand, while the addition of BCME to WUF again resulted in an 
increase in particle number, the addition of WCME caused a decrease in 5 samples. 
Individual plots of the particle formation kinetics are shown in Appendix 2, Figures 2.3 and 
2.4. The mean particle formation kinetics plots in Figure 4. 7 show two interesting features. 
Firstly, the baseline rate of particle formation (i.e. in the absence of protein extract) is 100% 
slower in BUF than in WUF (11.01 vs. 22.24). Secondly, addition of the extract in both 
ultrafiltered urines slows down the kinetics. 
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Table 4.3: Particle number (/500 !J.L) in black and white ultrafiltered urine (BUF and 
WUF) before and after the addition of BCME and WCME at 120 minutes, at 
final concentrations of 0.5 mg/L (n = 7). 
Pooled Sam pie BUF BUF+BCME BUF+WCME p-values 
1 11909 13496 12008 
2 14006 22881 24511 
3 21796 22450 25886 
4 22638 24036 23274 
5 17226 22408 19074 
6 7266 11825 8611 
7 19433 24162 20073 
Mean±SE 16325 ± 1533 20179 ± 1568 19062 ± 1846 
Pooled Sample WUF WUF+BCME WUF+WCME p-values 
1 20647 29755 16437 
2 19028 24288 16309 
3 21731 22264 22459 
4 22277 23914 17703 
5 20297 22929 21247 
6 19996 23082 16665 
7 18657 21641 16933 
Mean± SE 20376 ± 1533 23981 ± 1568 18250 ± 1846 
Comparisons p-values 
BUFvs. WUF 0.0864 
BUF + BCME vs. 0.728 
BUF+WCME 
*WUF + BCME vs. *0.001 
WUF+WCME 
BUF + BCME vs. 0.112 
WUF+BCME 
BUF + WCME vs. 0.763 
WUF+WCME 
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Figure 4.7: Mean plot of particle number vs. time in (a) BUF and (b) WUF before 
and after the addition of BCME and WCME and Na20x. The rate of particle formation 
is given by the slope of the graph at 0 to 30 minutes (trendline) of the experiment. 
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Comment 
These results demonstrate that BCME is a promoter of CaOx crystal nucleation and that it 
operates in this manner independently of the urine milieu. However, the role of WCME 
varies in accordance with urine composition, thereby drawing attention to the synergistic 
relationship between protein inhibitory performance and urine composition. Promotion of 
CaOx crystal nucleation kinetics is considered as a favourable phenomenon in retarding 
kidney stone pathogenesis as it rapidly lowers the supersaturation of urine (Hess et al. 1995). 
BCME has demonstrated a higher potency than WCME in this regard. 
Effect of CME on particle volume 
Table 4.4 and Figure 4.8 show the effect of BCME and WCME on particle volume of BUF 
and WUF at 120 minutes after the addition of each protein. It is readily noted that at baseline, 
the total particle volume is lower in BUF than in WUF. This is consistent with the previously 
observed lower particle number in the former. In 5 samples the addition of BCME to BUF 
induced an increase in particle volume whereas increases and decreases were observed for 
WCME. For WUF, an increase in particle volume was observed in 5 samples after the 
addition of both BCME and WCME. Individual values at 30 minute intervals to t = 120 
minutes are in Appendix 2, Table 2.5 and 2.6. 
The mean particle volume formation kinetics plots are shown in Figure 4.8. Individual plots 
from which the mean was plotted are shown in Appendix 2, Figures 2.5 and 2.6. The rate at 
which particle volume increased was much slower in BUF (range 0.25 - 0.41 J.!m3 /min) than 
in WUF (range 0.79-0.97 J.!m3/min). This is consistent with the slower rate of nucleation 
previously reported for BUF (page 74). Of interest is that the kinetics increased when the 
protein extract was added to its parent urine but decreased in the cross-over experiments. 
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Table 4.4: Particle volume (x 106 f.J.m3/500 f.l.L) in black and white ultrafiltered urine 
(BUF and WUF) before and after the addition of BCME and WCME at fmal 
concentrations of 0.5 mg/L (n = 7). 
Pooled Sample BUF BUF+ BCME BUF+WCME p-values 
1 9. 19 10.67 7.52 
2 10.72 17.76 18.96 
3 19.23 27.72 12.82 
4 36.73 29.06 27.85 
5 31.07 33.57 33.13 
6 7.00 10.86 8.14 
7 42.79 26.39 38.24 
Mean± SE 22.39 ± 6.565 22.29 ± 3.025 20.95 ± 5.137 
Pooled Sample WUF WUF+ BCME WUF+WCME p-valucs 
1 19.35 20.75 29.68 
2 26.95 31.46 29.99 
3 27.01 34.38 40.83 
4 27.06 27.83 49.87 
5 30.34 33.35 39.21 
6 59.12 40.05 65.14 
7 71.96 39.02 64.21 
' 
Mean± SE 37.39 ± 6.565 32.41 ± 3.025 45.56 ± 5.137 
Comparisons p-values 
BUFvs. WUF 0.132 
*BUF + BCME vs. * 0.036 
BUF+WCME 
*WUF + BCME vs. * 0.005 
WUF+WCME 
BUF + BCME vs. 0.822 
WUF+BCME 
*BUF + WCME vs. * 0.052 
WUF+WCME 
0 0 * md1cates that the difference 1s stat1s/ica/ly Significant: p ~ 00 05 
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Figure 4.8: Mean plot of particle volume vs. time in (a) BUF and (b) WUF before 
and after the addition of BCME and WCME and Na20x. The rate of particle 
formation is given by the slope of the graph at 0 to 30 minutes (trendline) of the 
experiment. 
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Comment 
An increase in particle volume can occur as a result of several mechanisms such as; 
(i) increased nucleation, 
(ii) increased growth of existing particles, and 
(iii) increased aggregation with concomitant entrapment of air and/or cellular debris. 
It seems likely that the increases in particle volume in the present series of experiments are 
consistent with the previously described increases in nucleation corresponding to the addition 
of BCME to both BUF and WUF. The only apparent inconsistency is the observation of an 
increase in particle volume when WCME was added to WUF as this conflicts with the 
decrease in particle number reported in the previous section (page 74). However, this is 
readily explained by the proposition that aggregation (with entrapment of non crystalline 
extraneous material) is occurring. This would account for the observed decrease in particle 
number and the (present) increase in particle volume. The increase in kinetics when the 
protein extract was added to its parent urine and a decrease in the cross-over experiments 
draws attention to the notion that urine composition influences the ultimate behaviour of the 
protein extract. 
Effect of CME on particle volume-size distribution 
The mean particle volume-size distribution plots at 120 minutes for both BUF (n = 7) and 
WUF (n = 7) before and after addition of the protein are shown in Figures 4.9 (a) and (b), 
respectively. Individual plots are presented in Appendix 2, Figures 2.7 and 2.8. 
In BUF (control), most particles lie in the size range below 15 Jlm, with an ill-defined peak at 
3 Jlm. Addition of WCME has no effect on this distribution. However, addition of BCME 
dramatically increases the number of particles at 3 Jlm. As a result, there are far fewer 
particles in the bigger size range. 
In WUF (control) the distribution is similar to that in BUF (control) except that there are 
more particles in all size ranges up to 50 Jlm. Addition of WCME reduces the number of 
small particles (particularly those at 3 Jlm), with a concomitant increase in the number of 
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particles in the range 10 - 30 J.J.m. Addition of BCME dramatically increases the number of 
smaller particles, the consequence of which is that there are few particles bigger than 20 Jlm. 
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Figure 4.9: Mean particle volume-size distribution by (a) BUF and (b) WUF before 
and after the addition ofBCME and WCME at fmal concentrations of0.5 mg/L and at 
120 minutes ofthe experiment. 
Comment 
Addition of BCME both in its parent urine and in WUF induced a remarkable increase in the 
number and a decrease in the size of particles. These results suggest that BCME is an 
inhibitor of growth and/or aggregation while the converse is true for WCME. 
Effect ofCME on {14C}-oxalate deposition 
The effect of CME on 14C-oxalate deposition in BUF (n = 7) and WUF (n = 7) is shown in 
Figure 4.10 below. This is reported as the percentage of precipitated or bound oxalate at 
increasing time intervals from t = 0 to t = 120 minutes. Individual graphs are presented in 
Appendix 2, Figures 2.9 and 2.1 0. 
It is noted that at baseline (i.e. in the absence of CME from either group), the percentage of 
precipitated 14C-oxalate is significantly lower in BUF (41 %) than in WUF (74 %), p < 0.05. 
The graphs also show a significant decrease in the amount of deposited CaOx when CME 
from either group is added to BUF and that the effect is significantly greater in the presence 
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of BCME (42% to 25 %) than in the presence of WCME (42% to 32 %). Of great interest 
and importance is that addition ofCME (from both groups) to WUF had no effect. 
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Figure 4.10: Mean percentage [14C]-Oxalate deposited in (a) BUF and (b) WUF 
before and after the addition ofBCME and WCME at fmal concentrations of0.5 
mg/1. 
Comment 
The significantly lower percentage of deposited 14C-oxalate in BUF (41 %) than in WUF (74 
%), p < 0.05 demonstrates that under exactly the same conditions, a sample of ultrafiltered 
urine from black subjects is more resistant to CaOx crystallization than an equivalent sample 
from white subjects. Addition of CME from either group to BUF retarded CaOx deposition 
and this was more pronounced by BCME whereas both proteins had no effect on WUF. 
These results show that BCME is an effective inhibitor of CaOx crystal formation in its own 
urine while WCME does not have the same capacity in its own urine. This is therefore an 
extremely important observation as it possibly contributes towards accounting for the 
difference in stone incidence between the black and white groups. 
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Effect of CME on COM and COD aggregation 
(a) Effect of CME on COM crystal aggregation 
The effect of CME (n = 7) on crystal aggregation was first tested in a COM crystal slurry in 
the absence of ultrafiltered urine. This was achieved by measuring the decline in UV 
absorbance as a function of time. Both BCME and WCME inhibited COM crystal 
aggregation (Table 4.5). BCME inhibited crystal aggregation to a significantly greater extent 
(91 %) compared to WCME (69 %), p < 0.05. A mean plot of absorption vs. time is shown in 
Figure 4.11. An arrow indicates the time at which stirring was stopped. Individual curves are 
presented in Appendix 2, Figures 2.11. 
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Table 4.5: Mean slopes of absorbance vs. time graphs, R2 and percentage aggregation 
inhibition CIA%) induced by BCME and WCME in COM slurry in the absence 
and presence of urine (n = 7). 
Sample Slope X -to--t I" 'Yo (p-valucs , wrt p-values 
(OD/scc); (R2) COM) 
COM 35; (0.993) 
COM+BCME 3.0; (0.989) 91 (p < 0.05) 
COM+WCME 11; (0.982) 69 (p < 0.05) 
*BCMEvs. WCME * 0.001 
COM+BUF 9.0; (0.997) 74 (p < 0.05) 
COM+ BUF + BCME 3.0; (0.982) 91 (p < 0.05) 
COM + BUF + WCME 3.0; (0.992) 83 (p < 0.05) 
COM+ BUF + BCME vs. 0.183 
COM+ BUF + WCME 
COM+WUF 6.0; (0.993) 83 (p < 0.05) 
COM+ WUF + BCME 3.0; (0.989) 91 (p < 0.05) 
COM + WUF + WCME 2.0; (0.985) 94 (p < 0.05) 
COM+ WUF + BCME vs. 0.778 
COM+ WUF + WCME 
Comparisons p-values 
BUFvs. WUF 0.508 
COM+ BUF + BCME vs. 0.579 
COM+ WUF + BCME 
COM+ BUF + WCME vs. 0.077 
COM+ WUF + WCME 
.. * md1cates that the difference IS stattsttcally stgnificant: p ~ 0.05 
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Figure 4.11: Mean COM crystal sedimentation plot of absorbance vs. time before 
and after the addition of BCME and WCME at final concentrations of 0.5 mg/L. An 
arrow indicates the time at which the stirrer was switched off and the trendline 
indicates the absorbance slope used for the calculation of aggregation inhibition. 
Thereafter, the experiment was repeated in the presence of ultrafiltered urine alone (n = 7) 
and finally, in the presence of the combination of the latter and crystal matrix extract (n = 7). 
Figure 4.12 shows a mean plot of absorbance vs. time for these experiments while Table 4.5 
shows the mean slopes and corresponding percentage inhibition of aggregation. Individual 
plots are in Appendix 2, Figures 2.12 and 2.13 and corresponding percentages of aggregation 
inhibition are in Appendix 2, Table 2.7. 
Addition of BCME in BUF significantly increased the inhibition of COM crystal aggregation 
from 74% to 91 %, the same inhibition level that BCME produced on its own without urine 
(Table 4.5). The addition of WCME to WUF also significantly increased the percentage 
inhibition, albeit by not quite the same amount (i.e. from 83 %to 94 %). Nevertheless, this 
was the highest level of inhibition achieved in the different experiments. In the cross-over 
experiments, percentage inhibition also increased relative to the control. Of the two 
experiments in this category, the synergistic combination of BCME in WUF was more 
efficacious than WCME in BUF. 
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Figure 4.12: Mean COM crystal sedimentation plot of absorbance vs. time before 
and after the addition of BCME and WCME in (a) BUF and (b) WUF at final 
concentrations of 0.5 mg/L. An arrow indicates the time at which the stirrer was 
switched off and the trendline indicates the absorbance slope used for the calculation 
of aggregation inhibition. 
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Comment 
It is immediately apparent that the ultrafiltered urines of both race groups have different 
inhibitory capacity with respect to COM crystal aggregation. In this regard WUF exerts a 
stronger (but statistically insignificant) effect than BUF (83 % vs. 74 %, p > 0.05). 
Interestingly, addition of CME increases the inhibition to 91 %in the black group and to 94 
% in the white group. Comparison with the results obtained for the protein extract alone 
(Table 4.5) shows the same level of inhibition for BCME (91 %) but a lower value for 
WCME (69 %). In the cross-over experiments, relatively stronger inhibition was achieved by 
BCME in WUF (91 %) compared to WCME in BUF (83 %). While these results demonstrate 
that the protein extract from both groups is an inhibitor of COM crystal aggregation, they 
cannot differentiate between their relative strengths in this regard. Similarly, while the 
synergistic role of both BUF and WUF is apparent, it is not obvious which one is superior. 
I 
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(b) Effect of CME on COD crystal aggregation 
Table 4.6 shows percentage inhibition of aggregation of COD induced by BCME and WCME 
in the absence of urine. Both BCME and WCME induced approximately the same level of 
aggregation inhibition of COD crystals; 46 and 42 %respectively. A mean plot of absorbance 
vs. time (7 experiments) is shown in Figure 4.13. Individual results are given in Appendix 2, 
Figure 2.14, and Table 2.8. 
Table 4.6 Mean slopes of absorbance vs. time graphs, R2 and percentage aggregation 
inhibition CIA%) induced by BCME and WCME in COD slurry in the absence 
of urine (n = 7). 
Sample Slope X -to·-' 1_,% (p-values, wrt p-value 
, (OD/sec); (R2) COD) 
COD 24; (0.991) 
COD+BCME 13; (0.983) 46 % (p < 0.05) 
COD+WCME 14; (0.989) 42 % (p < 0.05) 
BCME vs. WCME 0.326 
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Figure 4.13: Mean COD crystal sedimentation plot of absorbance vs. time before 
and after the addition of BCME and WCME at fmal concentrations of 0.5 mg/L. An 
arrow indicates the time at which the stirrer was switched off and the trendline 
indicates the absorbance slope used for the calculation of aggregation inhibition. 
Comment 
It is immediately noted that inhibition of COD crystal aggregation by the protein extracts 
(46 % and 42 % for BCME and WCME, respectively) is significantly different to that of 
COM crystal aggregation (91 %and 69% for BCME and WCME, respectively). The reason 
for this is unknown. However, it is anticipated that it is one of the defence mechanisms 
towards stone formation. It should be noted that inhibition of COM crystal aggregation 
relative to COD crystal aggregation could be of pathological importance because the former 
type of crystal cannot easily pass through the system as it is highly adherent to renal epithelial 
cells. On the other hand, COD crystals are less adherent to these cells, so even if they 
aggregate, to a less extent of course, they will be easily washed through. 
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Effect of CME on crystal nucleation 
Mean values for the percentage inhibition of nucleation (n = 7) are given in Table 4.7. This 
shows that both BCME and WCME induced inhibition of nucleation of CaOx crystals in an 
inorganic solution. However, BCME (90 %) showed a significantly higher inhibition 
compared to WCME (64 %), p < 0.05. A mean plot of 7 runs is shown in Figure 4.14, 
individual plots are in Appendix 2, Figure 2.15 and corresponding percentages of nucleation 
inhibition are in Appendix 2, Table 2.9. 
Table 4.7: Mean slopes of absorbance vs. time graphs, R2 and percentage nucleation 
inhibition (IN%) induced by BCME and WCME (n = 7). 
Sample Slope X -to--' h% (p-values, wrt p-value 
., 
(OD/sec); (R-) control) 
Control (Ctrl) 4.1; (0.991) 
Ctrl + BCME 0.4; (0.992) 90 (p < 0.05) 
Ctrl+WCME 1.5; (0.986) 64 (p < 0.05) 
*BCMEvs. WCME * 0.004 
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Figure 4.14: Mean CaOx crystal nucleation plots of absorbance vs. 
time before and after the addition of BCME and WCME at final 
concentrations of 0.5 mg/L. The trendline indicates the absorbance used 
for the calculation of nucleation inhibition. 
Comment 
In general, the effect of nucleation on CaOx crystallization is two-fold: 
91 
(i) It rapidly lowers urinary supersaturation without producing particles of significant 
stzes. 
(ii) It is an essential prerequisite for further formation of larger particles within the 
urinary tract which might eventually form a stone. 
In the context of the second point, retarding the rate of CaOx crystal nucleation might 
therefore be of great significance in reducing stone formation. The results reported above 
demonstrate that BCME (91 %) is a significant inhibitor of CaOx nucleation compared to 
WCME (64 %); p = 0.004. This observation might contribute towards understanding the 
rarity of stone incidence in the black population. 
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Effect of CME on COM crystal zeta potential 
Table 4.8 shows the individual zeta potential values of the COM crystal slurry before and 
after the addition ofBCME and WCME. Figure 4.15 shows the histogram of the mean values 
shown in Table 4.8. Addition of BCME to the COM slurry induced a significant increase in 
the zeta potential as indicated by an increase in the negative charge, whereas WCME did not 












Zeta potential (mV) of COM crystals before and after addition of BCME and 
WCME (n=9). 
-10.3 -15.8 -11.8 
-12.8 -18.9 -13.4 
-15.3 -20.8 -15.8 
-7.80 -15.4 -5.76 
-10.8 -14.1 -11.6 
-11.2 -16.0 -13.2 
-12.5 -16.3 -13.6 
-14.3 -18.2 -16.2 
-14.8 -9.81 -12.9 
-12.2 ± 0.92 -16.2 ± 0.92 (0.01) -12.7 ± 0.92 (0.419) *0.031 
* indicates that the difference is statistically significant: p ::::; 0. 05 
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Figure 4.15 : Mean zeta potential histogram before and after the addition of BCME and 
WCME to COM crystal slurry. 
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Effect of CME on COD crystal zeta potential 
Table 4.9 shows the individual zeta potential values of the COD crystal slurry before and 
after the addition ofBCME and WCME. Figure 4.16 shows the histogram of the mean values 
shown in Table 4.9. Addition of BCME to the COD slurry induced a significant increase in 
the zeta potential as indicated by an increase in the negative charge, whereas WCME induced 
a decrease in the zeta potential. Comparing BCME and WCME, the negative charge induced 












Zeta potential of COD crystals before and after the addition of BCME and 
WCME (n=9). 
-12.1 -16.6 -11.0 
-14.9 -17.2 -10.7 
-15.8 -19.6 -9.73 
-10.5 -17.4 -12.5 
-11.1 -18.4 -16.7 
-9.27 -17.0 -11.6 
-10.6 -12.8 -14.2 
-12.1 -14.2 -12.2 
-12.2 -12.2 -10.9 
-12.1 ± 0.77 -16.2 ± 0.775 (0.01) -9.79 ± 1.93 (0.419) *0.036 
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Figure 4.16: Mean zeta potential histogram before and after the addition of BCME 
and WCME to COD crystal slurry. 
Comment 
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These results demonstrate that BCME increases the magnitude of the negative zeta potential 
in COM crystals from -12.2 to -16.2 (p < 0.05), and in COD crystals from -12.1 to -16.2 (p < 
0.05) but that WCME has no such effect. Since a shift to more negative zeta potential is 
indicative of a greater capacity to inhibit crystal aggregation, it is concluded that BCME 
operates in this manner while WCME does not. 
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4.5 DISCUSSION 
The OPN immunoblot reported in this chapter (Figure 4.5) demonstrated that OPN is indeed 
the major protein included in COD crystals. This observation is in agreement with the results 
reported by several authors (Atmani et al. 1996; Webber et al. 2003; Ryall et al. 2005). OPN 
appeared as a continuous band from 50 to 100 kDa in both race groups. This might be due to 
degradation as OPN has been reported to be easily degraded by urinary proteases and no 
protease inhibitors were added to the samples (Bautista et al. 1996; Ryall et al. 2005). The 
band appearing at 120 kDa in both lanes may be aggregates of OPN (Johnson-Tardieu et al. 
2000. Webber et al. 2003). 
One of the main objectives of this chapter was to test the inhibitory effect of COD-
CME towards CaOx crystallization using various crystallization techniques. As explained 
earlier, the effect of nucleation on CaOx crystallization can be two-fold. Paradoxically, both 
promotion and inhibition of CaOx crystal nucleation are considered beneficial in this context. 
The results obtained for particle number and volume demonstrate that BCME is a promoter of 
CaOx crystal nucleation and this is independent of the urine milieu whereas for WCME this 
varies according to the urine composition. This observation in WCME indicates a synergistic 
role that exists between the urine milieu and the protein. 
Promotion of crystal nucleation is considered as a favourable process since it lowers 
urinary supersaturation without producing particles of significant sizes thus reducing the risk 
of forming stones (Hess et al. 1995). On the other hand, the actual nucleation assay 
demonstrated a highly significant inhibition of CaOx crystal nucleation by BCME (91 %) 
compared to WCME (64 %); p = 0.004. Nucleation is an essential prerequisite for further 
formation of larger particles within the urinary tract which might eventually form a stone 
(Hess et al. 1995). Therefore, retarding the rate of nucleation might therefore be of great 
pathological significance in order to reduce the rate of particle formation. The results reported 
here are contradictory in that they demonstrate that BCME is both a significant inhibitor and 
promoter of CaOx nucleation. It is therefore not possible to draw any conclusions from these 
particular experiments 
Particle size is also of great pathological importance as it determines whether particles 
will be trapped in the urinary tract or not (Hess and Kok 1996). A decrease in particle size 
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after the addition of CME is an indication of the role of this protein in delaying and reducing 
growth of CaOx crystals. The high reduction in size following addition of BCME compared 
to WCME suggests that the former is an inhibitor of CaOx crystal growth and aggregation. 
Unfortunately, SEM studies for this experiment were not performed. 
Because of the reported limitations of the Coulter Counter in distinguishing between a 
single particle and an aggregate (Ryall et al. 1995), 14C-oxalate deposition experiments were 
conducted in this study to supplement the Coulter counting and sizing data. The significantly 
lower CaOx deposition observed in BUF suggests high inhibition of CaOx formation by the 
black group. A more pronounced retardation of CaOx formation by BCME relative to 
WCME in BUF shows that the former is an effective inhibitor of CaOx crystal formation. 
However, neither BCME nor WCME had an effect in WUF. This is therefore yet another 
important observation for possibly accounting for the difference in stone incidence between 
the black and white groups. 
The higher percentage of inhibition of both COM and COD crystal aggregation by 
BCME compared to WCME is another indication of the potency of the former in reducing the 
risk of forming stones. This observation has been supported by the zeta potential results 
which determine the capacity of a protein to disaggregate the crystals. As stated earlier, the 
more negative the zeta potential, the higher the inhibition of crystal aggregation. BCME 
resulted in a more negative charge of COM and COD crystals (from -12.1 to -16.2 mV for 
both crystal phases) whereas WCME induced either a decrease in zeta potential or no change 
at all (-12.1 to -9.97 mV and -12.2 to -12.7 mV for COD and COM crystals, respectively). 
The increase in the negative charge arising from BCME might be due to the acidity of the 
proteins (Finlayson eta. 1984) in CME. Interestingly and most importantly, OPN is the most 
abundant and highly acidic protein in the latter (Kohri et al. 1990). The decrease in the zeta 
potential induced by WCME might be an indication of promotion of aggregation by this 
protein whereas BCME has demonstrated a strong capability to disaggregate both COM and 
COD crystals. 
Since OPN is the main intracrystalline protein in COD, it is proposed that it may 
provide superior protection against CaOx crystallization in the urine of black subjects 
compared to whites, thereby contributing to the stone rarity in the former. However, the 
contribution ofUPTF1 towards crystallization inhibition, if any, would be of great interest. 
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CHAPTER FIVE 
INHIBITORY CAPACITY OF COMMERCIAL OSTEOPONTIN (OPN) 
5.1 INTRODUCTION 
The process of kidney stone formation is inhibited by substances in urine that reduce the 
concentrations of calcium and oxalate that are required for new crystal formation, growth and 
aggregation (Coe et al. 1992). These substances also block the adhesion of calcium oxalate 
monohydrate (COM) crystals to renal epithelial cells (Lieske and Toback 1993). It has been 
reported that the majority of inhibition of crystal growth and aggregation observed in normal 
urine is due to the presence of macromolecules rather than lower molecular weight molecules 
(Nakagawa et al. 1983; Ryall 1997; Lieske et al. 1995). About 70-90 % of these 
macromolecules are glycoproteins (Medetognon-Benissan et al. 1999). Most of these proteins 
are rich in aspartic and glutamic acid which facilitate their binding to calcium ions. They 
contain an Arg-Gly-Asp (RGD) cell binding sequence that allows them to adhere to cells and 
in turn inhibit urinary tract stone formation (Kohri et al. 1990). Osteopontin (OPN) is one of 
these glycoproteins which have an RGD sequence and is also rich in aspartic and glutamic 
acid (Kohri et al. 1990; Chen et al. 1992). It has been reported to be one of the major 
components of the organic matrix of stones (Hoyer 1994) and probably the source of the high 
percentage of acidic amino acids found in stones (Kohri et al. 1990). 
As stated in Chapter 1, most researchers have reported that OPN inhibits nucleation, 
growth and aggregation of CaOx crystals (Prince et al. 1960: Shiraga et al. 1992: Denhartt 
and Guo 1993; Asplin et al. 1998; Hoyer 1994: Min et al. 1998) as well as attachment of 
crystals to renal epithelial cells (Shiraga et al. 1992; Chalko et al. 1992; Worcester et al. 
1995; Lieske et al. 1999: Konya et al. 2003: Wesson et al. 2003) at concentrations which are 
lower than those in urine (1.9 J..Lg/mL) (Lieske et al. 1995). This is mainly attributed to its 
high amino acid content and its ability to convert COM crystals to COD crystals which are 
less adherent to renal tubular cells. 
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Chapter 4 addressed the role of calcium oxalate dihydrate (COD) crystal matrix extract 
(CME) in the inhibition of CaOx crystallization. OPN was detected as the main 
intracrystalline protein in COD-CME. Notwithstanding the fact that there might be other 
proteins in COD-CME, the inhibition of CaOx crystallization by COD-CME was mainly 
attributed to OPN as it has been previously reported that it is the main intracrystalline protein 
in COD (Atmani et a!. 1996; Webber et a!. 2003; Ryall et a!. 2005). This notion was also 
supported by the gel and OPN immunoblot reported in Chapter 4, page 70. 
Moreover, the inhibitory capacity of COD-CMEs from the black and white race groups 
was found to be dependent on the composition of the urine in which they were tested. It is 
this latter result that provided the motivation and rationale for undertaking an investigation of 
the behaviour of commercial OPN in inorganic solutions as well as in ultrafiltered urine from 
black and white subjects. 
5.2 OBJECTIVES 
• Test the relative inhibitory capacity of commercial OPN in urine of black and white 
healthy South African male subjects by conducting several crystallization 
experiments. 
• Test the effect of commercial OPN on the zeta potential of COM and COD crystals. 
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5.3 Materials and Methods 
5.3.1 Urine collection and treatment 
Five pools of five 24 hour urine samples per pool (500 mL of each sample were used) from 
25 different black (B) and 25 different white (W) healthy males were obtained without 
preservatives and treated separately. The samples were tested and treated as previously 
described in Chapter 2. After filtration (0.75 JJ.m and 0.45 JJ.m) the samples were ultrafiltered 
through a 10 k:Da cut-off membrane (Millipore Corporation; Bedford USA). The ultrafiltrate 
was used for all the crystallization experiments. 
5.3.2 Crystallization Experiments 
CaOx Metastable Limit 
The metastable limit of the ultrafiltrate was determined as explained (and results reported) in 
Chapter 2 following the method described by Ryall et al. (1985). The metastable limit was 
not determined in the presence of the protein because previous reports have shown that this 
physicochemical parameter is not affected by OPN (Doyle et al. 1995; Grover et al. 1998). 
Effect of OPN on particle numbery volume and size 
This experiment was performed as described in Chapter 2. Briefly, two conical flasks each 
containing 50 mL of urine were set up. The first flask contained UF only (control). The 
second flask contained both UF and OPN at a final concentration of 0.5 mg/L. The OPN used 
was a recombinant human protein supplied by R & D Systems, Inc., USA. After the addition 
of 10 % (v/v) of Na20x at a concentration of 30 mmol!L above the previously determined 
MSL, the zero time particle number, volume and size distribution were determined using a 
Coulter Multisizer ll (Coulter Electronics Ltd, England) before the addition of OPN. The 
same measurements were repeated at 30 minute intervals during a 120-minute incubation 
period (37 °C, 100 rpm) after the addition ofOPN. 
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Scanning Electron Microscopy 
Crystals were prepared for scanning electron microscopy as previously described in Chapter 
2 and were viewed under the same operating conditions except that the probe current was 
changed (50 pA). 
Effect of OPN on {14 C)-oxalate deposition 
This experiment was conducted as previously described in Chapter 2. Two soda-lime glass 
bottles each containing 30 mL of urine. The first one contained UF alone (control) and the 
second one with UF and OPN at a final concentration of 0.5 mg/L of OPN. The experiment 
was continued as previously described in Chapter 2 and the percentage of precipitated 14C-
oxalate induced by OPN was determined. 
Effect of OPN on COM and COD crystal aggregation 
This experiment was conducted according to the method described in Chapters 2 and 4. As in 
Chapter 4, the inhibition of COM crystal aggregation was determined in the presence of UF 
alone, OPN alone and the combination thereof. The protocol was repeated using COD 
crystals except that the inhibition was determined in the absence ofUF. 
Effect of OPN on CaOx crystal nucleation 
The effect of OPN on CaOx crystal nucleation was determined as previously described in 
Chapters 2 and 4. The inhibition of nucleation was tested in the presence of urine or protein 
alone or a combination of both. 
Effect of OPN on COM and COD crystal Zeta Potential 
The effect of OPN on the zeta potential was determined as previously described in Chapter 2 
at a final concentration of 0.5 mg/L. 
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5.4 RESULTS 
5.4.1 Urine composition and physicochemical properties of pooled 24 hour samples 
The mean composition and physicochemical parameters of pooled 24 hour urine samples 
from black and white subjects are shown in Table 5.1 (n = 5). Individual parameters for each 
sample from both groups are shown in Appendix 3, Tables 3.1 and 3.2. Phosphate, potassium, 
relative supersaturation (RS) of brushite and RS of uric acid showed a significant difference 
(p:::; 0.05) between the two groups and are denoted by* next to the p-value. 
Table 5.1: Mean composition and physicochemical parameters (± SE) of pooled 24 hour 
urine samples (n = 5) from black and white male subjects. 
Parameters B w p-value 
pH 5.75 ± 0.23 5.99 ± 0.23 0.230 
Volume (mL/24hr) 3970 ± 658 4722 ± 658 0.441 
Calcium (mmoV24hr) 9.87 ± 1.12 10.9 ± 1.12 0.508 
Citrate (mmoV24hr) 13.3 ± 2.91 12.9 ± 2.91 0.934 
Chloride (mmoV24hr) 519 ± 72.4 505 ± 72.4 0.890 
Creatinine (mmoV24hr) 47.4 ± 6.59 58.4 ± 6.59 0.273 
Magnesium (mmol/24hr) 9.23 ± 1.93 10.7 ± 1.93 0.624 
Oxalate (mmoV24hr) 1.17 ± 0.240 0.800 ± 0.240 0.305 
Phosphate mmol/24hr) 59.6 ± 10.9 94.6 ± 10.9 *0.051 
Potassium (mmoV24hr) 131 ± 42.3 279 ± 42.3 *0.043 
Sodium (mmoV24hr) 464 ± 133 391 ± 133 0.719 
Sulphate (mmoV24hr) 62.3 ± 11.4 71.7 ± 11.4 0.582 
Uric acid (mmol/24hr) 9.88 ± 1.69 12.1 ± 1.69 0.397 
RS Brushite 0.291 ± 0.022 0.614 ± 0.022 *0.022 
RS CaOx 4.96 ± 0.453 3.29 ± 0.453 *0.031 
RS Uric acid 3.23 ± 0.323 1.98 ± 0.323 0.321 
. . .. 
*Dtfference ts stattsttcal/y stgmftcant: p :5 0. 05, B (Unne sample from black subjects); W (Urme sample 
from white subjects). RS: Relative Supersaturation. 
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5.4.2 Crystallization Experiments 
CaOx Metastable Limit 
Figure 5.1 below shows the mean MSL plots of pooled (a) BUF and (b) WUF respectively 
(n = 5). There is no difference observed in the mean plots between BUF and WUF as they 
both have 0.75 mol/L as the MSL. The individual metastable limit plots and tables from 
which these means have been calculated are shown in Appendix 3, Tables 3.3 and 3.4 and 
Figures 3.1 and 3 .2. 
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Figure 5.1: Mean MSL plots ofUF from (a) black (BUF) and (b) white (WUF) 
subjects. 
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Comment 
The observation of identical MSL values for BUF and WUF contradicts the finding of a 
higher value for BUF reported in Chapter 4. This contradiction can be attributed to 
uncontrollable compositional effects arising during the pooling process. 
Effect of OPN on particle number 
Table 5.2 shows the particle number of individual BUF (n = 5) and WUF (n = 5) samples 
before and after the addition of OPN. Figure 5.2 shows the rate of particle formation from 0 
to 30 minutes after the addition of Na20x. Individual values at 30-minutes intervals of the 
experiment are shown in Appendix 3, Tables 3.5 and 3.6. Addition of commercial OPN to 
BUF induced a decrease in particle number in four of the five urine samples from black 
subjects. The same trend was observed in all five of the WUF samples after the addition of 
commercial OPN. The mean number of particles was approximately the same for BUF and 
WUF before and after the addition of OPN. 
It is also seen that the rate of particle formation was slower in WUF than in BUF while 
addition of OPN slowed the rate in both urine samples (Figure 5.2). Individual plots are 
shown in Appendix 3, Figures 3.3 and 3.4. 
Chapter 5 105 
Table 5.2: Particle number (/500 !J.L) in ultrafiltered pooled urine from black (BUF, n = 
5) and white (WUF, n =5) subjects before and after the addition of commercial 
OPN at 120 minutes ofthe experiment at a final concentration of0.5 mg/L. 
Pooled Sample BUF BUF + OPN p-values 
1 32144 39443 
2 38436 19782 
3 23771 22044 
4 16031 5679 
5 12349 11120 
Mean±SE 24546± 4693 19613 ± 5803 
Pooled Sample WUF WUF+OPN 
1 25175 5520 
2 21644 20995 
3 13171 8448 
4 40735 37754 
5 28677 24850 
Mean±SE 25880±4693 19513 ± 5803 
Comparisons p-values 
BUFvs. WUF 0.846 
BUF vs. BUF + OPN 0.532 
WUF vs. WUF + OPN 0.414 
BUF+OPNvs. 0.991 
WUF+OPN 
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Figure 5.2: Mean plot of particle number vs. time in (a) BUF and (b) WUF before 
and after the addition of OPN and Na20x. The rate of particle formation is given by 
the slope of the graph at 0 to 30 minutes of the experiment. 
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If it is assumed that the particles which are being measured are indeed CaOx crystals, the 
results for this study suggest than OPN is an inhibitor of nucleation. No distinction is possible 
between the synergistic roles (if any) between BUF and WUF. Crystallization experiments, 
besides those conducted using the Coulter Counter, will allow a conclusion to be reached 
concerning the true nature of the "particles". 
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Effect of OPN on particle volume 
Table 5.3 shows particle volume of individual BUF (n = 5) and WUF (n = 5) samples before 
and after the addition of OPN. Figure 5.3 shows the rate of particle formation from 0 to 30 
minutes after the addition ofNa20x. Individual values at 30-minute time intervals are shown 
in Appendix 3, Tables 3.7 and 3.8. OPN resulted in a decrease in particle volume in three out 
of five BUF samples, while an increase was observed in two samples. The particle volume in 
WUF decreased after the addition of OPN in four out of five samples, while an increase was 
observed in only one sample. 
Addition of OPN to both BUF and WUF induced a decrease in the rate of particle volume as 
shown by the decrease in the slope of the graph from 0.091 to 0.076 1Jm3/min and 0.118 to 
0.072 1Jm3/min, respectively (Figure 5.2). Individual plots are in Appendix 3, Figures 3.5 and 
3.6. 
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Table 5.3: Particle volume (x 106 J.lm3/500 J.!L) in ultra:filtered pooled urine from black 
(BUF, n = 5) and white (WUF, n = 5) subjects before and after the addition of 
commercial OPN at 120 minutes at a final concentration of0.5 mg/L. 
Pooled Sample 
l 
BUF BUF+OPN p- values 
1 4.231 8.753 
2 4.196 2.168 
3 2.229 1.979 
4 4.254 1.111 
5 2.115 8.737 
Mean±SE 3.405 ± 0.481 (0.246) 4.549 ± 1.234 (0.990) 
Pooled Sample • \VUF \VUF+OPN 
1 3.876 1.344 
2 1.435 1.669 
3 2.957 1.101 




Mean±SE 2.553 ± 0.481 (0.246) 1.536 ± 1.234 (0.990) 
Comparisons ' p-valucs 
BUFvs. WUF 0.246 
BUF vs. BUF + OPN 0.541 
WUF vs. WUF + OPN 0.092 
*BUF + OPN vs. *0.012 
WUF+OPN 
* indicates that the difference is statistically significant: p ~ 0. 05 
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Figure 5.3: Mean plot of particle volume vs. time in (a) BUF and (b) WUF before 
and after the addition of OPN and Na20 x. The rate of particle formation is given by 
the slope of the graph at 0 to 30 minutes of the experiment. 
Comment 
109 
The reduction in particle volume is consistent with the notion (obtained from particle 
numbers) that OPN is an inhibitor of CaOx crystal nucleation. Results for WUF were more 
convincing in this regard. 
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Effect of OPN on particle volume-size distribution 
OPN induced a reduction in particle size in both BUF (n = 5) and WUF (n = 5). In BUF, the 
average size decreased from 5.83 to 4.74 J.l.m (19% reduction) compared to a 10% reduction 
induced by OPN in WUF (3.64 to 3.28 J.l.m). The mean particle volume-size distribution plots 
at 120 minutes for both BUF and WUF are presented in Figures 5.4 (a) and (b), respectively. 
Individual plots are indicated in Appendix 3, Figures 3.7 and 3.8. 
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Figure 5.4: Mean particle volume-size distribution of (a) BUF and (b) WUF before 
and after the addition ofOPN at a fmal concentration of0.5 mg/1 at 120 minutes of the 
experiment. 
Comment 
These results suggest that OPN is an inhibitor of CaOx crystal growth or aggregation or both. 
As with the other interpretations of Coulter data, the additional crystallization experiments 
which are described hereafter will help to reach firmer conclusion. 
Chapter 5 111 
Scanning Electron Microscopy (SEM) 
Representative scanning electron micrographs of crystals deposited after the induction of 
CaOx crystallization in ultrafiltered urine samples of black and white subjects before and 
after the addition of OPN are shown in Figures 5.5 and 5.6, respectively. Small loose and 
clustered COM crystals (6 J.liD) were deposited in BUF (Figure 5.5, left panel). Addition of 
OPN to BUF appeared to reduce the number and size of COM crystals (from 6 J.liD to 3 J.lm) 
but did not change the morphology of CaOx crystals deposited (Figure 5.5, right panel). A 
mixture of small COM (3 J.lm) and COD crystals (6 J.lm) were deposited in WUF 
(Figure 5.6, left panel). The addition of OPN did not change the number and size of these 
crystals (Figure 5.6, right panel). Instead an aggregate of COM crystals clustered around 
COD crystals was formed (Figure 5.6, right panel). 
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Figure 5.5: Scanning electron micrographs of crystals induced from the ultrafiltered 
urine of black subjects (BUF) before and after the addition of OPN at a final 
concentration of 0.5 mg/L at 4K magnification. Left panel shows BUF alone. Right 
panel shows BUF + OPN. 
Figure 5.6: Scanning electron micrographs of crystals induced from the ultrafiltered 
urine of white subjects (WUF) before and after the addition of OPN at a final 
concentration of 0.5 mg/L at 4K magnification. Left panel shows WUF alone. Right 
panel shows WUF + OPN. 
Comment 
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The observation of COM in BUF and a mixture of COM and COD in WUF is of great 
importance. As stated by Wesson et al. (1998), COM crystals have a lower epithelial cell 
binding affinity than COD crystals. The observations in BUF suggest that OPN acts as an 
inhibitor of nucleation (fewer particles) and as an inhibitor of either growth or aggregation 
(smaller sizes). On the other hand, the observation in WUF suggests that OPN promotes 
aggregation. Irrespective of the importance of these observations within the particular urine, 
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the results demonstrate that BUF and WUF elicit different responses in the role played by 
OPN, thereby highlighting a synergistic relationship between protein functionality and urine 
composition. 
Effect ofOPN on l 4C]-oxalate deposition 
The mean effect of commercial OPN on 14C-oxalate deposition in BUF (n = 5) and WUF (n = 
5) is presented in Figure 5.7 (a) and (b), respectively. Addition of OPN to BUF resulted in a 
considerable decrease in the amount of precipitated 14C-oxalate by 23 % relative to the 
control at 120 minutes. The protein also slightly reduced the amount of deposition in WUF. 
However, the decrease at 120 minutes was only 5 %. Individual plots are shown in Appendix 
3, Figures 3.9 and 3.10. 
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Figure 5.7: Mean percentage [14C]-Oxalate deposited in (a) BUF and (b) WUF 
before and after the addition of OPN at a fmal concentration of 0.5 mg/1. 
Comment 
These results show that OPN is an inhibitor of CaOx crystallization nucleation. More 
importantly, however, the synergistic role of the two urines is again apparent, with BUF 
being more actively involved than WUF in supporting the inhibition process. 
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Effect of OPN on COM and COD crystal aggregation 
The mean aggregation slopes and percentage inhibition of aggregation induced by each 
additive is shown in Table 5.4. Figure 5.8 shows the mean aggregation plots of a COM 
crystal slurry before and after the addition of BUF, WUF and OPN (n = 5 for all). Individual 
plots and aggregation slopes together with percentage inhibition of aggregation from which 
the means were calculated are given in Appendix 3, Figures 3.11 and 3.12 and Table 3.9. 
Addition of OPN to the COM slurry inhibited aggregation significantly (94 %, p < 0.05). 
When OPN was added in the presence of either BUF or WUF, inhibition dropped 
significantly. No difference was observed between BUF and WUF in this regard. 
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Table 5.4: Mean slopes of absorbance vs. time graphs, R 2 and percentage inhibition of 
aggregation (lA %) of the COM crystal slurry after the addition of BUF, WUF 
and OPN (n= 5 for all). 
Sample Slope X -10-4 (OD/sec); R2 1., 1Y., (p-values , p-value 
wrt COM) 
COM 34; (0.992) 
COM+OPN 2.0; (0.974) 94 (p < 0.05) 
COM+BUF 25; (0.984) 26 
COM+ BUF + OPN 21; (0.981) 38 
COM+WUF 17; (0.969) 50 
COM+ WUF + OPN 20; (0.971) 41 
*BUFvs. WUF *0.051 
BUF vs. BUF + OPN 0.147 
WUF vs. WUF + OPN 0.730 
BUF+OPNvs. 0.882 
WUF+OPN 
.. * md1cates that/he difference IS sta/Js/Jca/ly significant: p ~ 0. 05 
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Figure 5.8: Mean COM crystal sedimentation plot of absorbance vs. time before 
and after the addition of (a) OPN, BUF and BUF + OPN and (b) WUF and WUF + 
OPN at a final concentration of 0.5 mg/L of OPN. An arrow indicates the time at 
which the stirrer was switched off and the trendline indicates the absorbance slope 
used for the calculation of aggregation inhibition. 
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Table 5.5 and Figure 5.9 show the absorbance slopes and percentage aggregation inhibition 
and the average plot for COD slurry before and after the addition of OPN (n = 5). Individual 
results are shown in Appendix 3, Figure 3.13 and Table 3.10. The addition of OPN to the 
COD slurry resulted in 42 %inhibition of aggregation. Attention is drawn to the fact that, this 





Mean slopes of absorbance vs. time graphs, R2 and percentage inhibition of 
aggregation (IA %) of the COD crystal slurry after the addition ofOPN (n = 5). 
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Figure 5.9: Mean COD crystal sedimentation plot of absorbance vs. time before 
and after the addition of OPN at a final concentration of 0.5 mg/L. An arrow indicates 
the time at which the stirrer was switched off was and the trendline indicates the 
absorbance slope used for the calculation of aggregation inhibition. 
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Comment 
These experiments show that OPN is an inhibitor of both COM and COD crystal aggregation. 
Since inhibition of COD aggregation was not tested in the presence ofBUF or WUF, it is not 
possible to deduce whether the extent of the inhibition is greater in the mono- or di-hydrate. 
However, the experiments involving the protein in the absence of urine suggest that OPN is a 
stronger inhibitor of COM crystal aggregation than it is of COD crystal aggregation. It is not 
possible to deduce from these data whether BUF and WUF play a synergistic role in this 
regard. 
Effect of OPN on crystal nucleation 
The average nucleation inhibition percentages (n = 5) are given in Table 5.6 and the 
corresponding mean plots of absorbance vs. time are shown in Figure 5.10. Individual plots 
and percentage inhibition of nucleation values are in Appendix 3, Figures 3.14 and 3.15 and 
Table 3.11. OPN significantly inhibited nucleation of CaOx crystals in an inorganic solution 
(95 %) and in urine from both black (95 %) and white (93 %) male subjects. The mixture of 
the protein and the urine from either race group inhibited nucleation to a similar extent as the 
protein (95 %) or urine on its own, BUF (95 %) and WUF (93 %). 
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Table 5.6: Mean slopes of absorbance vs. time graphs, R2 values and percentage 
nucleation inhibition (IN%) induced by OPN (n = 5). 
Sample Slope (X -10._.; h '% (p-valucs, wrt p-valucs 
1 
OD/sec); R- control) 
Control (Ctrl) 43; (0.998) 
Ctrl + OPN 2.0; (0.982) 95 (p < 0.05) 
Ctrl + BUF 2.0; (0.993) 95 (p < 0.05) 
Ctrl + BUF + OPN 4.0; (0.996) 91 (p < 0.05) 
Ctrl + WUF 3.0; (0.995) 93 (p < 0.05) 
Ctrl + WUF + OPN 3.0; (0.994) 93 (p < 0.05) 
BUFvs. WUF 0.188 
BUF vs. BUF + OPN 0.172 











Gl 0.04 u 
c 
"' -e 0.03 
0 






















-+-Ctrl + BUF 
--tr- Ctrl + BUF + OPN 




-+- ctrl + WUF 
--tr- Ctrl + WUF + OPN 
1000 1500 2000 2500 3000 3500 
Time (sec) 
Figure 5.10: Mean CaOx crystal nucleation plots of absorbance vs. time before 
and after the addition of (a) BUF, OPN and BUF + OPN and (b) WUF, OPN 
and WUF + OPN at final concentrations of 0.5 mg/L of OPN. The trendline 
indicates the absorbance slope used for the calculation of nucleation inhibition. 
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These results provide strong evidence to support the hypothesis that OPN is an inhibitor of 
CaOx crystal nucleation. It is not possible to deduce the synergistic role (if any) of the 
respective urines. 
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Effect of OPN on COM crystal Zeta Potential 
Table 5.7 shows the individual zeta potential values of the COM crystal slurry before and 
after the addition of OPN (n = 9). Figure 5.11 shows the histogram of the averaged values 
shown in Table 5.7. Addition of OPN to the COM slurry induced an increase in the 
magnitude of the negative zeta potential in six of the nine experiments. There was no 
significant difference between the mean values for zeta potential of the control and that of the 
protein-dosed slurry. 
Table 5.7: Zeta potential of COM crystal before and after the addition of OPN (n = 9). 
Number of runs COM COM+OPN p- value 
1 -10.3 -15.2 
2 -12.8 -11.1 
3 -15.3 -11.7 
4 -7.8 -5.97 
5 -10.8 -13.6 
6 -11.2 -13.6 
7 -12.5 -15.9 
8 -14.3 -16.6 
9 -14.8 -17.9 
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Figure 5.11: Mean zeta potential histogram before and after the addition of OPN to 
COM crystal slurry. 
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Effect of OPN on COD crystal Zeta Potential 
Table 5.8 shows the individual zeta potential values of the COD crystal slurry before and 
after the addition of OPN (n = 9). Figure 5.12 shows the histogram of the averaged values 
shown in Table 5.8. Addition of OPN to the COM slurry induced a significant increase in the 
magnitude of the negative zeta potential as indicated by an increase in the negative charge. 
Table 5.8: Zeta potential of COD crystal before and after the addition of OPN (n = 9). 
Number of runs COD COD+OPN p- value 
1 -12.1 -12.4 
2 -14.9 -16.4 
3 -15.8 -19.2 
4 -10.5 -17.8 
5 -11.1 -14.8 
6 -9.27 -10.6 
7 -10.6 -10.5 
8 -12.1 -16.8 
9 -12.2 -17.3 
Mean±SE -12.1 ± 0.90 -15.1 ± 0.90 0.03 
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Figure 5.12: Mean zeta potential histogram before and after the addition ofOPN to 
COD crystal slurry. 
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As explained earlier, an increase in the magnitude of the negative zeta potential signifies an 
increase in the electrostatic forces of repulsion and is therefore interpreted as an increase in 
the inhibition of aggregation. The addition of OPN to the COM slurry did not produce a 
significant change in the zeta potential indicating that the protein had no effect on 
aggregation inhibition. However, in the COD slurry, a significant change was observed, 
thereby suggesting an increase in aggregation inhibition. Thus, the zeta potential 
measurements have shown that OPN strongly inhibits this process in COD but not in COM. 
This is in marked contrast to the results of the aggregation experiment involving crystal 
sedimentation. 
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5.5 DISCUSSION 
Composition data for the pooled urines demonstrated that phosphate, potassium and RS of 
brushite were significantly lower in urine samples from black subjects. The lower phosphate 
concentration in urine samples from black subjects is in agreement with the results published 
by Lewandowski et al. (2002). Contrary to the data obtained for individual urines in Chapter 
3, RS of CaOx was significantly higher in samples from black subjects. Considering the low 
incidence of kidney stone formation in the black population, the high RS of CaOx in samples 
from black subjects is puzzling. However, comparison of compositional data from pooled 
urines with individual urines is likely to yield discrepancies because components in any 
particular aliquot may dominate. These discrepancies might be also due to considerable 
variations in individual samples. 
As explained in Chapters 3 and 4, the Coulter Counter has limitations with regard to 
its ability to distinguish between a single particle and an aggregate. Aggregates which contain 
empty spaces between them are recorded by the instrument as if they are large particles, 
giving erroneously high crystal volume deposition (Ryall et al. 1995). Thus the Coulter 
Counter data proved difficult to interpret. Despite these limitations, OPN appeared to reduce 
the number, volume and rate of particle formation in both BUF and WUF. It is important to 
note that the addition of OPN in BUF and WUF induced a favourable reduction in particle 
size by 19% and 10 %, respectively. Since particle size is a determinant ofthe likelihood of 
crystal retention in the renal tubular cells (Kok and Khan 1994), the aforementioned 
reduction in size is a significant observation. 
The precipitation of COD in WUF as shown by scanning electron microscopy is not 
surprising considering the high (but not significantly different) urinary calcium concentration 
in the white group reported in this study and others (Modlin 1967: Whalley et a!. 1998: 
Rodgers and Lewandowski 2002) and the fact that COD precipitates at very high calcium 
concentrations (Webber et al. 2003. Ryall ct a!. 2005). An aggregate of COM and COD 
crystals resulting after the addition of OPN to WUF is an indication of promotion of 
aggregation in the urine of the white race group. Nonetheless, precipitation of COD crystals 
in WUF before and after the addition of OPN could be of considerable inhibitory benefit 
since COD crystals have been reported to be less adherent to renal epithelial cells (Wesson et 
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al. 1998). 14C-oxalate deposition data were also supportive of the above results that OPN 
inhibits CaOx crystal nucleation and that BUF is superior in this regard compared to WUF. 
The role of OPN in crystal nucleation and aggregation was also investigated to 
supplement the 14C-oxalate deposition data. OPN significantly inhibited both CaOx crystal 
nucleation and aggregation. A comparative study of COM and COD crystal aggregation by 
OPN demonstrated a high inhibition of COM crystal aggregation (94 %) compared to COD 
crystal aggregation (42 %). However it was not possible to deduce the synergism between 
OPN and the ultrafiltrates from both groups. 
The aggregation inhibition data were supported by the measurement of the magnitude 
ofthe zeta potential (more negative charge). Addition ofOPN to both COM and COD crystal 
slurries induced an increase in the negative charge. However, the significantly higher 
negative charge on COD crystals (-15.1 mV) compared to that on COM crystals (-13.6 mV) 
is noteworthy. This is an indication of high crystal disaggregation by COD crystals. As 
reported by several authors (Atmani et al. 1996: Webber et al. 2003: Ryall et al. 2005) and as 
shown in Chapter 4, OPN is the main intracrystalline protein in COD crystals and thus the 
high disaggregation by COD compared to COM could be attributed to the preferentially 
higher inclusion of this protein in the former. COD crystals have a higher positive charge 
which is due to the high concentration of calcium ions which results in high repulsion 
between crystals and thus favours disaggregation (Cerini et al. 1999). OPN has also been 
reported to have a high calcium binding affinity due to the presence of the RGD sequence 
(Kohri et al. 1990). Thi high calcium affinity together with the high positive charge of COD 
could be the main contributing factor to the significant repulsion observed from the zeta 
potential. 
The crystallization data reported in this study demonstrated that OPN is an inhibitor 
of CaOx crystal nucleation, growth and aggregation to a greater extent in BUF than WUF. 
OPN may therefore be a superior provider of protection against CaOx crystallization in the 
urine of black subjects compared to that of whites, thereby contributing to the low stone 
incidence in the black group. 
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CHAPTER SIX 
THE EFFECT OF SODIUM CHLORIDE, SODIUM BICARBONATE 
AND SODIUM CITRATE ON THE URINARY RISK FACTORS FOR 
CALCIUM OXALATE KIDNEY STONE FORMATION AND ON BONE 
TURNOVER MARKERS 
6.1. INTRODUCTION 
Excessive dietary sodium intake is associated with elevated blood pressure. Good blood 
pressure control has been linked with improvements in cardiac, cerebral and kidney function 
and in reduction in morbidity and mortality from cardiovascular and renal disease (Peterson 
et al. 1995). Dietary sodium is a well-known determinant of urinary calcium excretion (Burtis 
et al. 1994 ). Reducing dietary salt (sodium) helps to reduce the amount of calcium in the 
urine, which in turn reduces the tendency for calcium stone formation ( Kmg et a!. 196-k 
\tuldowne~ et al 1982: Shortt and Fl~ nn 1990: ~ho11t ct al. I 998). Dietary salt reduction is 
best accomplished by not adding salt to food and by avoiding high sodium foods such as 
processed meats, salty convenience foods (such as canned soups, noodle or rice mixes) and 
salty snacks. Even a moderate reduction of dietary sodium can reduce not only hypertension 
but also hypercalciuria, thereby preventing kidney stones and osteoporosis (Nordin ct al. 
I 992: Goulding I 990). 
Calcium has a high influence on skeletal development during growth and therefore is 
an important determinant of peak bone mass (i\latko\IC et al 1995). Maximal positive 
balance between calcium intake and obligatory losses of calcium is required for the 
attainment of peak bone mass ( t\1atk0\ ic et al. 1995 ). High losses of calcium in urine reduce 
calcium accumulation into bone, which may have a negative impact on skeletal development 
and ultimately on bone loss. As mentioned earlier in the main introduction chapter, it has 
been estimated that a 100 mmol increment in daily sodium intake is associated with an 
average loss of urinary calcium of approximately 1 mmoV24 hours ( ordin ct al. 1993 ). 
Calcium/sodium ratios (1 mmol Call 00 mmol Na) of more than 1 in normal living 
populations (no diet restrictions) of postmenoupausal women have been reported by 
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numerous researchers (Goulding et al. 1986: Nordin et al. 1991: hans et al. 1997: Gint~ et 
al. 1998: \ Iassey 2005 ). 
These ratios can have values of 1.2 (Nordin et al. 1991· Gint~ et al 1998 ), 2.2 ( Gouldinu et 
a!. 1986), 3.0 (\lassey .2005) and 3.7 (f\ans eta!. 1997). The dependence ofurinary calcium 
excretion on sodium intake is attributable to the existence of linked common reabsorption 
pathways of both calcium and sodium ions in the renal tubular system ( MatkO\ ic et a!. 1995: 
Gmt~ eta!. 1998). 
Of great interest is a study by Morris and Sebastian (2002) on alkali therapy in renal 
tubular acidosis. Acidosis is a renal tubular disorder caused by a restriction in reduction of 
urinary pH and titration of urinary buffers thus leading to the urinary excretion of acid. 
Metabolic acidosis is known to induce hypercalciuria and consequent negative calcium 
balance. It may also give rise to osteoporosis and other disorders of bone mineralization 
(Harrington et <tl. 1983 ). It does so by enhancing osteoclastic activity and inhibiting 
osteoblastic functioning and hence bone formation ( Lemann et a!. 1996 ). Conversely, 
metabolic alkalosis decreases bone calcium efflux by suppressing osteoclasts and stimulating 
osteoblasts (Bushmsk~ 1996 ). Osteoblasts are cells that mediate the formation of new bone 
and osteoclasts cause bone resorption. Osteoporosis occurs when bone resorption exceeds 
bone formation. 
Several authors have investigated bicarbonate and citrate as therapeutic treatments of 
osteoporosis. Sodium bicarbonate (NaHC03) as a supplement to alkali therapy of renal 
tubular acidosis was used by several researchers and was proven to increase plasma 
bicarbonate and reversely induce net renal acid excretion ('iakhaee et a!. 1981: I utz 1984: 
I emann et al 1989). This resulted in an improved external balance of calcium as 
demonstrated by reductions in the urinary excretion rate, followed by an increase in serum 
concentrations of osteocalcin and a decrease in urine hydroxyproline. This investigation was 
followed by that of Sebastian et al. ( 1994) who also demonstrated an increase in serum 
osteocalcin and a decrease in urinary hydroxyproline. 
As explained in Chapter 1, citrate has been reported to be a powerful therapeutic and 
prophylaxis alkali therapy in preventing the formation of stones which it accomplishes by 
forming soluble complexes with calcium resulting in low urinary excretion of calcium, and 
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inhibition of nucleation and agglomeration of CaOx crystals ( Kol-. et al. 1986: Pal-. 199-L 
-\lhe-Hamdula~ and R )dgers 2005). Preminger et al. ( 1985 (a): 1987) showed that citrate 
alkali therapy increased plasma bicarbonate which led to an increase in bone mineral density. 
Prior to this investigation, there was a report by Osther and co-workers ( 1993) that serum 
osteocalcin and urinary hydroxyproline were significantly decreased and increased, 
respectively, in kidney stone formers with renal tubular acidosis. Weger et al. ( 1999) in their 
study reported that patients who suffered from renal tubular acidosis, demonstrated symptoms 
of osteroporosis and some had either kidney stones or nephrocalcinosis (high concentration of 
calcium in the nephron). This justifies profound relationships between kidney stone disease 
and osteoporosis. 
Despite the reported high dietary sodium intake by the black South African 
population, it is surprising that they do not have elevated urinary calcium levels Uvlodlin 
196 7. \\ halle~ et a!. I C;98 ). As mentioned earlier in Chapter 1 (Introduction), other puzzling 
anomalies occur in the renal handling of various dietary and supplemental challenges in black 
subjects, prompting speculation that these mechanisms are different in black and white South 
African subjects ( Le\\ ando\\ ski et a!. 200 I: Rodgers and Le\\ andO\\ skt 2002 ). These factors, 
together with the observations reported earlier in this chapter that salts such as sodium citrate 
(~ebastian et al. 199-L Hushmsl-.~ 1996: [:ttinger et al. 1997: Laube et al. 2002 (a): Sellme~ er 
et al. 2002) and sodium bicarbonate ( l ut7 198-J.: I em<mn et a!. 1989: 'iebastian et a!. 199-J.. 
2005: Frassetto et al. 2005: Sakhaee et al. 2005) have inhibitory effects on CaOx stone 
formation and osteoporosis provided motivation for the study described in this chapter. 
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6.2 AIMS AND OBJECTIVES 
• To determine the effect of dietary salt (NaCl) ingestion on the unnary 
physicochemical risk factors for calcium oxalate stone formation in black and white 
healthy male South African subjects with a view to establishing whether the renal 
handling of this agent is different in the two groups. 
• To investigate the effect of the independent ingestion of sodium bicarbonate and a 
sodium citrate preparation on the urinary risk factors for CaOx stone formation in 
healthy black and white South African male subjects and to compare these parameters 
with those elicited by sodium chloride (NaCl) ingestion. 
• To determine the effect of the ingestion of these salts on the CaOx crystallization 
properties of urine in healthy black and white South African male subjects. 
• To determine the effect of the ingestion of the aforementioned salts on serum levels of 
osteocalcin (bone formation marker) and on urinary levels of deoxypyridinoline (bone 
resorption marker) in healthy black and white South African male subjects. 
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6.3 MATERIALS AND METHODS 
6.3.1 Study Population and Sample Size 
20 black and 19 white, age matched male volunteers were recruited for the study from the 
University of Cape Town student community via advertisement. The sample size was based 
on the degrees of freedom for error for each race group as calculated statistically. 
Inclusion Criteria 
Healthy male subjects in the age range 18-30 years without any family history of renal or 
kidney stone disease were recruited for the study. 
Exclusion Criteria 
Subjects were excluded if they had: 
• Family history of renal or kidney stone disease. 
• Urinary tract infections during the course of the study or in the previous year from the 
start of the study. 
• Hypertension, diabetes, liver disease, water retention and heart failure. 
Subjects who were on medication such as antibiotics, supplements and vitamins were also 
excluded. Participants were asked not to take alcohol while participating in the study. 
6.3.2 Study Design 
The study was divided into four experimental periods/protocols for each race group, each 
consisting of seven consecutive days. A Latin Square Design was followed for the random 
assignment of participants to sequences of protocols as shown in Table 6.1. This design was 
implemented for 20 black and 19 white subjects. 
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The four protocols followed were as follows: Protocol L; Low NaCl salt, 3 g/ day (Cerebos 
Ltd. SA;), Protocol H; High NaCl, 9 g/day (Cerebos Ltd.), Protocol C; Sodium bicarbonate, 
6 g/ day (Allied Drug Co. SA) and Protocol D; Sodium citrate, 16 g/day (Citro-Soda*, 
Adcock Ingram SA). 
*:Composition of Citro-soda (4 g sachet): 
Table 6.1: 
1716 mg sodium bicarbonate 
858mg tartaric acid 
702mg citric acid 
613mg sodium citrate 
Ill mg sugar 
Sequences followed by 20 subjects for four different protocols: L; low NaCl, 
H; high NaCl, C; sodium bicarbonate and D; sodium citrate. 
PERIOD/PROTOCOL 1 2 3 4 5 6 7 8 9 10 11 12 
1 L H CD L H CD L H CD 
2 H L DCC D L H DC H L 
3 CD L H DC H L H L DC 
4 DC H L H L DCC D L H 
1 
SUBJECT/SEQUENCE 
PERIOD/PROTOCOL 13 14 15 16 17 18 19 20 
1 L H c D L H c D 
2 H L D c c D L H 
3 c D L H D c H L 
4 D c H L H L D c 
This study was approved by the Clinical Research Ethics Committee of the University of 
Cape Town. Before participation, all subjects underwent a medical examination to assess if 




(a) Salt administration and diet control 
!
.,., _, _, 
A summary of the protocol that was followed by each subject while participating in the study 










Collect baseline 24 hr urine sample. 
l 
Deliver Day 0 urine sample, blood sample taken. 
Take salt (L/H/C/D) with self- selected standardized diet. 
Collect a 24 hr urine sample. 
Deliver Day 5 urine sample. 
Take salt (L/11/C/D) with controlled diet. 
Collect a 24 hr urine sample. 
Deliver Day 7 sample, blood sample taken before breakfast. 
Day 8- Day 14: Washout period. 
Day 15: Start on the next salt regimen (L/H/C/D) and follow the same schedule. 
Figure 6.1: A summary of the protocol followed by each subject while participating 
in the study. 
L: Low NaCl, H: High NaCl; C: Sodium bicarbonate; D: Sodium citrate 
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Prior to any restriction in diet and salt content, a 24-hour baseline/control urine sample was 
collected (Day 0). On Day 1 a blood sample was taken and collected into EDTA-free tubes 
(to avoid complexation with calcium) by a professional nurse on Day 1 before the ingestion 
of the salt. All the results obtained after the ingestion of the salts were compared to the 
control sample. Each participant/subject followed each protocol (L/H/C/D) and 
controlled/standardized diet for seven days. This consisted of the first five days (Day 1-Day 
5) on a self-selected standardized diet (where they had to eat a limited number of portions for 
each food type a day, Table 6.2) while taking the assigned salt (L/H/C/D) and the last two 
days (Day 6 - Day 7) on a strictly controlled diet shown in Tables 6.3 and 6.4 with strictly 
controlled nutrients, with all foods and water provided. Subjects were requested to collect 
urine samples on Day 5 and Day 7, and when delivering the samples on Day 8, a professional 
nurse took a second blood sample. There was a washout period of seven days (Day 8 - Day 
14) after each protocol. The blood samples were centrifuged at 1500 X g for 15 min, and a 
supernatant/serum was frozen at -80 °C within two hours of collection. Aliquots (5 mL) of 
Day 0 and Day 7 urine samples were also kept at -80 °C. The blood samples were used to 
analyze for osteocalcin (bone formation marker) and the frozen urine samples were used for 
deoxypyridinoline (DPD) analysis using an Enzyme Linked Immunosorbent Assay (ELISA). 
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Table 6.2 shows the self-selected standardized diet that the subjects followed for the first ftve 
days (Days 1-5) of each protocol. The daily allowance indicates the number of portions 
permitted from the listed food groups per day. Each item in the 'portion size' column is an 
example of 1 portion. Subjects were also instructed to drink 2.2 L of water each day. 
Table 6.2: Self-Selected Standardized Diet Sheet for 50 mmol/day salt (low salt). To 
achieve high salt levels, subjects were given 9 g of table salt a day. 
2 milk portion 
Choose any 5 fat portions 
Choose any 2 vegetable portions 
Choose any 2 fruit portions 
Choose any 12 starch portions 
Choose any 5 protein portions 
Choose any 3 sugar portions 
1 tsp butter 
1 tsp margarine 
1 tsp sunflower, canola or olive oil 
1 tsp mayonnaise 
Y4 of a avocado pear 
2 butter etc 
~ cup cooked vegetables 
1 cup green fresh salad 
* see critical food list etc 
any medium-sized fruit 
~ cup fruit juice 
* see critical food list etc 
1 slice of bread 
~ cup cooked porridge 
~ cup cereal 
1 weetbix 
3 provitas 
1 medium I 2 small potatoes 
~ cup cooked rice, samp, pasta 
~ cup legumes ( eg lentils, beans, chickpeas, 
etc 
30g meat/chicken/fish = !matchbox 
45g cottage cheese= 1 heaped Tbsp 
30g hard cheese = 1 matchbox 
2 cheese wedges/4tsp cheese spread 
1 etc 
1 tsp sugar 
200ml pudding 
50rnl cool drink 
2 blocks chocolate 
2 J Beans etc 
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Table 6.3 shows the controlled standardized diet that the subjects had to follow for the last 
two days (Days 6 and 7) of each protocol. All the meals were provided by the investigator. 
Subjects were instructed to eat and drink only what was provided, nothing else. 
Table 6.3: Composition of the 2-day (Day 6 and 7) controlled standardized diet for all 
the salts. To achieve high salt levels, subjects were given 9 g of table salt a 
day. 
' Meal Day6 Day 7 
Breakfast 2 bread rolls ( 1 00 g) 2 bread rolls (1 00 g) 
8 g unsalted butter 8 g unsalted butter 
1 X 15 g apricot jam 1 X 15 g apricot jam 
140 g mushroom saucet 140 g mushroom saucet 
200 ml coffee + 40 ml milk (2 %) 200 ml coffee + 40 ml milk (2 %) 
Snack 1 1 muesli bar (Jungle energy bar- 1 muesli bar (Jungle energy bar-
Berries, 40 g) Berries, 40 g) 
Yz cup fruit salad Yz cup fruit salad 
Lunch 145 ml cheese sauce* 145 g cheese sauce* 
120 g mixed vegetables + 1 0 g 120 g mixed vegetables+ 10 g 
unsalted butter unsalted butter 
120 g pasta 120 g pasta 
Snack2 1 medium apple (100 g) 1 medium apple (100 g) 
175 g yoghurt with fruit (low fat) 175 g yoghurt with fruit (low fat) 
Supper 2 boiled potatoes ( 190 g) 2 boiled potatoes (190 g) 
1 slice of whole-wheat bread 1 slice of whole-wheat bread 
8 g unsalted butter 8 g unsalted butter 
2 X 16 g cream cheese 2 X 16 g cream cheese 
(Simonsburg) (Simonsburg) 
1 tomato (50 g)+ 20 g cucumber 1 tomato (50 g)+ 20 g cucumber 
1 apple (1 00 g) 1 apple (1 00 g) 
Late meal 1 slice of whole-wheat bread 1 slice ofwhole-wheat bread 
15 g peanut butter 15 g peanut butter 
Beverages (2.2 Vday): 
200 ml coffee (2 g decaffeinated coffee powder sachet in 200 ml hot water) 
700 mllow mineral content water until 13h00 
600 mllow mineral content water until 1 7h00 
700 mllow mineral content water until21h00 
(Composition of low mineral water: Ca: 6.1 mg/L; Mg: 1.0 mg/L; Na: 17 mg/L). 
i" 
t mushroom sauce per person: 18 g unsalted butter, 30 g onion, 180 g button mushrooms, 50 
g creme, 5 g parsley 
* cheese sauce per person: 13 g unsalted butter, 13 g flour, 16 g cheddar cheese (2 slices), 
125 ml milk (2 %) 
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Table 6.4 shows the total amount of the controlled food constituents in Day 6 and Day 7 
standardized diet. 
Table 6.4: Controlled constituents in the standardized diet. 
·Description ' Total Amount 
. 
Energy (kJ) 10139 
Total protein (g) 57.3 
Total fat (g) 97.9 
Carbohydrate (g) 298 
Ca(mg) 800 
Na(mg) 1290 
Cl (mg) 1898 
Citric acid (mg) 2417 
Oxalic acid (mg) 48 
(b) Urine Analysis 
All the urinary parameters listed in Chapter 2 were analyzed in all the samples. In addition, 
bicarbonate, ammonia and free calcium were also analyzed. Bicarbonate was determined 
using standard titrimetic methods (de Andrade et al 2005) while an ammonia electrode (IS 
570-NH3, Metrohm, Switzerland) was used for determination of ammonia. A calcium ion 
specific electrode (Metrohm, Herisau Switzerland) was used for the measurement of free 
calcium. 
(c) Urine physicochemical risk factors 
The computer program, EQUIL2 was used to determine the relative supersaturation of 
brushite, CaOx and uric acid ( \\ erness et al 198 ') ). The Tiselius Risk Index (TRI) was also 
calculated (T1selius I %2). In addition, the BONN-Risk-Index (BRI), (a standardized in-vitro 
test used to assess the crystallization risk of calcium oxalate in urine) was also measured (682 
Photometer, Metrohm, Herisau Switzerland) (l au be et al. 2002 (b)). 
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6.3.4 Statistical Analysis 
Statistical analysis was performed by an Analysis of Variance (ANOVA) using a GenStat 
computer programme. In considering comparisons between diets, the Bonferroni technique 
was used at the 5 % level of significance. 
6.3.5 Crystallization experiments 
Urine collection, treatment and determination of the CaOx MSL 
Twenty-four hour urine samples were collected in plastic bottles without preservatives and 
filtered before use (0.75 ~m pre-filter and 0.45 ~m nitrocellulose) as described previously in 
Chapter 2. The CaOx metastable limit was determined using the Coulter Counter as 
previously described in Chapter 2. 
Particle formation kinetics 
The particle number, volume and size were determined as a function of time using the 
Coulter Counter as previously described in Chapter 2. 
Scanning Electron Microscopy (SEM) 
Crystals which formed after the kinetics experiment were examined by scanning electron 
microscopy as described in Chapter 2. 
14C-oxalate crystal deposition kinetics 
This experiment was performed as previously described in Chapter 2. 
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CaOx crystal aggregation 
Before this experiment was conducted, COM crystals were prepared as described in Chapter 
2 using the method of Pak et al. ( 1975 ). The percentage inhibition of aggregation was also 
determined as described in Chapter 2. 
CaOx crystal nucleation assay 
This experiment was conducted following the method developed by Hess et al. ( 1995 ). The 
absorbance was measured at 620 nm and the percentage inhibition of nucleation was 
determined. 
6.3.6 Analysis of Deoxypyridinoline (DPD) in urine using Enzyme-Linked 
Immunosorbent Assay (ELISA) 
The concentration of DPD in urine was determined using a competitive ELISA kit (Metra 
Biosystems, USA) with 96 well plates already coated with DPD. All the reagents, solutions 
and buffers were provided by the manufacturers. Firstly, a calibration curve of absorbance vs. 
DPD concentration was constructed using the range of standard solutions in the kit (0, 3, 10, 
30, 100, 300 nmol/L). In each case, 25 J.lL of each standard concentration (in duplicate) was 
diluted 10 times with the assay buffer (noionic detergent in a buffered solution). 50 J.lL of 
each dilute standard was added to each well, followed by the addition of 100 J.lL of the 
enzyme conjugate (alkaline phosphatase). The wells were covered with the provided cover 
tape and incubated for 2 hours at 4 °C. The wells were then washed 3 times with 250 J.lL of 
ice-cold wash buffer followed by incubation with 150 J.lL of working substrate solution (p-
nitrophenyl phosphate) for 60 minutes at room temperature. 100 J.lL of 0.5 N NaOH was 
added · to stop the reaction and the absorbance was read at 405 nm using an ELISA plate 
reader (Anthos LabTech Instrumnents, Australia). The resulting calibration curve is shown in 
Figure 6.2. Urine samples were then treated in the same way for the determination of their 
DPD concentrations. 
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6.3.7 Analysis of osteocalcin (OC) in serum using Enzyme-Linked Immunosorbent 
Assay (ELISA) 
The concentration of osteocalcin in serum was determined using a competitive ELISA kit 
(Metra Biosystems, USA), with 96 well plates already coated with osteocalcin. All the 
reagents, solutions and buffers were provided. Similarly to DPD determination, a calibration 
curve was first plotted. 25 J..lL of increasing concentrations of the standards (0, 2, 4, 8, I6 and 
32 ng/mL) were added to each of the coated wells. This was done in duplicate for each of the 
standards. All the incubations were carried out at room temperature. An anti-osteocalcin 
antibody (125 f..lL) was added to each well (that already contained the standard) and incubated 
for 2 hours at 25 °C. This was followed by 3 washes of each well with 300 f..lL of IX 
concentrated wash buffer. Each well was incubated in I 50 f..lL of the enzyme conjugate (lgG 
alkaline phosphatase) for I hour. The wells were then washed 3 times with 300 f..lL of the 
wash buffer. After the third wash, the wells were vigorously blotted dry on paper towels. The 
dried wells were incubated in a working substrate solution for 40 minutes. The reaction was 
stopped by the addition of 5 M NaOH and the absorbance was read at 405 nm using an 
ELISA plate reader (Anthos LabTech Instrurnnents, Australia). A calibration curve was 
plotted and is shown in Figure 6.3. 
For the determination of the concentration of osteocalcin in serum, the same procedure as 
above was followed and the same quantities of reagents and buffers were used. 
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6.3.8 Deoxypyridinoline (DPD) and Osteocalcin (OC) Calibration Curves 
Figure 6.2 and 6.3 below represent the standard calibration curves for deoxypyridinoline 
(DPD) and osteocalcin (OC), respectively from which the concentrations of urinary DPD and 
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Figure 6.3 : Calibration curve for osteocalcin (OC). 
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6.4RESULTS 
6.4.1 Urine composition and physicochemical properties of urine 
The mean composition and physicochemical parameters of urine samples from black (n = 20) 
and white subjects (n = 19) at baseline and at day 5 and 7 of each protocol are presented in 
Tables 6.5 to 6.13. Individual parameters are presented in Appendix 4, Tables 4.1 and 4.2. A 
p-value of :S 0.05 with a (*) indicates a statistically significant difference. 
Table 6.14 shows a summary of common and different physicochemical changes in samples 
from both groups after each protocol. 
At baseline, the BRI, RS of CaOx and RS of brushite were significantly lower in blacks than 
whites (Table 6.5). For all the protocols, significant changes were observed on day 7 samples 
than on day 5. There was also a significant increase in volume of urines from both groups at 
day 7 of each protocol. 
The low NaCl protocol did not result in any changes in urine parameters on day 5 but 
following the strictly controlled diet on day 7, a significant beneficial decrease in uric acid 
and free calcium was observed in blacks. For whites, there was a significant decrease in RS 
ofbrushite, CaOx and uric acid on day 7 of this protocol. 
As expected there was a significant increase in sodium and chloride after administration of 
high NaCl protocol. A significant and unexpected decrease in free calcium and RS of uric 
acid was also observed in samples from black subjects after this protocol whereas a 
significant decrease in RS of brushite and CaOx was depicted in samples from whites. 
A significant beneficial increase in pH, calcium, citrate, free calcium, BRI and RS of uric 
acid was revealed in both groups after administration of sodium bicarbonate and sodium 
citrate. A favourable decrease in RS of CaOx was also observed in samples from white 
subjects following the ingestion of these two protocols. 
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Table 6.5: Mean urinary parameters(± SE) of samples from black (n = 20) and white (n 
= 19) subjects at baseline. A p-value of ~ 0.05 with a (*) is only shown where 
there is a statistically significant difference. 
Parameter B .. w p-ndues 
pH 6.13 ± 0.107 6.12 ± 0.107 
Volume (mL/24hr) 1328 ± 143 1322 ± 143 
Ammonia (mg!L) 20.7 ± 4.16 20.9 ± 4.16 
Bicarbonate (mmoi/L) 1.45 ± 0.314 1.032 ± 0.314 
*Calcium (mmoV24hr) 2.28 ± 0.339 3.75 ± 0.339 <0.05* 
Citrate (mmoV24hr) 2.60 ± 0.282 2.29 ± 0.282 
Chloride (mmoV24hr) 139 ± 8.72 135 ± 8.72 
Creatinine (mmoV24hr) 13.8 ± 0.959 15.6 ± 0.959 
Magnesium (mmoV24hr) 2.29 ± 0.375 3.13 ± 0.375 
Oxalate (mmoV24hr) 0.329 ± 0.0257 0.343 ± 0.0257 
Phosphate (mmoV24hr) 23.4 ± 2.68 27.5 ± 2.68 
Potassium (mmoV24hr) 44.1 ± 6.72 60.3 ± 6.72 
Sodium (mmoV24hr) 117 ± 15.1 109 ± 15.1 
Sulphate (mmoV24hr) 18.8 ± 2.09 18.1 ± 2.096 
Uric acid (mmoV24hr) 3.06 ± 0.249 3.31 ± 0.24 
Free Calcium (Ca~+, mmol) 0.402 ± 0.0467 0.494 ± 0.0467 
BONN-Risk-Index (BRI) 1.02 ± 0.161 1.74 ± 0.161 < 0.05* 
Tiselius Risk Index (TRI) 285 ± 35.6 358 ± 35.6 
*RS Brushite 0.547 ± 0.343 1.51 ± 0.343 < 0.05* 
*RS CaOx 2.34 ± 0.568 5.87 ± 0.568 <0.05* 
RS Uric acid 1.87 ± 0.436 2.18 ± 0.568 
CaOx MSL (mmoi/L) 90 ± 10 75 ±10 
*Difference 1s statiStically s1gmficant: p s 0.05, B (Urme samples from black subjects); W (Urine 
samples from white subjects). RS: Relative Supersaturation. 
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Table 6.6: Mean urinary parameters (± SE) of samples from black (n = 20) and white (n 
= 19) subjects at day 5 of protocol L (low NaCl). A p-value of :S 0.05 with a 
(*) is only shown where there is a statistically significant difference. 
pH 6.13± 0.084 6.13±0.084 6.12±0.112 6.33±0.112 
Volume (mL/24hr) 1328±167 1645±167 1322±124 1560±124 
Ammonia (mg/L) 20.7±1.58 24.2±1.58 20.9±5.87 33.6±5.87 
Bicarbonate (mmol/L) 1.45±0.414 1.52±0.414 1.03±0.290 0.825±0.290 
*Calcium (mmol/24hr) 2.28±0.327 1.97±0.327 3.75±0.523 3.39±0.523 <0.05* 
Citrate (mmol/24hr) 2.60± 0.237 2.78±0.237 2.29±0.415 2.63±0.415 
Chloride (mrnol/24hr) 139±11.5 148±11.5 135±15.3 133±15.3 
Creatinine (mmol/24hr) 13.8±0.960 13.8±0.960 15.6±1.48 14.3±1.48 
Magnesium (mmol/24hr) 2.29±0.327 2.37±0.327 3.13±0.398 2.67±0.398 
Oxalate (mmol/24hr) 0.329±0.0296 0.316±0.0296 0.343±0.0269 0.335±0.0269 
Phosphate (mmol/24hr) 23.4±2.55 21.0±2.55 27.5±2.88 28.1±2.88 
Potassium (mmol/24hr) 44.1±0.698 42.3±0.698 60.3±7.89 54.7±7.89 
Sodium (mmol/24hr) 11 7±21.3 132±21.3 109±19.9 111±19.9 
Sulphate (mmol/24hr) 18.8±2.22 18.6±2.22 18.1±1.99 20.8±1.99 
Uric acid (mrnol/24hr) 3.06±0.222 3.11±0.222 3.31±0.296 3.43±0.296 
Free Calcium 0.402±0.099 0.289±0.099 0.481±0.0748 0.419±0.0748 
(Ca2+, mmol) 
*BONN-Risk-Index 1.02±0.176 0. 768±0.176 1.69±0.308 1.50±0.308 <0.05* 
(BRI) 
Tiselius Risk Index (TRI) 285±39.8 259±39.8 350±36.5 340±36.5 
*RS Brushite 0.547±0.123 0.412±0.123 1.51±0.362 0. 779±0.362 <0.05* 
*RS CaOx 2.34±0.363 2.53±0.636 5.87±0.609 3.94±0.609 <0.05* 
RS Uric acid 1.87±0.386 1.68±0.386 2.18±0.417 1.41±0.417 
CaOx MSL (mrnol/L) 90±8.39 60±8.39 75±12.4 75±12.4 
*Difference is statistically significant: p s; 0.05, B (Urine sample from black subjects); W (Urine 
sample from white subjects) . RS: Relative Supersaturation. 
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Table 6.7: Mean urinary parameters (± SE) of samples from black (n = 20) and white (n 
= 19) subjects at day 7 of protocol L (low NaCI). A p-value of :S 0.05 with a 
(*) is only shown where there is a statistically significant difference. 
pH 6.13±0.116 6.15±0.116 6.12±0.104 6.35±0.104 
*Volume (rnU24hr) 1328±161 2055±161 <0.05* 1322±105 1787±105 <0.05* <0.05* 
Ammonia (mg!L) 20.7±1.71 19.4±1.71 20.9±1.88 17.2±1.88 
Bicarbonate (mmoi/L) 1.45±0.414 0.714±0.414 1.03±0.291 0.830±0.291 
Calcium (mmoV24hr) 2.28±0.323 1.83±0.323 3.75±0.439 2.65±0.439 
Citrate (mmoV24hr) 2.60±0.246 2.90±0.246 2.29±0.392 3.17±0.392 
*Chloride (mmoV24hr) 139±9.16 84.6±9.16 <0.05* 135±13.1 83.1± 13.1 <0.05* 
Creatinine (mmoV24hr) 13.8±1.01 12.7±1.01 15.6±1.46 13.5±1.46 
Magnesium (mmoV24hr) 2.29±0.267 1.98±0.267 3.13±0.355 2.11±0.355 <0.05* 
Oxalate (mmoV24hr) 0.329± 0.025 0.289±0.025 0.343±0.021 0.303±0.021 
Phosphate (mmoV24hr) 23.4±2.54 16.6±2.54 27.5±0.187 20.7±0.187 
Potassium (mmoV24hr) 44.1±5.41 29.7±5.41 60.3±6.87 39.5±6.87 
*Sodium (mmoV24hr) 11 7±12.9 40.1±12.9 < 0.05* 109±11.2 38.2±11 .2 <0.05* 
Sulphate (mmoV24hr) 18.8±2.04 15.6±2.04 18.1±1.52 16.1±1.52 
*Uric acid (mmoV24hr) 3.06±0. 194 2.46±0.194 <0.05* 3.31±0.237 2.79±0.237 
*Free Calcium 0.402±0.055 0.263±0.055 < 0.05* 0.481±0.0635 0.321±0.0635 
(Ca2+, mmol) 
*BONN-Risk-Index 1.02±0.184 0.596±0. 184 1.69±0.272 1.48±0.272 <0.05* 
(BRI) 
Tiselius Risk Index 285±34.9 251 ±34.9 350±36.9 292±36.9 
(TRI) 
*RS Brushite 0.547±0.212 0.323±0.212 1.51±0.342 0.384±0.342 <0.05* 
*RS CaOx 2.34±0.712 2.56±0.712 5.87±0.569 2.63±0.569 < 0.05* 
*RS Uric acid 1.87±0.228 1.68±0.228 2.18±0.374 1.41±0.374 < 0.05* 
CaOx MSL (mmoi/L) 90±11.8 60±11.8 75± 12.8 75±12.8 
* Difference is statistically significant: p ~ 0.05, 8 (Urine sample from black subjects); W (Urine 
sample from white subjects). RS: Relative Supersaturation. 
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Table 6.8: Mean urinary parameters (± SE) of samples from black (n = 20) and white (n 
=19) subjects at day 5 of protocol H (high NaCl). A p-value of :S 0.05 with a 
(*)is only shown where there is a statistically significant difference. 
Blacks Whites B \'S. 
w 
Parameter Baseline High NaCI p Baseline High p High 
NaCI NaCI 
p 
pH 6.13±0.1 12 6.25±0.112 6.12± 0.099 6.29±0.099 
*Volume (mL/24hr) 1328±165 2026±165 <0.05* 1322±100 1523± 100 <0.05* 
Ammonia (mg!L) 20.7±1.91 22.5± 1.91 20.9±2.39 21 .6±2.39 
Bicarbonate (mmoi/L) 1.45±0.432 1.31±0.432 1.03±0.451 1.71±0.451 
*Calcium (mmoV24hr) 2.28±0.362 2.79±0.362 3.75±0.524 4.57±0.524 <0.05* 
*Citrate (mmoV24hr) 2.60±0.209 2.61±0.209 2.29±0.428 3.43±0.428 < 0.05* 
*Chloride (mmoV24hr) 139±16.7 237±16.7 < 0.05* 135±18.8 221 ±18.8 < 0.05* 
Creatinine (mmoV24hr) 13.8±1.01 14.7±1.01 15.6±1.59 16.1 ±1.59 
*Magnesium (mmoV24hr) 2.29±0.305 2.16±0.305 3.13±0.362 3.21±0.362 <0.05* 
Oxalate (mmoV24hr) 0.329±0.025 0.292±0.025 0.343±0.0182 0.303±0.0182 
Phosphate (mmoV24hr) 23.4±2.48 24.0±2.48 27.5±2.96 31.2±2.96 
Potassium (mmoV24hr) 44. 1±5.14 39.9±5.14 60.3±7.31 51.1±7.31 
*Sodium (mmoV24hr) 117±29.7 281 ±29.7 <0.05* 109±25.5 230±25.5 <0.05* 
*Sulphate (mmoV24hr) 18.8±1.98 20.0± 1.98 18.1±1.92 24.0±1.92 <0.05* 
Uric acid (mmol/24hr) 3.06±0.227 3.36±0.227 3.31±0.329 3.83±0.329 
Free Calcium 0.402±0.662 0.364±0.662 0.481±0.0912 0.563±0.0912 
(Ca2+, mmol) 
*BONN-Risk-Index (BRI) 1.02±0.198 0. 779±0.498 1.69± 0.356 1.947±0.356 < 0.05* 
Tiselius Risk Index (TRI) 285±34.3 251±34.3 350±41.1 308±41.1 
RS Brushite 0.547±0.142 0.615±0.142 1.51±0.358 0.932±0.358 
RS CaOx 2.34±0.363 2.68±0.363 5.87±0.595 4.556±0.595 
RS Uric acid 1.87±0.372 1.45±0.372 2.1 1.957±0.380 
CaOx MSL (mmoi/L) 90±11.4 120±11.4 75±9.72 75±9.72 <0.05* 
*Difference is statistically significant: p s 0.05, B (Urine sample from black subjects); W (Urine 
sample from white subjects) . RS: Relative Supersaturation. 
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Table 6.9: Mean urinary parameters (± SE) of samples from black (n = 20) and white (n 
= 19) subjects at day 7 of protocol H (high NaCl). A p-value of~ 0.05 with a 
(*) is only shown where there is a statistically significant difference. 
pH 6.13±0.105 6.35±0.105 6.12±0.108 6.37±0.108 
*Volume (mL/24hr) 1328±147 2038±147 <0.05* 1322±118 1809±118 <0.05* 
Ammonia (mg/L) 20.7±3.14 22.7±3.14 20.9±2.75 20.1±2.75 
Bicarbonate (mmoi!L) 1.45±0.595 1.59±0.595 1.03±0.297 1.09±0.297 
*Calcium (mmol/24hr) 2.28±0.343 2.03±0.343 3.75±0.461 4.86±0.461 <0.05* 
Citrate (mmol/24hr) 2.60±0.278 3.09±0.278 2.29±0.422 3.04±0.422 
Chloride (mmol/24hr) 139±14.3 163±14.3 135±14.4 159±14.4 
Creatinine (mmol/24hr) 13.8±0.985 12.2±0.985 15.6±1.42 12.8±1.42 
*Magnesium 2.29±0.276 1.86±0.276 3.13±0.353 2.46±0.353 <0.05* 
(mmol/24hr) 
*Oxalate (mmol/24hr) 0.329±0.0262 0.278±0.0262 0.343±0.021 0.276±0.021 <0.05* 
*Phosphate 23.4±2.39 15.6±2.39 <0.05* 27.5±2.16 17.8±2.16 <0.05* 
(mmol/24hr) 
*Potassium 44.1±5.08 31.7±5.08 60.3±6.88 37.0±6.88 <0.05* 
(mmol/24hr) 
Sodium (mmol/24hr) 117±17.4 112±17.4 109±14.7 87.7±14.7 
Sulphate (mmol/24hr) 18.8±2.02 13.6±2.02 18.1±1.53 15.6± 1.53 
*Uric acid (mmol/24hr) 3.06±0.216 2.44±0.216 <0.05* 3.31±0.222 2.79±0.222 
*Free Calcium 0.402±0.0482 0.228±0.0482 <0.05* 0.481±0.0671 0.347±0.0671 
(Ca2+, mmol) 
*BONN-Risk-Index 1.02±0.168 0.699±0.168 1.69±0.277 1.47±0.277 <0.05* 
(BRI) 
Tiselius Risk Index 285±33.4 267±33.4 350±39.3 301±39.3 
(TRI) 
*RS Brushite 0.547±0.118 0.302±0.118 1.51±0.0238 0.371±0.0238 <0.05* 
*RS CaOx 2.34±0.326 1.96±0.326 5.87±0.556 2.66±0.556 <0.05* 
*RS Uric acid 1.87±0.302 0.850±0.302 <0.05* 2.18±0.365 0.669±0.365 <0.05* <0.05* 
CaOx MSL (mmoi!L) 90±11.3 120±11.3 75±11.1 90±11.1 <0.05* 
*Difference is statistically significant: p :5 0.05, B (Urine sample from black subjects); W (Urine 
sample from white subjects). RS: Relative Supersaturation. 
Chapter 6 148 
Table 6.10: Mean urinary parameters (± SE) of samples from black (n = 20) and white (n 
= 19) subjects at day 5 of protocol C (sodium bicarbonate, NaHC03). A p-
value of S 0.05 with a (*) is only shown where there is a statistically 
significant difference. 
*pH 6.13±0.105 6.87±0.105 <0.05* 6.12±0.098 6.81±0.098 <0.05* 
Volume (mL/24hr) 1328± 166 1757±166 1322±123 1547±123 
Ammonia (mg/L) 20.7±4.39 25.4±4.39 20.9±2.54 18.1±2.54 
*Bicarbonate (mmoi!L) 1.45±0.625 2.76±0.625 1.03±0.548 2.52±0.548 <0.05* 
*Calcium (mmol/24hr) 2.28±0.329 1.81±0.329 3.75±0.543 3.66±0.543 <0.05* 
Citrate (mmol/24hr) 2.60±0.273 3.10±0.273 2.29±0.418 3.10±0.418 
Chloride (mmol/24hr) 139±12.3 126±12.3 135±17.5 168±17.5 
Creatinine (mmol/24hr) 13.8±0.995 12.6±0.995 15.6±1.51 14.4±1.51 
*Magnesium 2.29±0.251 1.78±0.251 3.13±0.413 2.63±0.413 <0.05* 
(mmol/24hr) 
*Oxalate (mmol/24hr) 0.329±0.0271 0.323±0.0271 0.343±0.0202 0.288±0.0202 <0.05* 
Phosphate (mmol/24hr) 23.4±2.54 20.3±2.54 27.5±2.77 25.4±2.77 
*Potassium 44.1±5.46 35.7±5.46 60.3±8.28 61.5±8.28 <0.05* 
(mmol/24hr) 
Sodium (mmol/24hr) 117±24.2 139±24.2 109±24.3 197±24.3 
Sulphate (mmol/24hr) 18.8±2.27 18.4±2.27 18.1±1.75 21.0±1.75 
Uric acid (mmol/24hr) 3.06±0.251 2.97±0.251 3.31±0.275 3.59±0.275 
*Free Calcium 0.402±0.0454 0.152±0.0454 <0.05* 0.481±0.0683 0.312±0.0683 <0.05* <0.05* 
(Ca2+, mmol) 
*BONN-Risk-Index 1.02±0.174 0.499±0.174 <0.05* 1.69±0.248 1.084±0.248 <0.05* <0.05* 
(BRI) 
Tiselius Risk Index 285±37.1 256±37.1 350±39.2 285±39.2 
(TRl) 
RS Brushite 0.54 7±0.159 0.585±0. 159 1.51±0.372 1.04±0.372 
*RS CaOx 2.34±0.371 2.207±0.371 5.87±0.649 0.429±0.649 <0.05* 
*RS Uric acid 1.87±0.298 0.561±0.298 <0.05* 2.18±0.361 1.09±0.361 <0.05* 
CaOx MSL (mmoi/L) 90±13.2 120±13.2 75± 11.4 75±11.4 <0.05* 
*Difference is statistically significant: p::;; 0.05, B (Urine sample from black subjects); W (Urine 
sample from white subjects). RS: Relative Supersaturation. 
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Table 6.11: Mean urinary parameters(± SE) of samples from black (n = 20) and white (n 
= 19) subjects at day 7 of protocol C (sodium bicarbonate, NaHC03). A p-
value of :S 0.05 with a (*) is only shown where there is a statistically 
significant difference. 
*pH 6.13±0.091 6.87±0.091 <0.05* 6.12±0.097 6.76±0.097 <0.05* 
*Volume (mL/24hr) 1328±172 2008±172 <0.05* 1322±131 1914±131 <0.05* 
Ammonia (mg/L) 20.7±3.88 20.4±3.88 20.9±3.93 19.6±3.93 
Bicarbonate (mmoi/L) 1.45±0.473 1.67±0.473 1.03±0.566 2.01±0.566 
*Calcium (mmoV24hr) 2.28±0.368 1.15±0.368 <0.05* 3.75±0.435 2.08±0.435 <0.05* 
*Citrate (mmol/24hr) 2.60±0.305 3.91±0.305 <0.05* 2.29±0.441 3.71±0.441 <0.05* 
*Chloride (mmoV24hr) 139 ±10.2 95.8±10.2 <0.05* 135±12.8 70.7±12.8 <0.05* 
Creatinine (mmol/24hr) 13.8±0.952 12.8±0.952 15.6±1.42 12.7±1.42 
Magnesium 2.29±0.276 2.11±0.276 3.13±0.362 2.15±0.362 
(mmol/24hr) 
Oxalate (mmol/24hr) 0.329±0.0444 0.366±0.0444 0.343±0.0184 0.261±0.0184 
*Phosphate 23.4±2.26 14.9±2.26 <0.05* 27.5±2.27 19.6±2.27 <0.05* 
(mmol/24hr) 
Potassium (mmol/24hr) 44.1 ±5.51 35.2±5.51 60.3±6.79 37.5±6.79 
Sodium (mmol/24hr) 117± 18.9 82.0±18.9 109±12.6 52.7±12.6 
Sulphate (mmol/24hr) 18.8±2.06 13.3±2.06 18.1±1.81 14.6±1.81 
Uric acid (mmol/24hr) 3.06±0.192 2.54±0.192 3.31±0.226 2.66±0.226 
*Free Calcium 0.402±0.462 0.134±0.0462 <0.05* 0.481±0.0566 0.163±0.0566 <0.05* 
(Ca2+, mmol) 
*BONN-Risk-Index 1.02±0.172 0.430±0.172 <0.05* 1.69±0.246 0.812±0.246 <0.05* 
(BRI) 
Tiselius Risk Index 285±37.6 241±37.6 350±40.5 257±40.5 
(TRI) 
*RS Brushite 0.547±0.125 0.368±0.125 1.51±0.346 0.497±0.346 <0.05* 
*RS CaOx 2.34±0.442 2.24±0.442 5.87±0.589 2.182±0.589 <0.05* 
*RS Uric acid 1.87±0.387 0.690±0.387 <0.05* 2.18±0.359 0.324±0.359 <0.05* 
CaOx MSL (mmoi/L) 90± 11.2 105±11.2 75±13.2 90±13.2 
*Difference is statistically significant: p :5 0.05, 8 (Urine sample from black subjects); W (Urine 
sample from white subjects). RS: Relative Supersaturation. 
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Table 6.12: Mean urinary parameters (± SE) of samples from black (n = 20) and white 
(n = 19) ubjects at day 5 of protocol D (sodium citrate). A p-value of::; 0.05 
with a (*) is only shown where there is a statistically significant difference. 
*pH 6.13±0.122 6.99±0.122 <0.05* 6.12±0.101 6.99±0.101 <0.05* 
*Volume (mL/24hr) 1328±174 1637±174 1322±115 1655± 115 <0.05* 
Ammonia (mg!L) 20.7±1.62 16.7±1.62 20.9±4.351 29.4±4.351 
*Bicarbonate (mmoi/L) 1.45±0.577 2.79±0.577 1.03±0.543 2.53±0.543 <0.05* 
Calcium (mmol/24hr) 2.28±0.329 1.79±0.329 3.75±0.485 2.53±0.485 
Citrate (mmol/24hr) 2.60±0.322 3.15±0.322 2.29±0.397 2.89±0.397 
Chloride (mmol/24hr) 139±12.8 126±12.8 135±15.8 115±15.8 
Creatinine (mmol/24hr) 13.8± 0.910 12.6±0.910 15.6±1.51 13.2±1.51 
Magnesium 2.29± 0.258 1.85±0.258 3.13±0.436 2.52±0.436 
(mmol/24hr) 
Oxalate (mmol/24hr) 0.329±0.335 0.343±0.335 0.343±0.0214 0.301±0.0214 
*Phosphate 23.4±2.27 19.4±2.27 27.5±3.59 28.5±3.59 <0.05* 
(mmol/24hr) 
*Potassium 44.1±5.09 16.7±5.09 <0.05* 60.3±7.69 46.9±7.69 <0.05* 
(mmol/24hr) 
Sodium (mmol/24hr) 117± 27.5 168±27.5 109±21.2 168±21.2 
Sulphate (mmol/24hr) 18.8±2.003 15.6±2.003 18.1±2.03 18.5±2.03 
Uric acid (mmol/24hr) 3.06± 0.210 2.81±0.210 3.31±0.315 3.33±0.315 
*Free Calcium 0.402±0.0511 0.153±0.0511 <0.05* 0.481±0.0547 0.148±0.0547 <0.05* 
(Ca2+, mmol) 
*BONN-Risk-Index 1.02±0.177 0.369±0.177 <0.05* 1.69±0.291 0.793±0.291 <0.05* 
(BRI) 
TiseHus Risk Index 285±37.5 289±37.5 350±38.5 292±38.5 
(TRI) 
*RS Brushite 0.547±0.134 0.534±0.134 1.51±0.359 0.912±0.359 <0.05* 
*RSCaOx 2.34±0.377 2.153±0.377 5.87±0.549 2.36±0.549 <0.05* 
*RS Uric acid 1.86±0.312 0.430±0.312 <0.05* 2.18±0.353 0.227±0.353 <0.05* 
CaOx MSL (mmoi/L) 90±14.2 105±14.2 75± 14.2 90±14.2 
*Difference is statistically significant: p s 0.05, 8 (Urine sample from black subjects); W (Urine 
sample from white subjects). RS: Relative Supersaturation. 
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Table 6.13: Mean urinary parameters (± SE) of samples from black (n = 20) and white (n 
= 19) subjects at day 7 of protocol D (sodium citrate). A p-value of :S 0.05 
with a (*) is only shown where there is a statistically significant difference. 
*pH 6.13±0.104 7.114±0.104 <0.05* 6.12±0.109 7.03±0.109 <0.05* 
*Volume (mL/24hr) 1328±189 1834±189 <0.05* 1322 ±151 1964±151 <0.05* 
*Ammonia (mg!L) 20.7±3.42 20.3±3.42 20.9±4.892 32.2±4.892 <0.05* 
*Bicarbonate (mmoi!L) 1.45±0.425 1.32±0.425 1.03±0.435 2.15±0.435 <0.05* 
*Calcium (mrnol/24hr) 2.28±0.315 1.37±0.615 <0.05* 3.75±0.456 2.32±0.456 <0.05* 
*Citrate (mmol/24hr) 2.60±0.277 3.42±0.277 <0.05* 2.29±0.446 4.06±0.446 <0.05* 
*Chloride (mmol/24hr) 139±10.7 93.8±10.7 <0.05* 135±15.8 115±15.8 <0.05* 
Creatinine (mrnol/24hr) 13.8±0.887 12.3±0.887 15.6±1.39 12.6±1.39 
Magnesium (mmol/24hr) 2.29± 0.267 2.06±0.267 3.13±0.382 2.56±0.382 
*Oxalate (mrnol/24hr) 0.329±0.032 0.331 ±0.032 0.343±0.0199 0.266±0.0199 <0.05* 
*Phosphate (mrnol/24hr) 23.4±2.14 15.5±2.14 <0.05* 27.5±2.13 16.9±2.13 
*Potassium (mrnol/24hr) 44.1±5.35 28.7±5.35 <0.05* 60.3±6.96 42.6±6.96 
Sodium (mrnol/24hr) 117±18.9 90.5±18.9 109±19.3 163±19.3 
Sulphate (mrnol/24hr) 18.8±1.98 14.5± 1.98 18.1±1.89 15.2±1.89 
*Uric acid (mrnol/24hr) 3.06±0.189 2.54±0.189 <0.05* 3.31±0.233 2.82±0.233 
*Free Calcium 0.402±0.0494 0.159±0.0494 <0.05* 0.481±0.0538 0.106±0.0538 <0.05* 
(Ca2+, mmol) 
*BONN-Risk-Index (BRI) 1.02±0.211 0.553±0.211 <0.05* 1.69±0.194 0.323±0.194 <0.05* 
*Tiselius Risk Index 285±38.9 262±38.9 350±34.5 223±34.5 <0.05* 
(TRI) 
RS Brushite 0.547±0.114 0.374±0.114 1.51±0.366 0.697±0.366 
*RS CaOx 2.34±0.387 1.26±0.387 <0.05* 5.87±0.549 1.85±0.549 <0.05* 
*RS Uric acid 1.87±0.279 0.271±0.279 <0.05* 2.18 ±0.425 0.601±0.425 <0.05* 
*CaOx MSL (mrnoi/L) 90±13.7 120±13.7 75±11.2 90±11.2 <0.05* <0.05* 
*Difference is statistically significant: p ~ 0.05, 8 (Urine sample from black subjects); W (Urine 
sample from white subjects). RS: Relative Supersaturation. 
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Table 6.14: A summary of common and different physicochemical changes in samples 
from black and white subjects after each protocol. 
Low NaCI(L) 
Day 5 (L5) 
(Table 6.6) 
Day 7 (L7) Volume j , Chloride ~' Uric acid~' Magnesium ~' 
(Table 6.7) Sodium~ RS brushite L 
RS CaOx ~ ' RS Uric acid~ 
High NaCI (B) 
Day 5 (H5) Chloride j, Sodium j Volume j Sulphate j 
(Table 6.8) 
Day 7 (H7) Volume j , Phosphate ~' Uric acid~' Oxalate~, Potassium ~, 
(Table 6.9) RS Uric acid ~ Ca
2
+ ~ RS brushite ~, 
RS CaOx ~ 
NaHC03 (C) 
Day 5 (C5) pHj, ~ ' BRI ~ ' Bicarbonate j , Oxalate L 
(Table 6.1 0) RS Uric acid ~ RS CaOx ~ 
Day 7 (C7) pH j , Volumej, Chloride~, RS brushite ~' RS CaOx ~ 
(Table 6.11) Calcium ~ ' Citrate j , Phosphate~ 
Ca
2
+ ~ ' BRI ~ ' 
RS Uric acid ~ 
Na-Citrate (D) 
Day 5 (D5) pH j , Ca ~ ' BRI L Potassium~, Volumej, Bicarbonate j, 
(Table 6.12) RS Uric acid ~ RS CaOx ~ 
Day 7 (D7) pH j , Volume j, Chloride~' Bicarbonate j , Oxalate j , 
(Table 6.13) Calcium ~ ' Citrate j , Phosphate ~ , TRI ~' MSL j 
Ca
2
+ ~ ' BRI ~ ' RS CaOx L Potassium L 
RS Uric acid ~ Uric acid~ 
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Comment 
In this study, baseline urine samples from black subjects had significantly lower calcium 
concentrations, lower BRI, and lower RS of brushite and RS of CaOx compared to those 
from their white compatriots (Table 6.5). All these parameters are important risk factors for 
kidney stone formation. The significant differences in these parameters are in accordance 
with the low incidence of kidney stone formation in the black South African race group. In 
particular, the lower RS of CaOx in black subjects is highly indicative of their lower stone 
incidence. 
The baseline urine composition values in this study (Table 6.5) do not agree with 
those reported in the study on macromolecules in Chapter 3 (Table 3.1), with the exception of 
RS of CaOx which was found to be significantly lower in black subjects in both studies. The 
discrepancies in the other compositional values are likely to be due to the higher statistical 
power of the present study which involved 20 subjects, as compared to only 10 subjects in the 
other. 
It is of some interest to consider the changes which commonly occurred in both race 
groups after each of the protocols (Tables 6.14). Regarding the sodium chloride protocols, it 
is not surprising that urinary sodium and chloride decreased (relative to baseline values) after 
the low NaCl protocol and increased after the high NaCl protocol. On the other hand, the 
decreases in urinary phosphate and RS of uric acid are unexpected as they have not been 
previously reported. The physiological mechanisms giving rise to these two effects are not 
apparent. 
Regarding the sodium bicarbonate protocols, pH increased in both groups. This was 
accompanied by a concomitant decrease in ionized calcium. This effect can be attributed to 
complexation of free calcium with citrate ( Lemann et al. 1989 l. Indeed, a recent study by 
Rodgers et al. (2005) identified a new calcium-citrate-phosphate complex which forms at 
elevated pH levels. The decrease in the BRI is a direct consequence of the decrease in ionized 
calcium. Of great interest in the present study is the observation of a decrease in total urinary 
calcium in both groups after administration of sodium bicarbonate. This has not been 
previously reported. In fact, to the contrary, Lemann et al. ( 1989) specifically drew attention 
to the fact that this effect was achieved by potassium bicarbonate but not by sodium 
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bicarbonate. Another interesting effect is the increase in urinary citrate. This observation has 
been previously reported by Lemann et al. ( 1989) and might be attributable to the expected 
rise in pH and the decrease (but not significant) in uric acid after administration of sodium 
bicarbonate ( Lemann et al. ). 
The common changes achieved after sodium citrate protocols (increase in urinary pH, 
decrease in ionized calcium and BRI) occurred for the same reasons as explained above for 
sodium bicarbonate. Furthermore, while the increase in urinary citrate is expected, the 
decrease in total urinary calcium has not been previously observed after administration of 
sodium citrate (Sakhaet 1983: Preminger 1988). However, this might be due to the fact that 
the preparation which was used in the present study contained tartrate and bicarbonate in 
addition to sodium citrate. 
It is noted that all the protocols (except low NaCl) induced a decrease in RS of uric 
acid. As mentioned above, the physiological mechanism that gives rise to this effect after the 
high NaCl protocol is unknown. However, with respect to the sodium bicarbonate and 
sodium citrate protocols, the effect is readily attributed to the increase in urinary pH. 
Finally, the failure of the high NaCl protocol to induce statistically significant 
increases in urinary calcium is surprising since this effect has been widely reported (Kleeman 
et al. 1964: Rao et al. 1985: Sak.haee et al. 1993: Ginty et al. 1998: Ho et al. 2001: Masse) 
2005: Wigerts et al. 2005). However, King et al. ( 1964 ), reported no significant increase in 
urinary calcium following administration of 8 g of NaCl for 6 days. This was attributable to 
the fact that the reserves of labile bone sodium gradually become depleted and repleted in a 
cycle form. In such cases, repletion requires a longer period to recover from the longer period 
of depletion (Neuman a•1d Neuman 1958 ). Nevertheless, despite the absence of a statistically 
significant increase in urinary calcium, it is noted that after 7 days on the high NaCl diet, 
urinary calcium increased by 29 % in whites, but decreased in blacks by 10.9 % (Table 6.9). 
There is thus a hint of different handling mechanisms in the two race groups. 
Of even greater interest than the common changes are the effects which occurred in 
one race group but not the other in each of the protocols. There were fewer changes in the 
urine chemistries of black subjects than in those of white subjects. All of the changes in both 
groups were favourable, i.e. they reduced the physiochemical risk of calcium oxalate 
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crystallization. The decreases in RS of CaOx, RS of uric acid and RS of brushite after the 
various protocols in white subjects have not been previously reported. 
However, irrespective of whether the effects have been previously reported or not and 
irrespective of the process giving rise to them, the observation of different responses in the 
two groups, despite identical conditions being imposed, indicates that handling of the 
protocols in the two groups proceeds via different mechanisms. 
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6.4.2 Crystallization Experiments 
CaOx Metastable Limit 
Although the mean MSL values and standard errors (SE) of samples from both black 9 (n = 
20) and white (n = 19) subjects on the various protocols have already been presented in 
Tables 6.5 -6.13, they have been consolidated into a single table (6.15) for ease of reference. 
Only the statistically significant comparisons are shown. Corresponding histograms are given 
in Figure 6.4. Qualitatively, urine samples from black subjects have relatively higher CaOx 
metastable limits than those from white subjects at baseline and after each protocol. 
However, statistically significant higher metastable limits in blacks were recorded after the 
H5, H7, C5 and D7 protocols. 
Table 6.15: Mean Metastable Limit (mmol/L), and standard errors (SE) of urine from 
black (B, n = 20) and white (W, n = 19) subjects at baseline and at Day 5 and 
Day 7 of each salt. 
Baseline 90 ± II 75 ±II 
Low NaCl, day 5 (L5) 60± IO 75 ± IO 
Low NaCI, day 7 (L7) 90± I4 90 ± I4 
High NaCI, day 5 (H5) 120 ± 11 < 0.05* 75 ± II < 0.05* 
High NaCI day 7 (H7) I20 ± I2 <0.05* 90± 12 < 0.05* 
NaHC03, day 5 (C5) I20 ± I4 <0.05* 75 ± I4 < 0.05* 
NaHC03, day 7 (C7) I05 ± I4 90 ± I4 
Na-Citrate, day 5 (05) I05 ± 17 90± I7 
Na-Citrate, day 7 (D7) I20 ± I4 <0.05* 90 ± I4 < 0.05* 
* Difference is statistically significant: p s 0.05, B (Urine sample from black subjects); W (Urine 
sample from white subjects). L5 and L7: day 5 and day 7 of low NaG/; H5 and H7: day 5 and day 7 of 
high NaG/; G5 and G7: day 5 and day 7 of NaHG03; 05 and 07: day 5 and day 7 of citrate. 
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Figure 6.4: Mean MSL histogram of urine samples from black (B) and white (W) 
subjects at baseline, day 5 and day 7 of each protocol. 
* : Difference is statistically significant relative to the corresponding W protocol. 
Comment 
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The higher MSL of urine samples from black subjects compared to those from white subjects 
is in agreement with that reported in Chapter 3 and supports the notion that crystallization of 
CaOx in the urine of the former group is more difficult to achieve. Interestingly, 
administration of high NaCl, high sodium bicarbonate and high sodium citrate induced a 
significant increase in the MSL in blacks whereas no change was observed in whites. This 
provides further support for the hypothesis that different handling mechanisms of lithogenic 
dietary challenges exist in the two groups. 
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Particle Number 
Tables 6.16 and 6.17 represent the particle number (/500 J.lL) of urine samples from black (n 
= 20) and white (n = 19) subjects, respectively at baseline and at day 5 and day 7 of each 
protocol. The corresponding histogram is shown in Figure 6. 5. Individual values are 
presented in Appendix 4, Tables 4.3 and 4.4. 
Table 6.16: Mean particle number (/500 J.lL), standard errors and p-values in urine samples 
from black subjects (n = 20) at baseline and at Day 5 and Day 7 of each 
protocol. A p-value of ~ 0.05 with a (*) is only shown where there is a 
statistically significant difference. 
Baseline 24100 ± 3218 
L5 28889 ± 3283 16.57 0.3109 
L7 27747 ± 2737 13.14 0.4244 < 0.05* 
H5 23037 ± 3119 4.41 0.8158 
H7 22183 ± 2822 7.95 0.6618 
C5 20160 ± 3182 16.35 0.3943 
C7 22911 ± 3196 4.93 0.8075 < 0.05* 
D5 24278 ± 4159 0.73 0.9770 
D7 16998 ± 2792 29.47 0.1307 
* Difference is statistically significant: p :s; 0. 05, B (Urine sample from black subjects); W (Urine 
sample from white subjects). L5 and L7: day 5 and day 7 of low NaCI; H5 and H7: day 5 and day 7 of 
high NaCI; C5 and C7: day 5 and day 7 of NaHC03; 05 and 07: day 5 and day 7 of citrate. 
Chapter 6 !59 
Table 6.17: Mean particle number (/500 IlL), standard errors and p-values in urine samples 
from white subjects (n = 19) at baseline and at Day 5 and Day 7 of each 
protocol. A p-value of :S 0.05 with a (*) is only shown where there is a 
statistically significant difference. 
Baseline 25137 ± 3218 
L5 26101 ± 3283 3.69 0.8368 
L7 17126 ± 2737 31.87 0.052 < 0.05* 
H5 26999 ± 3119 6.89 0.6843 
H7 20898 ± 2822 16.86 0.3325 
C5 25910 ± 3182 2.98 0.8656 
C7 16472 ± 3196 34.47 0.0508 < 0.05* 
D5 23445 ± 4159 6.73 0.6915 
D7 20504 ± 7292 18.43 0.2512 
* Difference is statistically significant: p s 0. 05, B (Urine sample from black subjects); W (Urine 
sample from white subjects). L5 and L7: day 5 and day 7 of low NaG/; H5 and H7: day 5 and day 7 of 
high NaG/; G5 and G7: day 5 and day 7 of NaHG03; 05 and 07: day 5 and day 7 of citrate. 
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Figure 6.5: Mean particle number (/500J..tL in urine samples from black (B) and 
white (W) subjects at baseline, day 5 and day 7 of each protocol. 
* : Difference is statistically significant relative to the corresponding W protocol. 
B (Urine sample from black subjects); W (Urine sample from white subjects). L5 and L7: day 5 and 
day 7 of low NaCI; H5 and H7: day 5 and day 7 of high NaCI; C5 and C7: day 5 and day 7 of 
NaHC03; 05 and 07: day 5 and day 7 of citrate. 
There was no significant difference in particle numbers in both race groups after the ingestion 
of each protocol. However, in white subjects, decreases which tended towards significance 
were observed after the low NaCl diet on day 7 (L7, Table 6.16) and after NaHC03 diet on 
day 7 (C7, Table 6.16). Comparison of the two groups themselves showed a significantly 
higher number of particles in black subjects on day 7 of the low NaCl diet (L 7). 
Comment 
Although the physiological explanation for the above observations is not immediately 
apparent, the importance of these observations is that differences between the groups, 
irrespective of their reasons, do indeed exist. 
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Particle Volume 
Table 6.18 and 6.19 show the mean particle volume of urine samples from black (n = 20) and 
white (n = 19) subjects, respectively at baseline and at day 5 and day 7 of each protocol. The 
corresponding histogram is shown in Figure 6. 6. The individual data are shown in Appendix 
4, Tables 4.5 and 4.6. 
Table 6.18: Mean particle volume (x 106 Jlm3 /500 J.!L), standard errors and p-values in 
urine samples from black subjects (n = 20) at baseline and at Day 5 and Day 7 
of each protocol. A p-value of :S 0.05 with a (*) is only shown where there is a 
statistically significant difference. 
Baseline 1.34 ± 0.213 < 0.05* 
L5 4.26 ± 0.339 68.47 < 0.05* 
L7 1.48 ± 0.117 9.32 
H5 1.30 ± 0.113 2.83 < 0.05* 
H7 1.60 ± 0.187 16.13 
C5 1.682 ± 0.234 20.21 < 0.05* 
C7 0.834 ± 0.091 37.85 
D5 0.661 ± 0.212 50.75 < 0.05* 
D7 1.866 ± 0.321 28.08 
* Difference is statistically significant: p s 0. 05, B (Urine sample from black subjects); W (Urine 
sample from white subjects). L5 and L7: day 5 and day 7 of low NaCI; H5 and H7: day 5 and day 7 of 
high NaCI; C5 and C7: day 5 and day 7 of NaHC03; 05 and 07: day 5 and day 7 of citrate. 
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Table 6.19: Mean particle volume, standard errors and p-values of urine samples from 
white subjects (n = 19) at baseline and at Day 5 and Day 7 of each protocol. A 
p-value of :S 0.05 with a (*) is only shown where there is a statistically 
significant difference. 










volume ± S. E. wrt baseline 
(x 106 '-'m3/500 
'-'L) 
2.19 ± 0.2 13 
2.18 ± 0.339 
1.46 ± 0.11 7 
2.75 ± 0.113 20.16 
1.61 ± 0.187 
3.12 ± 0.234 42.13 
1.25 ± 0.091 
3.30 ± 0.21 2 33.59 














* Difference is statistically significant: p :s; 0.05, B (Urine sample from black subjects); W (Urine 
sample from white subjects). L5 and L7: day 5 and day 7 of low NaG/; H5 and H7: day 5 and day 7 of 
high NaG/; G5 and G7: day 5 and day 7 of NaHG03; 05 and 07: day 5 and day 7 of citrate. 
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Figure 6.6: Mean particle volume in urine samples from both black (B) and white (W) 
subjects at baseline and at day 5 and day 7 of each protocol. 
* : Difference is statistically significant relative to the corresponding W protocol. 
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* Difference is statistically significant: p s 0. 05, 8 (Urine sample from black subjects); W (Urine 
sample from white subjects). L5 and L7: day 5 and day 7 of low NaG/; H5 and H7: day 5 and day 7 of 
high NaG/; G5 and G7: day 5 and day 7 of NaHG03; 05 and 07: day 5 and day 7 of citrate. 
There was no significant difference in the particle volume in both race groups after the 
ingestion of each protocol. However, several statistically significant differences were 
recorded when comparisons were made between the two ethnic groups themselves. Particle 
volume at baseline is lower in samples from black subjects than in those from white subjects 
(Figure 6.6). While this relationship was retained after protocols H5, C5, C7 and D5, it was 
reversed after protocol L5 (Figure 6.6). 
Comment 
The higher total particle volume in white subjects (despite non significant differences in 
baseline particle numbers reported in Tables 6.16 and 6.17) is indicative of larger particles or 
a greater extent of aggregation (with occluded air and debris) or both. However, 
interpretation of the reversal of the trend after protocol L5 is not apparent at this stage. 
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Particle Volume-Size Distributions 
The mean particle-size distribution plots in the urine of blacks (n = 20) and whites (n = 19) 
before and after each protocol are shown in Figure 6. 7 (a) and (b), respectively. Individual 
plots are in Appendix 4, Figures 4.1 and 4.2. The corresponding mean particle size values 
with p-values are presented in Tables 6.20 and 6.21. 
The size of crystals induced in samples from white subjects at baseline and at day 5 and 7 of 
each protocol was significantly higher than those from black subjects. When inter-group 
comparisons were made, there were no significant changes in particle size after each protocol 
relative to the control. However, all the protocols resulted in a decrease in particle size in 
samples from black subjects relative to the baseline whereas an increase was observed in 
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Table 6.20: Mean particle sizes, standard errors and p-values in urine samples from black 
subjects at baseline, and at Day 5 and Day 7 of each protocol. A p-value of :S 












Particle ! <Yo Decrease wrt p-Value 
size (f.lm) ± S. E. baseline baseline 
(p > 0.05) 
4.53 ± 0.985 
4.27 ± 1.03 5.74 
4.09 ± 0.695 9.71 
4.39 ± 0.844 3.09 
4.13 ± 0.731 8.83 
4.03 ± 1.14 11.0 
3.93 ± 0.926 13.3 
4.29 ± 1.67 5.29 
4.28 ± 1.23 5.52 











* Difference is statistically significant: p :5 0.05, B (Urine sample from black subjects); W (Urine 
sample from white subjects). L5 and L7: day 5 and day 7 of low NaG/; H5 and H7: day 5 and day 7 of 
high NaG/; G5 and G7: day 5 and day 7 of NaHG03; 05 and 07: day 5 and day 7 of citrate. 
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Table 6.21: Mean particle sizes, standard errors and p-values in urine samples from white 
subjects at baseline and at Day 5 and Day 7 of each protocol. A p-value of< 
0.05 with a (*) is only shown where there is a statistically significant 
difference. 
*Baseline 9.89 ± 1.01 < 0.05* 
*L5 10.1 ± 1.05 2.08 < 0.05* 
*L7 10.3 ± 0.713 4.07 < 0.05* 
*H5 10.7 ± 0.866 7.39 < 0.05* 
*H7 9.99 ± 0.751 0.90 < 0.05* 
*C5 9.99 ± 1.16 0.90 < 0.05* 
*C7 10.7 ± 0.951 7.82 < 0.05* 
*D5 13.2 ± 1.72 25.1 < 0.05* 
*D7 10.1 ± 1.23 1.88 < 0.05* 
* Difference is statistically significant: p s 0.05, B (Urine sample from black subjects); W (Urine 
sample from white subjects). L5 and L7: day 5 and day 7 of low NaG/; H5 and H7: day 5 and day 7 of 
high NaG/; G5 and G7: day 5 and day 7 of NaHG03; 05 and 07: day 5 and day 7 of citrate. 
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Comment 
Particle volume-size distribution curves reveal a significantly high particle size in samples 
from whites compared to those from blacks after all the protocols. This suggests promotion of 
crystal growth or aggregation in the samples from white subjects. Notwithstanding the fact 
that the differences were non-significant, a decrease in particle size was observed in blacks 
whereas an inverse was shown in samples from white subjects after all the protocols. This 
demonstrates inhibition of crystal growth or aggregation in blacks following the 
administration of the protocols whereas promotion occurred in whites. 
Scanning Electron Microscopy (SEM) 
Figure 6.8 shows representative scanning electron micrographs of crystals precipitated after 
induction of CaOx crystallization in baseline and day 7 urine samples obtained from black 
male subjects. At baseline, relatively few single COM crystals and a few tiny aggregates of 
COD crystals were observed (B Ctrl). After the NaCl protocols the number of COM crystals 
increased dramatically. These effects were significantly reduced after sodium bicarbonate and 
sodium citrate ingestion. 
Figure 6.9 shows representative scanning electron micrographs of crystals precipitated after 
induction of CaOx crystallization in baseline and day 7 urine samples obtained from white 
male subjects. At baseline, medium-sized COD crystals were precipitated while after the low 
NaCl protocol, only one tiny aggregate was observed. Ingestion of high NaCl resulted in a 
change in morphology from medium-sized COD crystals to medium-sized single and 
aggregated COM crystals. The number of COM crystals was significantly reduced after 
sodium bicarbonate. Nevertheless, several were still present. After ingestion of sodium 
citrate, very few single or aggregated crystals were observed. 
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Figure 6.8: Scanning electron micrographs of crystals induced in urine samples from 
black (B) subjects at baseline and at day 7 of each protocol at 4 K magnification. B Ctrl 
(Baseline); BL (Low NaCl); BH (High NaCl); BC (Sodium Bicarbonate) and BD 
(Sodium citrate). 
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Figure 6.9: Scanning electron micrographs of crystals induced from in samples from 
white (W) subjects at baseline and at day 7 of each protocol at 4 K magnification. W 
Ctrl (Baseline); WL (Low NaCl); WH (High NaCl); WC (Sodium Bicarbonate) and WD 
(Sodium citrate). 
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Comment 
It is noted that the various protocols culminated in a change of morphology from COD to 
COM in white subjects while in black subjects the morphology was consistently that of the 
monohydrate. Two other differences were observed in the urines of the two ethnic groups. 
The frrst occurred after the L protocol in which several crystals occurred in urine from black 
subjects but virtually none in that from white subjects. The second difference occurred after 
the C protocol which culminated in fewer crystals in the urine of black subjects. 
Although the reasons for these differences are not immediately apparent, their mere existence 
is important in the context of the general hypothesis that the two ethnic groups respond 
differently to the various salt challenges. 
c ''" l , _ •' ' c'- • ' ' ' ' <c ' 
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[
14 C)-Oxalate crystal deposition kinetics 
The mean percentage plots of 14C-oxalate precipitated as a function of time by urine samples 
from black (n = 12) and white (n = 12) subjects at baseline and on days 5 and 7 of each salt 
protocol are shown in Figures 6.10 (a) and (b), respectively. Individual plots are in Appendix 
4, Figures 4.3 and 4.4. The mean values and standard errors from which the graph was plotted 
and the standard errors (SE) are shown in Table 6.22. Comments on the results are offered on 
page 174. 
Table 6.22: Mean values for% 14C-oxalate precipitated after 120 minutes, standard error 
and p-values in urine samples from black (n = 12) and white (n = 12) subjects 











B ± SE ·! B: Baselin'e. 
vs. Protocol 
p-values 
24 ± 2.34 
30±3.21 
18 ± 2.15 
35 ± 3.38 
24 ± 2.39 
22 ± 1.58 
10 ± 0.99 < 0.05* 
20 ± 1.56 
11 ± 1.87 < 0.05* 
W±SE 
29 ± 2.34 
39 ± 3.21 
28 ± 2.15 
45 ± 3.38 
32 ± 2.39 
17 ± 1.58 
21 ± 0.99 
17 ± 1.56 
22 ± 1.87 








* Difference is statistically significant: p ~ 0. 05, 8 (Urine sample from black subjects); W (Urine 
sample from white subjects). L5 and L7: day 5 and day 7 of low NaCI; H5 and H7: day 5 and day 7 of 
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Figure 6.10: Mean [14C]-Oxalate deposited by urine samples from (a) black (b) and 
white subjects at baseline and day 5 and day 7 of each protocol. 
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Comment 
The sodium chloride protocols tended to increase the deposition kinetics while the sodium 
bicarbonate and sodium citrate protocols tended to decrease the kinetics in both groups, 
relative to their respective baseline values. 
Qualitative consideration of these results within the two groups shows several 
interesting features. Firstly, the percentage of 14C-oxalate deposited at baseline is lower in 
blacks than in white subjects. This relationship is maintained for most of the protocols except 
C5 and D5. Secondly, the same increase or decrease (relative to their respective baseline 
values) occurred in the black and white groups for all protocols (except H7 where there was 
only a small change in whites and no change in blacks). 
Of greater interest however, are the quantitative comparisons which show highly 
significant decreases in black subjects for C7 (from 24% to 10 %) and D7 (from 24% to 11 
%) while less dramatic differences are observed in white subjects (from 29% to 21 %and to 
22% respectively). 
The qualitative increase in the percentage deposition of crystals containing 14C 
oxalate in both groups after administration of the low and high NaCl protocols suggests that 
subtle changes in the urine composition, undetected by urine analyses, must have occurred. A 
similar argument is valid for the observed changes after the other protocols. These small 
compositional changes are likely to have been in the urinary calcium. In the case of the NaCl 
diets, it can be speculated that this parameter increased (due to the physiological action of 
sodium) while in the case of the sodium bicarbonate and sodium citrate protocols, it can be 
speculated that this parameter decreased due to pH and complexation effects. 
The quantitative results again demonstrate that blacks and whites subjects respond 
differently to salt challenges. While the groups have had a favourable response (which is 
expected after administration of sodium bicarbonate or sodium citrate), it was significantly 
greater in black subject . 
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CaOx Crystal Aggregation 
The mean percentage inhibition of CaOx crystal aggregation in urine samples from black (n = 
20) and white (n = 19) subjects at baseline and at day 5 and day 7 for each protocol are shown 
in Table 6.23 and the corresponding histogram is presented in Figure 6.11. Individual data are 
shown in Appendix 4, Tables 4.7 and 4.8. 
Qualitatively, the urine samples from black subjects displayed relatively higher percentages 
of inhibition of CaOx crystal aggregation than those from white subjects after each protocol 
except for H5. It is noted that in black subjects, one of the protocols resulted in increased 
inhibition of aggregation relative to baseline (D5) while no such effect occurred with any of 
the protocols in white subjects. 
Table 6.23: Mean percentage of inhibition of CaOx crystal aggregation, standard errors 
and p-values in urine from black (n = 20) and white (n = 19) subjects at 
baseline and at day 5 and day 7 of each protocol. 
Sample B ±SE B: Baseline vs. W±SE W: Baseline vs. Bvs. W 
Protocol (p > 0.05) Protocol (p > 0.05) p-value 
Protocol 76 ± 5.01 73 ± 5.01 
L5 73 ± 3.52 69 ± 3.52 
L7 76 ± 4.19 70 ± 4.19 
H5 68 ± 4.37 73 ± 4.37 
H7 75 ± 3.45 70 ± 3.45 
C5 75 ± 3.29 71 ± 3.29 
C7 73 ± 3.29 70 ± 3.29 
*D5 81 ± 3.33 72 ± 3.33 < 0.05* 
D7 75 ± 3.29 72 ± 3.29 
* Difference is statistically significant: p :;; 0.05, B (Urine sample from black subjects); W (Urine 
sample from white subjects). L5 and L7: day 5 and day 7 of low NaG/; H5 and H7: day 5 and day 7 of 
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Figure 6.11: Mean percentage inhibition of aggregation at baseline and at Day 5 
and Day 7 of each protocol in both black (B) and white (W) subjects. 
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B (Urine sample from black subjects); W (Urine sample from white subjects). L5 and L7: day 5 and 
day 7 of low NaG/; H5 and H7: day 5 and day 7 of high NaG/; G5 and G7: day 5 and day 7 of 
NaHG03; 05 and 07: day 5 and day 7 of citrate. 
Comment 
The qualitative results show that inhibition of CaOx crystal aggregation occurs to a greater 
extent in the urine of black subjects than in white subjects. This is consistent with particle 
size, SEM and 14C-oxalate deposition results. The solitary quantitative difference between the 
groups again demonstrates that the two groups handle salt challenges differently and urines 
from black subjects have a superior ability to inhibit against CaOx crystal aggregation. 
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CaOx Crystal Nucleation 
The mean percentages of inhibition of CaOx crystal nucleation induced by urine samples 
from black (n = 20) and white (n = 19) subjects at baseline and at day 5 and day 7 of each 
protocol are shown in Table 6.24 and the corresponding histogram is presented in Figure 
6.12. Individual data are shown in Appendix 4, Tables 4.9 and 4.1 0. 
Qualitatively, the samples from black subjects showed a relatively higher inhibition of 
nucleation for all protocols. Quantitatively, protocols C7 and D7 produced significantly 
different effects in black and white subjects. 
Table 6.24: Mean percentages of nucleation inhibition, standard errors and p-values by 
urine from black (n = 20) and white (n = 19) subjects at baseline and at day 5 
and day 7 of each salt. 
·sample B±SE 'B: Baseline vs. W±SE W: Baseline vs. Bvs. W 
Protocol (p > 0.05) Protocol (p > 0.05) p-values 
Protocol 74±4.88 65 ± 4.88 
L5 78 ± 4.08 72 ± 4.08 
L7 69 ± 3.61 69 ± 3.61 
H5 79 ± 4.25 73 ± 4.25 
H7 72 ± 3.54 66 ± 3.54 
C5 77 ± 3.38 68 ± 3.38 
*C7 79 ± 3.38 59± 3.38 < 0.05* 
D5 79 ± 3.42 70 ± 3.42 
*D7 75 ± 3.39 60 ± 3.39 < 0.05* 
* Difference is statistically significant: p ::;; 0.05, 8 (Urine sample from black subjects); W (Urine 
sample from white subjects). L5 and L7: day 5 and day 7 of low NaG/; H5 and H7: day 5 and day 7 of 
high NaG/; G5 and G7: day 5 and day 7 of NaHG03; 05 and 07: day 5 and day 7 of citrate. 
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Figure 6.12: Mean percentage inhibition of nucleation before and at Day 5 and Day 
7 of each protocol in both black (B) and white (W) subjects. 
B (Urine sample from black subjects); W (Urine sample from white subjects). L5 and L7: day 5 and 
day 7 of low NaG/; H5 and H7: day 5 and day 7 of high NaG/; G5 and G7: day 5 and day 7 of 
NaHG03; 05 and 07: day 5 and day 7 of citrate. 
Comment 
Inhibition of CaOx crystal nucleation occurs to a superior extent in the urine of black subjects 
than that of white subjects. Despite the non-significant changes, sodium bicarbonate and 
sodium citrate inhibited CaOx crystal nucleation in both groups. 
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6.4J Urinary Deoxypyridinoline (DPD) and serum Osteocalcin (OC) Analyses 
Urinary Deoxypyridinoline (DPD) Concentration 
Table 6.25 shows the concentration of urine DPD in samples from black (n = 8) and white (n 
= 8) subject's baseline and at day 8 of each protocol. Individual values are in Appendix 4, 
Tables 4.11 and 4.12. There were no significant changes in DPD levels for all the salts in 
both race groups, and therefore no p-values were tabulated. 
Table 6.25: Mean urinary DPD levels (nmol/L), standard errors and percentage changes in 
samples from black (n = 8) and white (n = 8) subjects at baseline and at day 8 
of each protocol. 
'Protocol B: Con'c. (% W: Co.nc. (% B vs. W ' 
Urinary decrease/increase Urinary decrease/increase (% 
DPD wrt baseline) DPD wrt baseline) difference) 
(nmoi/L) (nmoi/L) 
Baseline 4.63 ± 1.01 4.84 ± 1.01 4% 
LowNaCI (L) 5.41 ± 0.98 14% 5.79 ± 0.98 16% 6% 
High NaCI (H) 5.69 ± 1.12 18% 6.73 ± 1.12 28% 16% 
NaHC03 (C) 5.57 ± 0.70 17% 6.06 ± 0.70 20% 8% 
Na-Citrate (D) 4.00 ± 0.71 -14% 5.72 ± 0.71 16% 28% 
Intergroup comparisons show that that urinary DPD levels are lower in blacks than in whites 
at baseline and after each salt protocol. Within group comparisons show that urinary DPD 
levels increased in whites after all four salt protocols, while in blacks, increases occurred 
after low NaCI (L), high NaCl (H), and sodium bicarbonate (C) protocols but decreased after 
the sodium citrate (D) protocol. Moreover, the percentage increases in DPD levels after low 
salt, high NaCl and sodium bicarbonate protocols were generally higher in whites than in 
blacks, particularly after the high NaCl protocol. 
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Comment 
The lower DPD levels in blacks are consistent with lower bone resorption and lower urinary 
calcium in this ethnic group. The different qualitative and quantitative effects which occurred 
between the groups after the various protocols again draws attention to the possibility of 
different handling mechanisms within the two race groups. Within group comparisons show 
that all the protocols, except D raised urinary DPD, suggesting that they promote bone 
resorption irrespective of the race group. 
Serum Osteocalcin (OC) concentration 
Table 6.26 shows the concentration of serum OC in samples from black (n = 8) and white (n 
= 8) subjects at baseline and at day 8 of each protocol. Individual values are presented in 
Appendix 4, Tables 4.13 and 4.14. The OC level is 24 % lower in blacks than whites at 
baseline. After low NaCl, OC is 8 % higher and 8 % lower after sodium citrate ingestion in 
whites than blacks. OC is favourably increased in blacks after each salt and even relatively 
higher after sodium citrate compared to the other three protocols. All the protocols except for 
low NaCl resulted in an unfavourable decrease in OC levels in whites. There were no 
significant changes in OC levels for all the protocols in both race groups, and therefore no p-
values are tabulated. 
Table 6.26: Mean serum OC levels (ng/mL), standard errors and percentage changes in 
serum from black and white subjects at baseline and at day 8 of each protocol. 
;>Protocol B: Corte. ('Yo W: Cone. (% Bvs. W 
Serum OC decrease/increase Serum OC decrease/increase (of., 
' .. ·{;· 
(ng/mL) wrt baseline) (ng/mL) wrt baseline) difference) 
Baseline 9.17 ± 1.07 12.07 ± 1.07 24% 
LowNaCI (L) 11.84 ± 1.67 22% 12.90 ± 1.67 6% 8% 
High NaCI (H) 11.57 ± 2.05 21% 11.47 ± 2.05 -5% 1% 
NaHC03 (C) 12.66 ± 2.52 28% 10.40 ± 2.52 -13% 18% 
Na-Citrate (D) 12.89 ± 1.99 41% 11.80 ± 1.99 -2% 8% 
. 
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Comment 
The lower OC levels in blacks (24 %) compared to their white counterparts at baseline are 
consistent with the lower bone formation reported by Delmas et al. (2000) in the former race 
group. An increase in OC levels in the black group after all the protocols demonstrates that 
these protocols (including NaCI) help in regulation and absorption of calcium whereas they 
tend not to be as effective in whites. This again supports the lower urinary excretion in urine 
samples from black subjects reported in this study. This observation demonstrates that 
different handling mechanisms of lithogenic and anti-lithogenic challenges exist in the two 
South African race groups. 
Chapter 6 182 
6.4 DISCUSSION 
As mentioned in the introductory section of this chapter, the strong positive correlation 
between urinary calcium and sodium intake is well documented (McCarron et al. 1981: 
Bresleau et al. 1982: Si•\er et al. 1983: Burtis et al. 1994: Massey and Whiting 1996: Lin et 
a!. 2003: Masse~ 2005 ). However, this effect was not observed in the present study, possibly 
because the duration of the trial was too short (7 days). Nevertheless, it is of importance to 
note that high NaCl intake in this study induced an unexpected and counter-intuitive 
significant decrease in urinary free calcium in samples from black subjects. In addition, the 
occurrence of some effects in one race group but not the other demonstrates different 
handling mechanisms of an ingested NaCl challenge in the two South African race groups. 
These findings are in agreement with the reported studies in other countries (such as Indiana, 
USA and Europe) comparing racial differences in calcium retention, that race is a major 
determinant of calcium retention (Kleerekoper et al. 199-J.: Br: ant et al. 2003: \\'igertz et al. 
2005 ). With increasing dietary salt, calcium retention is reported to be greater in blacks than 
in whites; this is attributed to greater calcium absorption and less urinary excretion of calcium 
in the former group (Kleereh.oper et al. 199-J.: Bryant et al. 2003: \\'igertz et al. 2005: Hui et 
al. 2003 ). 
Since other sodium salts (such as bicarbonate and citrate) induced different urinary 
effects relative to sodium chloride in this and other studies ( Sah.haee et al. 1983: Lemann et 
al. 1989: Morris and Sebastian 2002), it has been suggested that the anion bound to sodium is 
as important as sodium itself. Therefore, the chloride anion bound to sodium is as important 
as sodium in inducing hypercalciuria while the bicarbonate (Lemann et al. 1979: 1986: 1989: 
Morris and Sebastian ~002) and citrate ( Sakhaee et a!. 1983) ions help in reducing this 
condition. 
Supplemental bicarbonate and citrate induced a favourable significant decrease in 
urinary total calcium, free calcium, BRI, RS of CaOx and the RS of uric acid in both groups. 
Decreases in urinary calcium excretion following sodium bicarbonate and citrate 
supplementation have been reported by several authors (Lemann et al. 1965: Lutz 1984: 
~ah.haee et al. 1983 ). It is suggested that these two anions (bicarbonate and citrate) promote 
calcium retention, thereby negating the calcium lost by sodium. This finding has been 
demonstrated in Kurtz et al. 's study where equimolar amounts of NaCl and sodium citrate 
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were administered (Kurtz et al. 1983). The NaCl study resulted in increased urinary calcium 
excretion whereas sodium citrate had no effect on this parameter (Kurtz et a!. 1983 ). Some 
researchers have demonstrated that urinary calcium excretion decreases following 
administration of sodium bicarbonate (Lemann eta!. 1965: Lut? 1984 ). 
Another important effect of sodium bicarbonate and citrate administration in this 
present study is a significant increase in pH. Pak et al. ( I 994) attribute this increase in pH to 
the in vivo oxidation of citrate to bicarbonate which results in disturbances in the acid-base 
balance of the urine. An increase in pH following administration of sodium bicarbonate and 
sodium citrate is considered as the main factor in the success of these protocols in the 
management of CaOx stone formation (Pak et a!. 1985: Pak. and Fuller 1986: Lemann et al. 
1989: Borghi ct al. 2002: Morris and Sebastian 2002 ). Increased urinary pH is associated with 
an increase in inhibition of CaOx crystallization ( Pak 1994 ). This is due to the fact that at a 
higher pH, more phosphate and citrate ions are dissociated thus promoting the complexation 
of calcium and citrate ions which in tum lowers the relative supersaturation of CaOx ( Pak 
1994 ). As mentioned previously, Rodgers et al. (2005) have recently demonstrated the 
theoretical existence of a new calcium-citrate-phosphate complex which significantly lowers 
the RS of CaOx. In support of the notion that a higher pH is favourable, it has been 
previously reported that CaOx stone formers have significantly lower urinary pH values 
compared to healthy controls (Pak et al. 2002: Tiselius .2003: Hess 2006). 
To support the physicochemical data, crystallization experiments were conducted to 
determine whether the urines from the two groups behaved differently after the various 
protocols even though compositional differences were not necessarily detected. 
The Coulter Counter data showed a decrease in particle number and size in urines 
from black subjects at baseline and after all the protocols, thereby demonstrating a lower risk 
of CaOx crystal nucleation, aggregation and growth in this group whereas promotion of these 
unfavourable mechanisms was noted in samples from white subjects. 
These data were supported by scanning electron microscopy which also provided 
some interesting results. COD crystals precipitated at baseline were in agreement with the 
higher urinary calcium concentration reported in the samples from whites in this study. It has 
been previously reported that whites have very higher urinary calcium concentrations 
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(Goulding 1990; Nordin et al. 1992; Burtis et al. 1994), and these high concentrations favour 
the formation of COD crystals (Webber et al. 2002). The change in morphology from COM 
to COD crystals in samples from white subjects following sodium citrate ingestion is 
considered beneficial since the latter are less adherent to renal tubular cells (Wesson et al. 
1998). A decrease in crystal size in samples from black subjects after sodium bicarbonate and 
sodium citrate administration is in agreement with the previously reported results that these 
protocols reduce and retard CaOx crystal growth (Pak et al. 1983: Lemann et al. 1989; Laube 
et al. 2002 (a); Morris et al. 2002). The lower 14C-oxalate deposition in blacks compared to 
whites at baseline and after all of the protocols is in agreement with particle size and SEM 
data. This could offer an explanation to the rarity of kidney stone disease in the black group. 
This also indicates that black and white subjects respond differently to dietary lithogenic and 
anti-lithogenic challenges. 
Spectrophotometric analyses also demonstrated a greater extent of inhibition of CaOx 
crystal nucleation and aggregation in samples from black subjects than those from white 
subjects. Despite the non-significant differences, the slight increase in the extent of inhibition 
of nucleation in blacks after all the protocols except for high NaCl indicates the potency of 
these protocols in reducing the risk of stone formation. These observation are in agreement 
with those reported by several authors that supplemental bicarbonate and citrate retard CaOx 
crystal nucleation, aggregation and growth (Pak et al. 1983: Lemann et al. 1989; Kok et al. 
1986; Pak 1994; Laube et al. 2002 (a); Morris et al. 2002; Allie-Hamdulay and Rodgers 
2005). 
In retrospect, the choice of Citro-Soda as a source of citrate may not have been 
entirely appropriate as it contains bicarbonate which might have confounded the influence of 
citrate itself. Nevertheless, the additive effect, if any, is of interest. 
As explained in Chapter 1, osteoporosis just like kidney stone disease is a multi-
factorial disease. There is a profound link between these two diseases as they both depend on 
calcium absorption and excretion. High urinary calcium excretion subsequently reduces 
calcium transportation into bone which has a negative impact on skeletal development which 
adversely leads to osteoporosis. Furthermore, elevated urinary calcium results in a high risk 
of it complexing with oxalate to form an insoluble complex of CaOx which is the main 
component of kidney stones. Maximal positive balance between calcium intake and 
obligatory losses of calcium are required for the attainment of peak bone mass and for the 
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reduction of kidney stone formation risk. Indeed, patients suffering from osteoporosis due to 
renal tubular acidosis have been reported as having kidney stones (Weger et al. 1999; 
Roudsari et al. 2005). 
As one of the objectives of this study, the effect of the already discussed three sodium salts 
on bone formation and bone resorption in both black and white South African male subjects 
was investigated. However, baseline values of these markers are of interest. The lower DPD 
and OC levels in blacks demonstrate fundamental physiological differences between the 
groups which ultimately determine urinary calcium and stone formation. 
Several studies have investigated the effect of sodium chloride on bone turnover 
markers but conflicting results have been reported (Goulding 1981: Goulding and Lim, 1983; 
Shortt and Flynn, 1990; Matkovic, et al. 1995; Evans et al. 1997; Lietz et al. 1997: Ginty et 
al. 1998; Sellmeyer et al. 2002; Lin et al. 2003: Massey 2005; Wigertz et al. 2005). Several 
authors have reported a decrease in OC levels (bone formation marker) following a high 
sodium intake and no change in bone resorption markers (Evans et al. 1997; Sellmeyer et al. 
2002; Lin et al. 2003). Others have reported an increase in OC levels and a decrease in bone 
resorption markers (Sebastian et al. 1994: Wigertz et al. 2005). Not unexpectedly, some 
investigators have shown no effect on bone formation and resorption markers (Lietz et al. 
1997; Ginty et al. 1998). 
The qualitatively smaller increases in urinary DPD levels in blacks after low NaCl, 
high NaCl and sodium bicarbonate protocols are indicative of a weaker bone resorption 
response to these challenges than in whites. On the other hand increases in serum OC in 
blacks after high NaCl, sodium bicarbonate and sodium citrate protocols but corresponding 
decreases in whites surprisingly demonstrate a bone formation response in the former. Thus, 
the notion of different renal handling mechanisms in the two race groups is again apparent. 
This supports the findings of several researchers who believe that race is a major determinant 
of calcium retention (Kleerekoper et al. 1994; Bryant et al. 2003; Hui et al. 2003; Wigertz et 
al. 2005). Indeed, blacks are reported to have significantly higher bone mineral density and 
bone mineral content than whites which could be due to higher calcium retention by the 
former group (Wigertz et al. 2005). 
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CHAPTER SEVEN 
CONCLUDING COMMENTS 
On the basis of the well established observation that the South African black population 
rarely forms kidney stones (Modlin 1967: Whalle; et a!. 1998: Pinnock et a!. 2004 ), the 
present thesis was undertaken to investigate various aspects of this phenomenon, with a view 
to identifying the factors which afford this protection. 
The present study corroborated previous findings (Lewandowski et a!. 2001; Rodgers 
and Lewandowski 2002) that the urinary composition and CaOx MSL data alone do not 
explain rarity of kidney stone disease in the black group. Therefore crystallization 
experiments measuring as particle formation kinetics, 14C-oxalate deposition, CaOx crystal 
aggregation and nucleation were conducted. These studies were also supplemented with SEM 
to view the extent of crystallization and the morphology of the crystals precipitated. The zeta 
potential of crystals was also measured. 
Crystallization studies conducted in prefiltered, ultrafiltered and concentrated urine 
portions from black and white subjects demonstrated that macromolecules in the urine of the 
former were more effective at inhibiting CaOx crystal deposition and aggregation. This result 
is in agreement with that demonstrated by Tiselius et al. ( 1995) and Asplin ( 1999) that 
healthy men show greater CaOx aggregation inhibition than stone prone men. This 
demonstrated the inhibitory role of macromolecules and gave some explanation as to the 
stone rarity in the black South African population. 
Investigation of the crystal matrix extract included in COD derived from the urines of 
both race groups showed that the extract from black subjects (BCME) was a superior 
inhibitor of CaOx crystallization processes. The total protein content in BCME was higher 
than in WCME. SDS-PAGE and Western Blotting revealed OPN to be the main 
intracrystalline protein in both BCME and WCME. This observation is in agreement with the 
results reported by several authors (Atmani eta!. 1996: Webber eta!. 2003; R;all eta!. 2005). 
On the basis of this finding, the inhibitory activity of the CMEs was mainly attributed to 
OPN. 
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Complimentary studies on the role of the race groups' respective unne compositions, 
demonstrated that commercially available OPN performed as an inhibitor to a better extent in 
the urine from black subjects compared to that from white subjects. This was in support of 
the observation that OPN is the main intracrystalline protein in COD-CME. 
Investigation of the ingestion of three sodium salt protocols gave rise to changes in 
the urinary biochemical risk factors for CaOx stone formation in both groups. Several of 
these changes were common to both groups and were generally favourable. In addition to the 
common changes, several urinary risk factors changed in the one group but not in the other. 
The significantly lower urinary calcium in baseline samples from black subjects compared to 
those from their white counterparts was in agreement with the previously reported data in 
South Africa (Modlin 1967; Whalley et al. 1998; Rodgers and Lewandowski 2002). Of 
importance however, was an indication that the changes in black subjects were more 
prominent in providing physicochemical protection against kidney stones. An unexpected and 
counter-intuitive significant decrease in free calcium in urine samples from black subjects, 
but not in those from white subjects after NaCl ingestion was also noteworthy. These findings 
are in agreement with other studies that reported racial differences in calcium retention, with 
retention being greater in blacks than in whites (Kieerekoper et al. 1994; Bryant et al. 2003: 
Wigertz et al. 2005). This is attributed to greater calcium absorption and less urinary 
excretion of calcium in the black group (Kieerekoper et al. 1994; Bryant et al. 2003; Wigertz 
et al. 2005; Hui et al. 2::>03). This provides important evidence in support of the notion that 
different physiological handling mechanisms of lithogenic and antilithogenic dietary 
challenges occur in the two race groups. Similarly, the observation of qualitative and 
quantitative differences in bone turnover markers in both groups following the ingestion of 
different sodium salts, provides further support of this notion. 
Thus, the overall results of the various studies presented in this thesis have demonstrated 
several superior physicochemical, biochemical and physiological protective mechanisms 
against CaOx kidney stones in black South African subjects compared to their white 
compatriots. These mechanisms are likely to be important contributory factors towards 
accounting for the rarity of urolithiasis in this race group. 
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